# Patent

## Title
Quinolone compound

## Abstract

The present invention provides a compound represented by the formula (I)




wherein X is a hydrogen atom or a fluorine atom; R is a hydrogen atom or alkyl; R1 is (1) cyclopropyl optionally substituted by 1 to 3 halogen atoms or (2) phenyl optionally substituted by 1 to 3 halogen atoms; R2 is alkyl, alkoxy, haloalkoxy, a halogen atom, cyano, etc.; and R3 is 7-oxo-7,8-dihydro-1,8-naphthyridinyl, 3-pyridyl, etc., or a salt thereof. The compound of the present invention has excellent antimicrobial activity against Clostridium difficile and is useful for the prevention or treatment of intestinal infection such as Clostridium difficile-associated diarrhea.

## Background
This is a continuation of application Ser. No. 14/193,656, filed Feb. 28, 2014, which is a continuation of International Application No. PCT/CN2012/080753, filed on Aug. 30, 2012, which claims priority of International Application No. PCT/CN2011/001477, filed on Aug. 31, 2011, and International Application No. PCT/CN20121001044, filed on Aug. 6, 2012. The contents of all four applications are incorporated herein by reference.


TECHNICAL FIELD
The present invention relates to quinolone compounds and pharmaceutical use thereof.
BACKGROUND ART
Clostridium difficile infection is associated with consumption of antibiotics which disrupt the normal microbial flora of the gut, allowing Clostridium difficile to establish itself and produce disease. Currently, only vancomycin or metronidazole is recommended for treatment and many patients suffer from relapse on infection (Expert Opin. Ther. Patents (2010) 20(10), pp. 1389-1399).
EP2177214 A1 describes use of ozenoxacin for Clostridium difficile. 
Some quinolone compounds useful as antibacterial agents are disclosed in JP1-319463 A, WO99/51588, WO99/03465, JP3-66301 B and WO99/07682.
SUMMARY OF INVENTION
The object of the present invention is to provide a novel quinolone compound which has excellent antimicrobial activity, particularly excellent antimicrobial activity against Clostridium difficile. Another object of the present invention is to provide a pharmaceutical composition containing said quinolone compound, which is useful for the prevention or treatment of various infectious diseases including antibiotics-associated diarrhea (AAD) such as Clostridium difficile-associated diarrhea (CDAD). A further object of the present invention is to provide a method for preventing or treating a bacterial infection including AAD such as CDAD, which comprises administering said quinolone compound to a human or an animal.
The present invention provides a quinolone compound, a pharmaceutical composition comprising said compound, use of said compound, and a method for preventing or treating a bacterial infection, as described in items 1 to 27 below.
Item 1. A compound represented by the formula (I)




wherein

X is a hydrogen atom or a fluorine atom;

R is a hydrogen atom or alkyl;

R1 is (1) cyclopropyl optionally substituted by 1 to 3 halogen atoms or (2) phenyl optionally substituted by 1 to 3 halogen atoms;

R2 is a hydrogen atom; alkyl optionally substituted by 1 or 2 substituents selected from the group consisting of a halogen atom and hydroxyl; alkoxy; haloalkoxy; a halogen atom; cyano; cyclopropyl; nitro; amino; formyl; alkenyl or alkynyl; or

R1 and R2 are bonded to form a 5- or 6-membered ring optionally substituted by alkyl;

R3 is

    (1) a fused heterocyclic group of the formula






wherein

represents a single bond or a double bond,

X1 is C(R5) or N,

R4 is a hydrogen atom or alkyl, and

R5 is (a) a hydrogen atom,

    
    
        (b) a halogen atom,
        (c) cyano,
        (d) nitro,
        (e) hydroxy,
        (f) alkyl optionally substituted by 1 to 3 halogen atoms,
        (g) alkenyl or alkynyl,
        (h) aryl, or
        (i) alkoxy optionally substituted by 1 to 3 halogen atoms,

when X1 is C(R5), R4 and R5 are optionally bonded to form a 5- or 6-membered ring optionally substituted by oxo,

said fused heterocyclic group is optionally substituted by 1 or 2 substituents selected from the group consisting of a halogen atom, cyano, nitro, hydroxy and alkyl,

    
    
    (2) a group of the formula






wherein

X2 is C(R8) or N, and

R6, R7 and R8 are each independently,

    
    
        (a) a hydrogen atom,
        (b) a halogen atom,
        (c) cyano,
        (d) nitro,
        (e) amino,
        (f) alkyl optionally substituted by 1 to 3 substituents selected from the group consisting of a halogen atom, alkoxy and amino,
        (g) alkenyl,
        (h) alkynyl,
        (i) aryl,
        (j) formyl or CH═N—OH,
        (k) carboxy,
        (l) carbamoyl,
        (m) a 5- to 10-membered aromatic heterocyclic group optionally substituted by alkyl, or
        (n) alkenyloxy,
    
    
    (3) a group of the formula






wherein

X3 and X4 are N, or

X3 is N and X4 is CR′′, wherein R′′ is hydrogen atom, amino, hydroxy, alkyl optionally substituted by 1 to 3 substituents selected from the group consisting of alkoxy and dimethylamino or mercapto, or

X3 is CH and X4 is N,

R′ is a hydrogen atom or alkyl optionally substituted by 1 to 3 substituents selected from the group consisting of substituted hydroxyl and amino, and

R6 is as defined above,

    (4) a group of the formula






wherein

 represents a single bond or a double bond and R6 is as defined above,

    (5) 3-pyridyl optionally substituted by 1 or 2 substituents selected from the group consisting of
    
        (a) a halogen atom,
        (b) cyano,
        (c) nitro,
        (d) hydroxy,
        (e) amino,
        (f) alkyl optionally substituted by 1 to 3 substituents selected from the group consisting of a halogen atom, alkylamino, dialkylamino and hydroxy,
        (g) alkenyl, alkynyl
        (h) aryl,
        (i) cycloalkyl,
        (j) alkoxy,
        (k) alkylamino,
        (l) dialkylamino,
        (m) phenylamino optionally substituted by 1 to 3 halogen atoms,
        (n) a cyclic amino group optionally substituted by alkoxycarbonyl,
        (o) formyl,
        (p) carbamoyl optionally substituted by alkyl optionally substituted by hydroxy, and
        (q) a 5- to 10-membered aromatic heterocyclic group optionally substituted by alkyl,
    
    
    (6) 4-pyridyl optionally substituted by a halogen atom,
    (7) 5-pyrimidinyl optionally substituted by 1 or 2 substituents selected from the group consisting of amino, alkylamino, dialkylamino and carboxy,
    (8) 2-indolyl, 3-indolyl, 5-indolyl, 6-indolyl, benzofuranyl, benzothiophenyl, benzoxazolyl or benzothiazolyl, each optionally substituted by 1 or 2 substituents selected from the group consisting of
    
        (a) a halogen atom,
        (b) cyano,
        (c) nitro,
        (d) hydroxy,
        (e) alkyl optionally substituted by 1 to 3 substituents selected from the group consisting of amino, alkoxycarbonylamino, alkylamino and dialkylamino,
        (f) alkoxy,
        (g) formyl,
        (h) carboxy, and
        (j) amino optionally substituted by 1 or 2 substituents selected from the group consisting of
        
            (i) alkoxycarbonyl,
            (ii) alkylcarbonyl optionally substituted by a substituent selected from the group consisting of
            
                (A) cycloalkyloxy optionally substituted by 1 to 3 alkyl,
                (B) alkylamino,
                (C) dialkylamino,
                (D) a cyclic amino group optionally substituted by alkoxycarbonyl, and
                (E) a halogen atom,
            
            
            (iii) phenylcarbonyl optionally substituted by 1 to 3 substituents selected from the group consisting of alkyl and alkoxy,
            (iv) cycloalkylcarbonyl,
            (v) a 5- to 10-membered aromatic heterocyclylcarbonyl group optionally substituted by alkyl optionally substituted by 1 to 3 halogen atoms,
            (vi) benzylcarbonyl optionally substituted by 1 to 3 substituents selected from the group consisting of a halogen atom and alkoxy,
            (vii) arylsulfonyl optionally substituted by alkoxy,
            (viii) cycloalkylalkylsulfonyl optionally substituted by 1 to 3 substituents selected from the group consisting of alkyl and oxo,
            (ix) a 5- to 10-membered aromatic heterocyclylsulfonyl group optionally substituted by 1 to 3 alkyl, and
            (x) —C(═N—CN)—SR9 wherein R9 is alkyl,
        
        
    
    
    (9) a group of the formula






wherein

one of Y1, Y2, Y3 and Y4 is N or N+(—O−), and the remaining three are each C(R25), C(R26) and C(R27),

W is O, S, NH or N(R23)

R23 is a hydrogen atom or alkyl, and

R24, R25, R26 and R27 are each independently,

    
    
        (a) a hydrogen atom,
        (b) cyano, or
        (c) nitro,
    
    
    (10) a group of the formula






wherein

R28 is a hydrogen atom or hydroxy, and

R29 is a hydrogen atom or alkyl,

    (11) a group of the formula






wherein

X5 is C(R11) or N,

X6 is CH2, C(═O), O, S, SO2 or N(R12),

X7 is CH(R13), C(═O) or N(R14),

X8 is CH(R15) or C(═O),

R10, R12 and R14 are each independently,

    
    
        (a) a hydrogen atom or
        (b) alkyl, and

R11, R13 and R15 are each independently,

        (a) a hydrogen atom,
        (b) a halogen atom,
        (c) cyano,
        (d) nitro,
        (e) amino,
        (f) alkylamino,
        (g) dialkylamino,
        (h) alkyl optionally substituted by hydroxy, or
        (i) alkenyl,

when X5 is C(R11), R10 and R11 are optionally bonded to form a 5- or 6-membered ring optionally substituted by alkyl or oxo, and when X6 is N(R12) and X7 is CH(R13), R12 and R13 are optionally bonded to form a 5- or 6-membered ring,

    
    
    (12) a group of the formula






wherein R16 is

    
    
        (a) a hydrogen atom,
        (b) alkyl optionally substituted by 1 to 3 substituents selected from the group consisting of cyano, alkylamino and dialkylamino,
        (c) alkenyl optionally substituted by carboxy,
        (d) formyl,
        (e) carboxy,
        (f) carbamoyl,
        (g) —C(R17)═N—OH wherein R17 is a hydrogen atom, cyano or hydroxy,
        (h) a 5- to 10-membered aromatic heterocyclic group optionally substituted by alkyl, alkoxycarbonyl, carboxy or phenyl, or
        (i) cyano,
    
    
    (13) a group of the formula






wherein

R18 is a hydrogen atom or alkyl optionally substituted by 1 to 3 substituents selected from the group consisting of a halogen atom and phenyl,

n is 0 or 1,

R19, R20 and R33 are each independently,

    
    
        (a) a hydrogen atom,
        (b) a halogen atom,
        (c) cyano,
        (d) alkyl optionally substituted by 1 to 3 substituents selected from the group consisting of
        
            (i) a halogen atom,
            (ii) cyano,
            (iii) hydroxy,
            (iv) amino,
            (v) alkylamino,
            (vi) dialkylamino, and
            (vii) a cyclic amino group optionally substituted by alkyl,
        
        
        (e) alkoxy,
        (f) amino optionally substituted by 1 or 2 substituents selected from the group consisting of
        
            (i) alkylcarbonyl optionally substituted by a cyclic amino group,
            (ii) alkylsulfonyl,
            (iii) carbamoyl,
            (iv) alkyl, cycloalkyl or cycloalkylalkyl, and
            (v) 5- to 10-membered saturated heterocyclic group,
        
        
        (g) carboxy,
        (h) alkoxycarbonyl,
        (i) carbamoyl optionally substituted by alkyl optionally substituted by amino, alkylamino, dialkylamino or alkoxycarbonylamino,
        (j) formyl,
        (k) a 5- to 10-membered aromatic heterocyclic group optionally substituted by alkyl,
        (l) —CH═N—OR21 wherein R21 is a hydrogen atom or alkyl optionally substituted by alkylamino or dialkylamino,
        (m) nitro,
        (n) a 5- to 10-membered saturated heterocyclic group optionally substituted by amino,
        (o) phenyl, or
        (p) —NHC(SMe)═CHCN,
    
    
    (14) a group of the formula






wherein

R30 is (a) a hydrogen atom,

    
    
        (b) a halogen atom,
        (c) cyano,
        (d) alkyl optionally substituted by 1 to 3 substituents selected from the group consisting of a halogen atom and hydroxy,
        (e) alkenyl,
        (f) alkynyl,
        (g) alkoxy,
        (h) formyl,
        (i) —CH═N—OH, or
        (j) carbamoyl,
    
    
    (15) naphthyl or isochromenyl,
    (16) quinolyl or isoquinolyl, or their oxide derivatives,
    (17) a group of the formula






    (18) a group of the formula






wherein

U is O or S, and

R31 is (a) a hydrogen atom,

    
    
        (b) a halogen atom,
        (c) alkyl optionally substituted by 1 to 3 halogen atoms,
        (d) carboxy,
        (e) nitro,
        (f) cyano, or
        (g) amino,
    
    
    (19) a group of the formula






wherein

R32 is (a) a halogen atom,

    
    
        (b) phenyl, or
        (c) a group of the formula
    
    






    (20) a group of the formula






wherein

R34 and R35 are each independently,

    
    
        (a) a hydrogen atom, or
        (b) aminoalkyl,

or

R34 and R35 are bonded to form a 6-membered ring optionally substituted by amino or oxo,

    
    
    (21) a group of the formula






wherein R36 is

    
    
        (a) a hydrogen atom,
        (b) a halogen atom,
        (c) nitro, or
        (d) thienyl, or
    
    
    (22) a group of the formula






or a salt thereof.

Item 1A. The compound of item 1, wherein
X is a hydrogen atom or a fluorine atom;
R is a hydrogen atom or alkyl;
R1 is (1) cyclopropyl optionally substituted by 1 to 3 halogen atoms or (2) phenyl optionally substituted by 1 to 3 halogen atoms;
R2 is alkyl, alkoxy, haloalkoxy, a chlorine atom or cyano; or
R1 and R2 are bonded to form a 5- or 6-membered ring optionally substituted by alkyl; and
R3 is


    (1) a fused heterocyclic group of the formula






wherein

 represents a single bond or a double bond,

X1 is C(R5) or N,

R4 is a hydrogen atom or alkyl, and

R5 is (a) a hydrogen atom,

    
    
        (b) a halogen atom,
        (c) cyano,
        (d) nitro,
        (e) hydroxy,
        (f) alkyl optionally substituted by 1 to 3 halogen atoms,
        (g) alkenyl or alkynyl,
        (h) aryl, or
        (i) alkoxy optionally substituted by 1 to 3 halogen atoms,

when X1 is C(R5), R4 and R5 are optionally bonded to form a 5- or 6-membered ring optionally substituted by oxo,

said fused heterocyclic group is optionally substituted by 1 or 2 substituents selected from the group consisting of a halogen atom, cyano, nitro, hydroxy and alkyl,

    
    
    (2) a group of the formula






wherein

X2 is C(R6) or N, and

R6, R7 and R8 are each independently,

    
    
        (a) a hydrogen atom,
        (b) a halogen atom,
        (c) cyano,
        (d) nitro,
        (e) amino,
        (f) alkyl optionally substituted by 1 to 3 substituents selected from the group consisting of a halogen atom, alkoxy and amino,
        (g) alkenyl,
        (h) alkynyl,
        (i) aryl,
        (j) formyl or CH═N—OH,
        (k) carboxy,
        (l) carbamoyl, or
        (m) a 5- to 10-membered aromatic heterocyclic group optionally substituted by alkyl,
    
    
    (3) a group of the formula






wherein

X3 and X4 are N, or

X3 is N and X4 is CR′′, wherein R′′ is a hydrogen atom, amino, hydroxy, alkyl or mercapto, or

X3 is CH and X4 is N,

R′ is a hydrogen atom or alkyl optionally substituted by 1 to 3 substituents selected from the group consisting of substituted hydroxy and amino, and

R6 is as defined above,

    (4) a group of the formula






wherein

 represents a single bond or a double bond and R6 is as defined above,

    (5) 3-pyridyl optionally substituted by 1 or 2 substituents selected from the group consisting of
    
        (a) a halogen atom,
        (b) cyano,
        (c) nitro,
        (d) hydroxy,
        (e) amino,
        (f) alkyl optionally substituted by 1 to 3 substituents selected from the group consisting of a halogen atom, alkylamino, dialkylamino and hydroxy,
        (g) alkenyl or alkynyl,
        (h) aryl,
        (i) cycloalkyl,
        (j) alkoxy,
        (k) alkylamino,
        (l) dialkylamino,
        (m) phenylamino optionally substituted by 1 to 3 halogen atoms,
        (n) a cyclic amino group optionally substituted by alkoxycarbonyl,
        (o) formyl,
        (p) carbamoyl optionally substituted by alkyl optionally substituted by hydroxy, and
        (q) a 5- to 10-membered aromatic heterocyclic group optionally substituted by alkyl,
    
    
    (6) 4-pyridyl optionally substituted by a halogen atom,
    (7) 5-pyrimidinyl optionally substituted by 1 or 2 substituents selected from the group consisting of amino, alkylamino, dialkylamino and carboxy,
    (8) 2-indolyl, 3-indolyl, 5-indolyl, 6-indolyl, benzofuranyl, benzothiophenyl, benzoxazolyl or benzothiazolyl, each optionally substituted by 1 or 2 substituents selected from the group consisting of
    
        (a) a halogen atom,
        (b) cyano,
        (c) nitro,
        (d) hydroxy,
        (e) alkyl optionally substituted by 1 to 3 substituents selected from the group consisting of amino, alkoxycarbonylamino, alkylamino and dialkylamino,
        (f) alkoxy,
        (g) formyl,
        (h) carboxy, and
        (j) amino optionally substituted by 1 or 2 substituents selected from the group consisting of
        
            (i) alkoxycarbonyl,
            (ii) alkylcarbonyl optionally substituted by a substituent selected from the group consisting of
            
                (A) cycloalkyloxy optionally substituted by 1 to 3 alkyl,
                (B) alkylamino,
                (C) dialkylamino,
                (D) a cyclic amino group optionally substituted by alkoxycarbonyl, and
                (E) a halogen atom,
            
            
            (iii) phenylcarbonyl optionally substituted by 1 to 3 substituents selected from the group consisting of alkyl and alkoxy,
            (iv) cycloalkylcarbonyl,
            (v) a 5- to 10-membered aromatic heterocyclylcarbonyl group optionally substituted by alkyl optionally substituted by 1 to 3 halogen atoms,
            (vi) benzylcarbonyl optionally substituted by 1 to 3 substituents selected from the group consisting of a halogen atom and alkoxy,
            (vii) arylsulfonyl optionally substituted by alkoxy,
            (viii) cycloalkylalkylsulfonyl optionally substituted by 1 to 3 substituents selected from the group consisting of alkyl and oxo,
            (ix) a 5- to 10-membered aromatic heterocyclylsulfonyl group optionally substituted by 1 to 3 alkyl, and
            (x) —C(═N—CN)—SR9 wherein R9 is alkyl,
        
        
    
    
    (9) a group of the formula






wherein

one of Y1, Y2, Y3 and Y4 is N or N+(—O−), and the remaining three are each C(R25), C(R26) and C(R27),

W is O, S or N(R23)

R23 is a hydrogen atom or alkyl, and

R24, R25, R26 and R27 are each independently,

    
    
        (a) a hydrogen atom,
        (b) cyano, or
        (c) nitro,
    
    
    (10) a group of the formula






wherein

R28 is a hydrogen atom or hydroxy, and

R29 is a hydrogen atom or alkyl,

    (11) a group of the formula






wherein

X5 is C(R11) or N,

X6 is CH2, C(═O), O, S, SO2 or N(R12),

X7 is CH(R13), C(═O) or N(R14),

X8 is CH(R15) or C(═O),

R10, R12 and R14 are each independently,

    
    
        (a) a hydrogen atom or
        (b) alkyl, and

R11, R13 and R15 are each independently,

        (a) a hydrogen atom,
        (b) a halogen atom,
        (c) cyano,
        (d) nitro,
        (e) amino,
        (f) alkylamino,
        (g) dialkylamino,
        (h) alkyl optionally substituted by hydroxy, or
        (i) alkenyl,

when X5 is C(R11), R10 and R11 are optionally bonded to form a 5- or 6-membered ring optionally substituted by alkyl or oxo, and when X6 is N(R12) and X7 is CH(R13), R12 and R13 are optionally bonded to form a 5- or 6-membered ring,

    
    
    (12) a group of the formula






wherein R16 is

    
    
        (a) a hydrogen atom,
        (b) alkyl optionally substituted by 1 to 3 substituents selected from the group consisting of cyano, alkylamino and dialkylamino,
        (c) alkenyl optionally substituted by carboxy,
        (d) formyl,
        (e) carboxy,
        (f) carbamoyl,
        (g) —C(R17)═N—OH wherein R17 is a hydrogen atom, cyano or hydroxy,
        (h) a 5- to 10-membered aromatic heterocyclic group optionally substituted by alkyl, alkoxycarbonyl, carboxy or phenyl, or
        (i) cyano,
    
    
    (13) a group of the formula






wherein

R18 is a hydrogen atom or alkyl optionally substituted by 1 to 3 substituents selected from the group consisting of a halogen atom and phenyl, and

R19 and R20 are each independently,

    
    
        (a) a hydrogen atom,
        (b) a halogen atom,
        (c) cyano,
        (d) alkyl Optionally substituted by 1 to 3 substituents selected from the group consisting of
        
            (i) a halogen atom,
            (ii) cyano,
            (iii) hydroxy,
            (iv) amino,
            (v) alkylamino,
            (vi) dialkylamino, and
            (vii) a cyclic amino group optionally substituted by alkyl,
        
        
        (e) alkoxy,
        (f) amino optionally substituted by 1 or 2 substituents selected from the group consisting of
        
            (i) alkylcarbonyl optionally substituted by a cyclic amino group,
            (ii) alkylsulfonyl,
            (iii) carbamoyl, and
            (iv) alkyl or cycloalkyl,
        
        
        (g) carboxy,
        (h) alkoxycarbonyl,
        (i) carbamoyl optionally substituted by alkyl optionally substituted by amino, alkylamino, dialkylamino or alkoxycarbonylamino,
        (j) formyl,
        (k) a 5- to 10-membered aromatic heterocyclic group optionally substituted by alkyl,
        (l) —CH═N—OR21 wherein R21 is a hydrogen atom or alkyl optionally substituted by alkylamino or dialkylamino, or
        (m) nitro,
    
    
    (14) a group of the formula






wherein

R30 is (a) a hydrogen atom,

    
    
        (b) a halogen atom,
        (c) cyano,
        (d) alkyl optionally substituted by 1 to 3 substituents selected from the group consisting of a halogen atom and hydroxy,
        (e) alkenyl,
        (f) alkynyl,
        (g) alkoxy,
        (h) formyl, or
        (i) —CH═N—OH,
    
    
    (15) naphthyl or isochromenyl, or
    (16) quinolyl or isoquinolyl, or oxide derivative thereof,

or a salt thereof.



Item 2. The compound of item 1 or 1A, wherein X is a fluorine atom, or a salt thereof.
Item 3. The compound of item 1 or 1A, wherein R3 is a fused heterocyclic group of the formula




wherein , X1 and R4 are as defined in item 1, and said fused heterocyclic group is optionally substituted by 1 or 2 substituents selected from the group consisting of a halogen atom, cyano, nitro, hydroxy and alkyl, or a salt thereof.

Item 4. The compound of item 1 or 1A, wherein R3 is a group of the formula




wherein X2, R6 and R7 are as defined in item 1, or a salt thereof.

Item 5. The compound of item 1 or 1A, wherein R3 is a group of the formula




wherein X3, X4, R6 and R′ are as defined in item 1, or a salt thereof.

Item 6. The compound of item 1 or 1A, wherein R3 is a group of the formula




wherein  and R6 are as defined in item 1, or a salt thereof.

Item 7. The compound of item 1 or 1A, wherein R3 is a group of the formula




wherein R22 is

    
    
        (a) a halogen atom,
        (b) cyano,
        (c) nitro,
        (d) alkyl optionally substituted by 1 to 3 substituents selected from the group consisting of a halogen atom, alkylamino, dialkylamino and hydroxy,
        (e) alkenyl or alkynyl,
        (f) aryl,
        (g) cycloalkyl,
        (h) alkoxy,
        (i) formyl, or
        (j) carbamoyl optionally substituted by alkyl optionally substituted by hydroxy,

or a salt thereof.

    
    


Item 8. The compound of item 1 or 1A, wherein R3 is 5-pyrimidinyl substituted by 1 or 2 substituents selected from the group consisting of amino, alkylamino, dialkylamino and carboxy, or a salt thereof.
Item 9. The compound of item 1 or 1A, wherein R3 is 2-indolyl optionally substituted by 1 or 2 substituents selected from the group consisting of

    
    
        (a) a halogen atom,
        (b) cyano,
        (c) nitro,
        (d) hydroxy,
        (e) alkyl optionally substituted by 1 to 3 substituents selected from the group consisting of amino, alkoxycarbonylamino, alkylamino and dialkylamino,
        (f) alkoxy,
        (g) formyl,
        (h) carboxy, and
        (j) amino optionally substituted by 1 or 2 substituents selected from the group consisting of
        
            (i) alkoxycarbonyl,
            (ii) alkylcarbonyl optionally substituted by a substituent selected from the group consisting of
            
                (A) cycloalkyloxy optionally substituted by 1 to 3 alkyl,
                (B) alkylamino,
                (C) dialkylamino,
                (D) a cyclic amino group optionally substituted by alkoxycarbonyl, and
                (E) a halogen atom,
            
            
            (iii) phenylcarbonyl optionally substituted by 1 to 3 substituents selected from the group consisting of alkyl and alkoxy,
            (iv) cycloalkylcarbonyl,
            (v) a 5- to 10-membered aromatic heterocyclylcarbonyl group optionally substituted by alkyl optionally substituted by 1 to 3 halogen atoms,
            (vi) benzylcarbonyl optionally substituted by 1 to 3 substituents selected from the group consisting of a halogen atom and alkoxy,
            (vii) arylsulfonyl optionally substituted by alkoxy,
            (viii) cycloalkylalkylsulfonyl optionally substituted by 1 to 3 substituents selected from the group consisting of alkyl and oxo,
            (ix) a 5- to 10-membered aromatic heterocyclylsulfonyl group optionally substituted by 1 to 3 alkyl, and
            (x) —C(═N—CN)—SR9 wherein R5 is alkyl,

or a salt thereof.

        
        
    
    


Item 10. The compound of item 1 or 1A, wherein R3 is a group of the formula




wherein Y1, Y2, Y3, Y4, W and R24 are as defined in item 1, or a salt thereof.

Item 11. The compound of item 1 or 1A, wherein R3 is a group of the formula




wherein R28 and R29 are as defined in item 1, or a salt thereof.

Item 12. The compound of item 1 or 1A, wherein R3 is a group of the formula




wherein X5, X6, X7, X8 and R10 are as defined in item 1, or a salt thereof.

Item 13. The compound of item 1 or 1A, wherein R3 is a group of the formula




wherein R16a is

    
    
        (a) alkyl optionally substituted by 1 to 3 substituents selected from the group consisting of cyano, alkylamino and dialkylamino,
        (b) alkenyl optionally substituted by carboxy,
        (c) formyl,
        (d) carboxy,
        (e) carbamoyl,
        (f) —C(R17)═N—OH wherein R17 is a hydrogen atom, cyano or hydroxy,
        (g) a 5- to 10-membered aromatic heterocyclic group optionally substituted by alkyl, alkoxycarbonyl, carboxy or phenyl, or
        (h) cyano,

or a salt thereof.

    
    


Item 14. The compound of item 1 or 1A, wherein R3 is a group of the formula




wherein

R18a is alkyl, and

R19a is (a) a halogen atom,

    
    
        (b) cyano,
        (c) alkyl optionally substituted by 1 to 3 substituents selected from the group consisting of
        
            (i) a halogen atom,
            (ii) cyano,
            (iii) hydroxy,
            (iv) amino,
            (v) alkylamino,
            (vi) dialkylamino, and
            (vii) a cyclic amino group optionally substituted by alkyl,
        
        
        (d) alkoxy,
        (e) amino optionally substituted by 1 or 2 substituents selected from the group consisting of
        
            (i) alkylcarbonyl optionally substituted by a cyclic amino group,
            (ii) alkylsulfonyl,
            (iii) carbamoyl, and
            (iv) alkyl or cycloalkyl,
        
        
        (f) carboxy,
        (g) alkoxycarbonyl,
        (h) carbamoyl optionally substituted by alkyl optionally substituted by amino, alkylamino, dialkylamino or alkoxycarbonylamino,
        (i) formyl,
        (j) a 5- to 10-membered aromatic heterocyclic group optionally substituted by alkyl,
        (k) —CH═N—OR21 wherein R21 is a hydrogen atom or alkyl optionally substituted by alkylamino or dialkylamino, or
        (l) nitro,

or a salt thereof.

    
    


Item 15. The compound of item 1 or 1A, wherein R3 is a group of the formula




wherein R30 is as defined in item 1, or a salt thereof.

Item 16. The compound of item 1 or 1A, wherein R3 is naphthyl or isochromenyl, or a salt thereof.
Item 17. The compound of item 1 or 1A, wherein R3 is quinolyl or isoquinolyl, or oxide derivative thereof, or a salt thereof.
Item 18. The compound of item 1 or 1A, wherein R is a hydrogen atom, or a salt thereof.
Item 19. The compound of item 1 or 1A, wherein R1 is cyclopropyl, 2-fluorocyclopropyl or 2,4-difluorophenyl, or a salt thereof.
Item 20. The compound of item 1 or 1A, wherein R2 is methyl, methoxy or a chlorine atom, or a salt thereof.
Item 21. A pharmaceutical composition comprising a compound of item 1 or 1A or a salt thereof and a pharmaceutically acceptable carrier.
Item 22. An antimicrobial agent comprising a compound of item 1 or 1A or a salt thereof.
Item 23. A compound of item 1 or 1A or a salt thereof for use as a medicament.
Item 24. A compound of item 1 or 1A or a salt thereof for use as an antimicrobial agent.
Item 25. A compound of item 1 or 1A or a salt thereof for use in the prevention or treatment of a bacterial infection.
Item 26. Use of a compound of item 1 or 1A or a salt thereof for the manufacture of a medicament for preventing or treating a bacterial infection.
Item 27. A method for preventing or treating a bacterial infection which comprises administering an effective amount of a compound of item 1 or 1A or a salt thereof to a human or an animal.
The compound of the formula (I) or a salt thereof (hereinafter sometimes to be abbreviated as compound (I)) has excellent antibacterial activity against various gram positive and gram negative bacteria, and is useful for the prevention or treatment of various infectious diseases induced by various bacteria in human, other animals and fish and is also useful as an external antimicrobial or disinfectant agent for medical instruments or the like.



BRIEF DESCRIPTION OF DRAWINGS
FIG. 1 is a graph showing the results of the animals administered with compound 2-18 in Experimental Example 2.
FIG. 2 is a graph showing the results of the animals administered with vancomycin in Experimental Example 2.



DETAILED DESCRIPTION OF THE INVENTION
Specific examples of groups in the formula (I) are as follows.
Examples of “halogen atom” include fluorine atom, chlorine atom, bromine atom, and iodine atom.
Examples of “alkyl” and “alkyl” moiety in “alkylamino”, “dialkylamino”, “alkylcarbonyl”, “cycloalkylalkylsulfonyl”, “cycloalkylalkyl”, “aminoalkyl” and “alkylsulfonyl” include straight or branched C1-6 alkyl such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, 1-ethylpropyl, isopentyl, neopentyl, tert-pentyl, hexyl, 1,2,2-trimethylpropyl, 3,3-dimethylbutyl, 2-ethylbutyl, isohexyl, 3-methylpentyl, etc.
Examples of “alkenyl” include straight or branched C2-6 alkenyl such as vinyl, 1-propenyl, 2-propenyl, 1-butenyl, 2-butenyl, 3-butenyl, l-methyl-2-propenyl, 2-pentenyl, 2-hexenyl, etc.
Examples of “alkynyl” include straight or branched C2-6 alkynyl such as ethynyl, 2-propynyl, 2-butynyl, 3-butynyl, 1-methyl-2-propynyl, 2-pentynyl, 2-hexynyl, etc.
Examples of “alkoxy” and “alkoxy” moiety in “haloalkoxy”, “alkoxycarbonyl” and “alkoxycarbonylamino” include straight or branched C1-6 alkoxy such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy, tert-butoxy, pentyloxy, isopentyloxy, neopentyloxy, tert-pentyloxy, hexyloxy, isohexyloxy, 3-methylpentyloxy, etc.
Examples of “haloalkoxy” include straight or branched C1-6 alkoxy substituted by 1 to 3 halogen atoms. Examples thereof include fluoromethoxy, difluoromethoxy, trifluoromethoxy, chloromethoxy, dichloromethoxy, trichloromethoxy, bromomethoxy, dibromomethoxy, dichlorofluoromethoxy, 2,2,2-trifluoroethoxy, 2-chloroethoxy, 3,3,3-trifluoropropoxy, 2-chloropropoxy, 3-chloropropoxy, 3-bromopropoxy, 4,4,4-trifluorobutoxy, 2-chlorobutoxy, 4-chlorobutoxy, 4-bromobutoxy, 5,5,5-trifluoropentyloxy, 5-chloropentyloxy, 6,6,6-trifluorohexyloxy, 6-chlorohexyloxy, etc. Preferable examples thereof include difluoromethoxy.
Examples of “alkenyloxy” include straight or branched C2-6 alkenyloxy such as vinyloxy, 1-propenyloxy, 2-propenyloxy, 1-butenyloxy, 2-butenyloxy, 3-butenyloxy, 1-methyl-2-propenyloxy, 2-pentenyloxy, 2-hexenyloxy, etc.
Examples of “aryl” and “aryl” moiety in “arylsulfonyl.” include C6-14 (preferably C6-10) aryl such as phenyl, naphthyl (e.g., 1-naphthyl, 2-naphthyl), etc. Preferable examples thereof include phenyl.
Examples of “5- to 10-membered aromatic heterocyclic group” and “5- to 10-membered aromatic heterocyclyl” moiety in “5- to 10-membered aromatic heterocyclylcarbonyl group” and “5- to 10-membered aromatic heterocyclylsulfonyl group” include 5- to 10-membered (preferably 5- or 6-membered) aromatic heterocyclic group containing 1 to 4 (preferably 1 to 3, more preferably 1 or 2) heteroatoms selected from a nitrogen atom, an oxygen atom and a sulfur atom. Examples thereof include furyl, thienyl, pyrrolyl, pyrazolyl, imidazoiyl, triazolyl (e.g., 1,2,3-triazolyl, 1,2,4-triazolyl), tetrazolyl, isoxazolyl, oxazolyl, furazanyl, isothiazolyl, thiazolyl, pyridyl (e.g., 2-pyridyl, 3-pyridyl, 4-pyridyl), pyridazinyl, pyrimidinyl, pyrazinyl, benzofuranyl, isobenzofuranyl, benzo[b]thiophenyl, benzo[c]thiophenyl, indolyl, isoindolyl, indolizinyl, indazolyl, benzimidazolyl, benzotriazolyl, benzoxazolyl, 1,2-benzisoxazolyl, benzothiazolyl, 1,2-benzisothiazolyl, purinyl, quinolyl, isoquinolyl, quinolizinyl, cinnolinyl, quinazolinyl, quinoxalinyl, phthalazinyl, naphthyridinyl, pteridinyl, etc. Preferable examples thereof include pyrrolyl, imidazolyl, oxazolyl, triazolyl (e.g., 1,2,3-triazolyl, 1,2,4-triazolyl), tetrazolyl, pyridyl (e.g., 2-pyridyl, 3-pyridyl, 4-pyridyl), benzimidazolyl, etc.
Examples of “alkylamino” include C1-6 alkylamino such as methylamino, ethylamino, propylamino, isopropylamino, butylamino, isobutylamino, sec-butylamino, tert-butylamino, pentylamino, isopentylamino, neopentylamino, tert-pentylamino, hexylamino, etc.
Examples of “dialkylamino” include di(C1-6 alkyl)amino such as dimethylamino, diethylamino, dipropylamino, diisopropylamino, dibutylamino, diisobutylamino, di(sec-butyl)amino, di(tert-butyl)amino, dipentylamino-, di(tert-pentyl)amino, dihexylamino, ethylmethylamino, etc.
Examples of “aminoalkyl” include amino-C1-6 alkyl such as aminomethyl, 2-aminoethyl, 3-aminopropyl, 4-aminobutyl, 5-aminopentyl, 6-aminohexyl, etc.
Examples of “cycloalkyl” and “cycloalkyl” moiety in “cycloalkyloxy”, “cycloalkylcarbonyl”, “cycloalkylalkyl” and “cycloalkylalkylsulfonyl” include C3-6 cycloalkyl such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, norbornanyl (e.g., 2-norbornanyl), etc.
Examples of “cycloalkylalkyl” include C3-6 cycloalkyl-C1-6 alkyl such as cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl, cyclohexylmethyl, cycloheptylmethyl, cyclooctylmethyl, norbornanylmethyl (e.g., norbornan-2-ylmethyl), etc.
Examples of “cyclic amino group” includes a 4- to 7-membered (preferably 5- or 6-membered) cyclic amino group containing one nitrogen atom and optionally further containing one heteroatom selected from a nitrogen atom, an oxygen atom and a sulfur atom. Examples thereof include 1-azetidinyl, 1-pyrrolidinyl, 1-imidazolidinyl, 1-pyrazolidinyl, piperidino, 1-piperazinyl, morpholino, thiomorpholino, 1-azepanyl, 1,4-oxazepan-4-yl, etc. Preferable examples thereof include 1-pyrrolidinyl, piperidino, 1-piperazinyl, morpholino, thiomorpholino, etc.
Examples of “alkoxycarbonyl” include C1-6 alkoxy-carbonyl wherein the alkoxy moiety is C1-6 alkoxy. Examples thereof include methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, butoxycarbonyl, isobutoxycarbonyl, sec-butoxycarbonyl, tert-butoxycarbonyl, pentyloxycarbonyl, hexyloxycarbonyl, etc.
Examples of “alkoxycarbonylamino” include C1-6 alkoxy-carbonylamino wherein the alkoxy moiety is C1-6 alkoxy. Examples thereof include methoxycarbonylamino, ethoxycarbonylamino, propoxycarbonylamino, isopropoxycarbonylamino, butoxycarbonylamino, isobutoxycarbonylamino, sec-butoxycarbonylamino, tert-butoxycarbonylamino, pentyloxycarbonylamino, hexyloxycarbonylamino, etc.
Examples of “alkylcarbonyl” include C1-6 alkyl-carbonyl wherein the alkyl moiety is C1-6 alkyl. Examples thereof include acetyl, ethylcarbonyl, propylcarbonyl, isopropylcarbonyl, butylcarbonyl, isobutylcarbonyl, sec-butylcarbonyl, tert-butylcarbonyl, pentylcarbonyl, hexylcarbonyl, etc.
Examples of “cycloalkyloxy” include C3-8 cycloalkyloxy such as cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy, cycloheptyloxy, cyclooctyloxy, etc.
Examples of “cycloalkylcarbonyl” include C3-8 cycloalkylcarbonyl such as cyclopropylcarbonyl, cyclobutylcarbonyl, cyclopentylcarbonyl, cyclohexylcarbonyl, cycloheptylcarbonyl, cyclooctylcarbonyl, etc.
Examples of “5- to 10-membered aromatic heterocyclylcarbonyl group” include a 5- to 10-membered (preferably 5- or 6-membered) aromatic heterocyclylcarbonyl group wherein the heterocyclyl moiety contains 1 to 4 (preferably 1 to 3, more preferably 1 or 2) heteroatoms selected from a nitrogen atom, an oxygen atom and a sulfur atom. Examples of the heterocyclyl moiety are same as the examples of the 5- to 10-membered aromatic heterocyclic group mentioned above. Preferable examples of “5- to 10-membered aromatic heterocyclylcarbonyl group” include pyridylcarbonyl (e.g., 2-pyridylcarbonyl, 3-pyridylcarbonyl, 4-pyridylcarbonyl).
Examples of “arylsulfonyl” include C6-14 (preferably C6-10) arylsulfonyl such as phenylsulfonyl, naphthylsulfonyl (e.g., 1-naphthylsulfonyl, 2-naphthylsulfonyl), etc. Preferable examples thereof include phenylsulfonyl.
Examples of “cycloalkylalkylsulfonyl” include C3-8 cycloalkyl-C3-6 alkylsulfonyl such as cyclopropylmethylsulfonyl, cyclobutylmethylsulfonyl, cyclopentylmethylsulfonyl, cyclohexylmethylsulfonyl, cycloheptylmethyl sulfonyl, cyclooctylmethylsulfonyl, norbornanylmethylsulfonyl (e.g., norbornan-2-ylmethylmethylsulfonyl), etc.
Examples of “5- to 10-membered aromatic heterocyclylsulfonyl group” include a 5- to 10-membered (preferably 5- or 6-membered) aromatic heterocyclylsulfonyl group wherein the heterocyclyl moiety contains 1 to 4 (preferably 1 to 3, more preferably 1 or 2) heteroatoms selected from a nitrogen atom, an oxygen atom and a sulfur atom. Examples of the heterocyclyl moiety are same as the examples of the 5- to 10-membered aromatic heterocyclic group mentioned above. Preferable examples of “5- to 10-membered aromatic heterocyclylsulfonyl group” include imidazolylsulfonyl.
Examples of “alkylsulfonyl” include C1-6 alkylsulfonyl wherein the alkyl moiety is C1-6 alkyl. Examples thereof include methylsulfonyl, ethylsulfonyl, propylsulfonyl, isopropylsulfonyl, butylsulfonyl, isobutylsulfonyl, sec-butylsulfonyl, tert-butylsulfonyl, pentylsulfonyl, hexylsulfonyl, etc.
Examples of “cyclopropyl optionally substituted by 1 to 3 halogen atoms” include cyclopropyl optionally substituted by 1 fluorine atom such as cyclopropyl, 2-fluorocyclopropyl, etc.
Examples of “phenyl optionally substituted by 1 to 3 halogen atoms” include phenyl substituted by two fluorine atoms such as 2,4-difluorophenyl, etc.
Examples of “5- to 10-membered saturated heterocyclic group” include a 5- to 10-membered (preferably 5- or 6-membered) saturated heterocyclic group containing 1 to 4 (preferably 1 to 3, more preferably 1 or 2) heteroatoms selected from a nitrogen atom, an oxygen atom and a sulfur atom. Examples thereof include pyrrolidinyl, piperidyl, piperazinyl, morpholinyl, thiomorpholinyl, etc.
Examples of “6-membered ring optionally substituted by amino or oxo” formed by R34 and R35 include a 6-membered ring optionally containing one nitrogen atom, and said ring is optionally substituted by amino or oxo. Examples thereof include cyclohexene and dihydropyridine, each optionally substituted by amino or oxo.
Examples of “5- or 6-membered ring optionally substituted by alkyl” formed by R1 and R2 include a 5- or 6-membered (preferably 6-membered) ring containing one nitrogen atom and optionally further containing one oxygen atom, and said ring is optionally substituted by alkyl. Preferably, R1 and R2 are optionally bonded to form —O—CH2—CH(CH3)— wherein the oxygen atom is bonded to the phenyl ring of the quinolone ring as shown below.




Examples of “5- or 6-membered ring optionally substituted by oxo” formed by R4 and R5 include a 5- or 6-membered (preferably 6-membered) ring containing one nitrogen atom and optionally further containing one oxygen atom, and said ring is optionally substituted by oxo. Preferably, R4 and R5 are optionally bonded to form —CH2—O—(C═O)— wherein the carbonyl is bonded to the phenyl ring of the quinolone ring as shown below.




Examples of “5- or 6-membered ring optionally substituted by alkyl or oxo” formed by R10 and R11 include a 5- or 6-membered (preferably 5-membered) ring containing 2 or 3 nitrogen atoms, and said ring is optionally substituted by alkyl or oxo. Preferably, R10 and R11 are optionally bonded to form —(C═O)—NH—, —C(R31)═N— or —N═N— wherein R31 is a hydrogen atom or alkyl, and the nitrogen atom is bonded to the phenyl ring of the fused ring, as shown below.




Examples of “5- or 6-membered ring” formed by R12 and R13 include a 5- or 6-membered (preferably 6-membered) ring containing one nitrogen atom. Preferably, R12 and R13 are optionally bonded to form —(CH2)4— as shown below.




X is a hydrogen atom or a fluorine atom, preferably, a fluorine atom.
R is a hydrogen atom or alkyl, preferably, a hydrogen atom.
R1 is (1) cyclopropyl optionally substituted by 1 to 3 halogen atoms or (2) phenyl optionally substituted by 1 to 3 halogen atoms, preferably, cyclopropyl, 2-fluorocyclopropyl or 2,4-difluorophenyl.
R2 is a hydrogen atom; alkyl optionally substituted by 1 or 2 substituents selected from the group consisting of a halogen atom and hydroxyl; alkoxy; haloalkoxy; a halogen atom; cyano; cyclopropyl; nitro; amino; formyl; alkenyl or alkynyl, preferably, alkyl, alkoxy, haloalkoxy, a chlorine atom or cyano, more preferably, C1-6 alkyl, C1-6 alkoxy, C1-6 alkoxy substituted by 1 to 3 halogen atoms, a chlorine atom or cyano, still more preferably, methyl, methoxy or a chlorine atom.
Examples of a fused heterocyclic group of the formula (A) or (B) include a fused heterocyclic group of the formula




wherein X1 and R4 are as defined above, and said fused heterocyclic group is optionally substituted by 1 or 2 substituents selected from the group consisting of a halogen atom, cyano, nitro, hydroxy and alkyl.

Preferable examples of a fused heterocyclic group of the formula (A) or (B) include a fused heterocyclic group of the formula




wherein R4 and R5 are as defined above, and said fused heterocyclic group is optionally substituted by 1 or 2 substituents selected from the group consisting of a halogen atom, cyano, nitro, hydroxy and alkyl.

Other preferable examples of a fused heterocyclic group of the formula (A) or (B) include a fused heterocyclic group of the formula




wherein X1 and R4 are as defined above, and said fused heterocyclic group is optionally substituted by 1 or 2 substituents selected from the group consisting of a halogen atom, cyano, nitro, hydroxy and alkyl.

Examples of a group of the formula (C) include a group of the formula




wherein X2, R6 and R7 are as defined above.

Preferable examples of a group of the formula (C) include a group of the formula




wherein R6, R7 and R8 are as defined above.

In the above formulas, R6, R7 and Re are each independently,

    
    
        (a) a hydrogen atom,
        (b) a halogen atom,
        (c) cyano,
        (d) nitro,
        (e) amino,
        (f) alkyl optionally substituted by 1 to 3 substituents selected from the group consisting of a halogen atom and amino,
        (g) alkenyl,
        (h) alkynyl,
        (i) aryl,
        (j) formyl,
        (k) carboxy,
        (l) carbamoyl, or
        (m) a 5- to 10-membered aromatic heterocyclic group (e.g., pyridyl, triazolyl) optionally substituted by alkyl.
    
    


Examples of a group of the formula (D) or (E) include a group of the formula




wherein R6 is as defined above. R6 is preferably a hydrogen atom, a halogen atom, nitro or amino.

Preferably, R3 is 3-pyridyl optionally substituted by 1 or 2 substituents selected from the group consisting of

    
    
        (a) a halogen atom,
        (b) cyano,
        (c) nitro,
        (d) hydroxy,
        (e) amino,
        (f) alkyl optionally substituted by 1 to 3 substituents selected from the group consisting of a halogen atom, alkylamino, dialkylamino and hydroxy,
        (g) alkenyl,
        (h) aryl,
        (i) cycloalkyl,
        (j) alkoxy,
        (k) alkylamino,
        (l) dialkylamino,
        (m) phenylamino optionally substituted by 1 to 3 halogen atoms,
        (n) a cyclic amino group (e.g., 1-piperazinyl, morpholino) optionally substituted by alkoxycarbonyl,
        (o) formyl,
        (p) carbamoyl, and
        (q) a 5- to 10-membered aromatic heterocyclic group (e.g., triazolyl) optionally substituted by alkyl.
    
    


More preferably, R3 is a group of the formula




wherein R22 is

    
    
        (a) a halogen atom,
        (b) cyano,
        (c) nitro,
        (d) alkyl optionally substituted by 1 to 3 substituents selected from the group consisting of a halogen atom, alkylamino, dialkylamino and hydroxy,
        (e) alkenyl,
        (f) aryl,
        (g) cycloalkyl,
        (h) alkoxy,
        (i) formyl, or
        (j) carbamoyl.
    
    


Preferably, R22 is

    
    
        (a) cyano,
        (b) nitro,
        (c) aryl,
        (d) formyl, or
        (e) carbamoyl.
    
    


Preferably, R3 is 5-pyrimidinyl substituted by 1 or 2 substituents selected from the group consisting of amino, alkylamino and dialkylamino.
Preferably, R3 is 2-indolyl, 3-indolyl, 5-indolyl or 6-indolyl, each optionally substituted by 1 or 2 substituents selected from the group consisting of

    
    
        (a) a halogen atom,
        (b) cyano,
        (c) nitro,
        (d) hydroxy,
        (e) alkyl optionally substituted by 1 to 3 substituents selected from the group consisting of amino, alkoxycarbonylamino, alkylamino and dialkylamino,
        (f) alkoxy,
        (g) formyl,
        (h) carboxy, and
        (j) amino optionally substituted by 1 or 2 substituents selected from the group consisting of
        
            (i) alkoxycarbonyl,
            (ii) alkylcarbonyl optionally substituted by a substituent selected from the group consisting of
            
                (A) cycloalkyloxy optionally substituted by 1 to 3 alkyl,
                (B) alkylamino,
                (C) dialkylamino,
                (D) a cyclic amino group (e.g., morpholino, 1-piperazinyl) optionally substituted by alkoxycarbonyl, and
                (E) a halogen atom,
            
            
            (iii) phenylcarbonyl optionally substituted by 1 to 3 substituents selected from the group consisting of alkyl and alkoxy,
            (iv) cycloalkylcarbonyl,
            (v) a 5- to 10-membered aromatic heterocyclylcarbonyl group (e.g, pyridylcarbonyl) optionally substituted by alkyl optionally substituted by 1 to 3 halogen atoms,
            (vi) benzylcarbonyl optionally substituted by 1 to 3 substituents selected from the group consisting of a halogen atom and alkoxy,
            (vii) arylsulfonyl optionally substituted by alkoxy,
            (viii) cycloalkylalkylsulfonyl optionally substituted by 1 to 3 substituents selected from the group consisting of alkyl and oxo (e.g., camphorsulfonyl),
            (ix) a 5- to 10-membered aromatic heterocyclylsulfonyl group (e.g., imidazolylsulfonyl) optionally substituted by 1 to 3 alkyl, and
            (x) —C(═N—CN)—SR9 wherein R9 is alkyl.
        
        
    
    


More preferably, R3 is 2-indolyl optionally substituted by 1 or 2 substituents selected from the group consisting of

    
    
        (a) a halogen atom,
        (b) cyano,
        (c) nitro,
        (d) hydroxy,
        (e) alkyl optionally substituted by 1 to 3 substituents selected from the group consisting of amino, alkoxycarbonylamino, alkylamino and dialkylamino,
        (f) alkoxy,
        (g) formyl,
        (h) carboxy, and
        (j) amino optionally substituted by 1 or 2 substituents selected from the group consisting of
        
            (i) alkoxycarbonyl,
            (ii) alkylcarbonyl optionally substituted by a substituent selected from the group consisting of
            
                (A) cycloalkyloxy optionally substituted by 1 to 3 alkyl,
                (B) alkylamino,
                (C) dialkylamino,
                (D) a cyclic amino group (e.g., morpholino, 1-piperazinyl) optionally substituted by alkoxycarbonyl, and
                (E) a halogen atom,
            
            
            (iii) phenylcarbonyl optionally substituted by 1 to 3 substituents selected from the group consisting of alkyl and alkoxy,
            (iv) cycloalkylcarbonyl,
            (v) a 5- to 10-membered aromatic heterocyclylcarbonyl group (e.g, pyridylcarbonyl) optionally substituted by alkyl optionally substituted by 1 to 3 halogen atoms,
            (vi) benzylcarbonyl optionally substituted by 1 to 3 substituents selected from the group consisting of a halogen atom and alkoxy,
            (vii) arylsulfonyl optionally substituted by alkoxy,
            (viii) cycloalkylalkylsulfonyl optionally substituted by 1 to 3 substituents selected from the group consisting of alkyl and oxo (e.g., camphorsulfonyl),
            (ix) a 5- to 10-membered aromatic heterocyclylsulfonyl group (e.g., imidazolylsulfonyl) optionally substituted by 1 to 3 alkyl, and
            (x) —C(═N—CN)—SR9 wherein R9 is alkyl.
        
        
    
    


Examples of a group of the formula (F) or (G) include a group of the formula




wherein

R23 is a hydrogen atom or alkyl, and

R24, R25, R26 and R27 are each independently,

(a) a hydrogen atom,
(b) cyano, or
(c) nitro.
Examples of a group of the formula (K) include a group of the formula




wherein X5, X6, X7, X8 and R10 are as defined above.

Preferable examples of a group of the formula (K) include a group of the formula




wherein R10, R11, R12, R13, R14 and R15 are as defined above.

When R10 and R11 are bonded to form a 5- or 6-membered ring optionally substituted by alkyl or oxo, preferable examples of a group of the formula (K) include a group of the formula




wherein R31 is a hydrogen atom or alkyl.

When R12 and R13 are bonded to form a 5- or 6-membered ring, preferable examples of a group of the formula (K) include a group of the formula




More preferable examples of a group of the formula (K) include a group of the formula




wherein R10a is

    
    
        (a) a hydrogen atom or
        (b) alkyl, and

R11a, R13a and R15a are each independently,

        (a) a hydrogen atom,
        (b) a halogen atom,
        (c) cyano,
        (d) nitro,
        (e) amino,
        (f) alkylamino,
        (g) dialkylamino,
        (h) alkyl optionally substituted by hydroxy, or
        (i) alkenyl,

R10a and R11a are optionally bonded to form a 5- or 6-membered ring optionally substituted by alkyl or oxo,

provided that R10a, R11a, R13a and R15a are not simultaneously hydrogen atom.

    
    


Preferably, R3 is a group of the formula




wherein R16 is

    
    
        (a) a hydrogen atom,
        (b) alkyl optionally substituted by 1 to 3 substituents selected from the group consisting of cyano, alkylamino and dialkylamino,
        (c) alkenyl optionally substituted by carboxy,
        (d) formyl,
        (e) carboxy,
        (f) carbamoyl,
        (g) —C(R17)═N—OH wherein R17 is a hydrogen atom, cyano or hydroxy, or
        (h) a 5- to 10-membered aromatic heterocyclic group (e.g., tetrazolyl, pyrrolyl, oxazolyl, benzimidazolyl, triazolyl) optionally substituted by alkyl, alkoxycarbonyl, carboxy or phenyl.
    
    


More preferably, R3 is a group of the formula




wherein R16a is

    
    
        (a) alkyl optionally substituted by 1 to 3 substituents selected from the group consisting of cyano, alkylamino and dialkylamino,
        (b) alkenyl optionally substituted by carboxy,
        (c) formyl,
        (d) carboxy,
        (e) carbamoyl,
        (f) —C(R17)═N—OH wherein R17 is a hydrogen atom, cyano or hydroxy, or
        (g) a 5- to 10-membered aromatic heterocyclic group (e.g., tetrazolyl, pyrrolyl, oxazolyl, benzimidazolyl, triazolyl) optionally substituted by alkyl, alkoxycarbonyl, carboxy or phenyl.
    
    


Preferably, R3 is a group of the formula




wherein

R18 is alkyl optionally substituted by 1 to 3 substituents selected from the group consisting of a halogen atom and phenyl, and

R19 and R20 are each independently,

    
    
        (a) a hydrogen atom,
        (b) a halogen atom,
        (c) cyano,
        (d) alkyl optionally substituted by 1 to 3 substituents selected from the group consisting of
        
            (i) a halogen atom,
            (ii) cyano,
            (iii) hydroxy,
            (iv) amino,
            (v) alkylamino,
            (vi) dialkylamino, and
            (vii) a cyclic amino group (e.g., 1-piperazinyl) optionally substituted by alkyl,
        
        
        (e) alkoxy,
        (f) amino optionally substituted by 1 or 2 substituents selected from the group consisting of
        
            (i) alkylcarbonyl optionally substituted by a cyclic amino group (e.g., morpholino),
            (ii) alkylsulfonyl, and
            (iii) carbamoyl,
        
        
        (g) carboxy,
        (h) alkoxycarbonyl,
        (i) carbamoyl optionally substituted by alkyl optionally substituted by amino, alkylamino, dialkylamino or alkoxycarbonylamino,
        (j) formyl,
        (k) a 5- to 10-membered aromatic heterocyclic group (e.g., oxazolyl, benzimidazolyl), or
        (l) —CH═N—OR21 wherein R21 is a hydrogen atom or alkyl optionally substituted by alkylamino or dialkylamino.
    
    


More preferably, R3 is a group of the formula




wherein

R18a is alkyl, and

R19a is (a) a halogen atom,

    
    
        (b) cyano,
        (c) alkyl optionally substituted by 1 to 3 substituents selected from the group consisting of
        
            (i) a halogen atom,
            (ii) cyano,
            (iii) hydroxy,
            (iv) amino,
            (v) alkylamino,
            (vi) dialkylamino, and
            (vii) a cyclic amino group (e.g., 1-piperazinyl) optionally substituted by alkyl,
        
        
        (d) alkoxy,
        (e) amino optionally substituted by 1 or 2 substituents selected from the group consisting of
        
            (i) alkylcarbonyl optionally substituted by a cyclic amino group (e.g., morpholino),
            (ii) alkylsulfonyl, and
            (iii) carbamoyl,
        
        
        (f) carboxy,
        (g) alkoxycarbonyl,
        (h) carbamoyl optionally substituted by alkyl optionally substituted by amino, alkylamino, dialkylamino or alkoxycarbonylamino,
        (i) formyl,
        (j) a 5- to 10-membered aromatic heterocyclic group (e.g., oxazolyl, benzimidazolyl), or
        (k) —CH═N—OR21 wherein R21 is a hydrogen atom or alkyl optionally substituted by alkylamino or dialkylamino.
    
    


Preferable examples of compound (I) are as described below.
[Compound I-1]
A compound of the formula (I) wherein
R is a hydrogen atom;
R1 is cyclopropyl, 2-fluorocyclopropyl or 2,4-difluorophenyl;
R2 is C1-6 alkyl (e.g., methyl), C1-6 alkoxy (e.g., methoxy) or a chlorine atom; or
R1 and R2 are optionally bonded to form —O—CH2—CH(CH3)— wherein the oxygen atom is bonded to the phenyl ring of the quinolone ring; and
R3 is a fused heterocyclic group of the formula




wherein

X1 is C(R5) or N,

R4 is a hydrogen atom or C1-6 alkyl, and

R5 is (a) a hydrogen atom,

    
    
        (b) a halogen atom,
        (c) cyano,
        (d) nitro,
        (e) hydroxy,
        (f) C1-6 alkyl optionally substituted by 1 to 3 halogen atoms,
        (g) C2-6 alkynyl,
        (h) C6-14 aryl, or
        (i) C1-6 alkoxy optionally substituted by 1 to 3 halogen atoms,

when X1 is C(R5), R4 and R5 are optionally bonded to form —CH2—O—(C═O)— wherein the carbonyl is bonded to the phenyl ring of the quinolone ring,

said fused heterocyclic group is optionally substituted by 1 or 2 substituents selected from the group consisting of a halogen atom, cyano, nitro, hydroxy and C1-6 alkyl,

or a salt thereof.

[Compound I-2]

    
    


A compound of the formula (I) wherein
R is a hydrogen atom;
R1 is cyclopropyl, 2-fluorocyclopropyl or 2,4-difluorophenyl;
R2 is C1-6 alkyl (e.g., methyl), C1-6 alkoxy (e.g., methoxy) or a chlorine atom; or
R1 and R2 are optionally bonded to form —O—CH2—CH(CH3)— wherein the oxygen atom is bonded to the phenyl ring of the quinolone ring; and
R3 is a group of the formula




wherein

X2 is C(R8) or N, and

R6, R7 and R8 are each independently,

    
    
        (a) a hydrogen atom,
        (b) a halogen atom,
        (c) cyano,
        (d) nitro,
        (e) amino,
        (f) C1-6 alkyl optionally substituted by 1 to 3 substituents selected from the group consisting of a halogen atom and amino,
        (g) C2-6 alkenyl,
        (h) C2-6 alkynyl,
        (i) C6-14 aryl,
        (j) formyl,
        (k) carboxy,
        (l) carbamoyl, or
        (m) a 5- to 10-membered aromatic heterocyclic group (e.g., pyridyl, triazolyl) optionally substituted by C1-6 alkyl,

or a salt thereof.

[Compound I-3]

    
    


A compound of the formula (I) wherein
R is a hydrogen atom;
R1 is cyclopropyl, 2-fluorocyclopropyl or 2,4-difluorophenyl;
R2 is C1-6 alkyl (e.g., methyl), C1-6 alkoxy (e.g., methoxy) or a chlorine atom; and
R3 is a group of the formula




wherein

X3 and X4 are N, or

X3 is N and X4 is CH, or

X3 is CH and X4 is N, and

R6 is a hydrogen atom, a halogen atom, nitro or amino,

or a salt thereof.

[Compound I-4]

A compound of the formula (I) wherein
R is a hydrogen atom;
R1 is cyclopropyl, 2-fluorocyclopropyl or 2,4-difluorophenyl;
R2 is C1-6 alkyl (e.g., methyl), C1-6 alkoxy (e.g., methoxy) or a chlorine atom; and
R3 is a group of the formula




or a salt thereof.

[Compound I-5]

A compound of the formula (I) wherein
R is a hydrogen atom;
R1 is cyclopropyl, 2-fluorocyclopropyl or 2,4-difluorophenyl;
R2 is C1-6 alkyl (e.g., methyl), C1-6 alkoxy (e.g., methoxy) or a chlorine atom; or
R1 and R2 are optionally bonded to form —O—CH2—CH(CH3)— wherein the oxygen atom is bonded to the phenyl ring of the quinolone ring; and
R3 is a group of the formula




wherein R22 is

    
    
        (a) a halogen atom,
        (b) cyano,
        (c) nitro,
        (d) C1-6 alkyl optionally substituted by 1 to 3 substituents selected from the group consisting of a halogen atom, C1-6 alkylamino, di(C1-6 alkyl)amino and hydroxy,
        (e) C2-6 alkenyl,
        (f) C6-14 aryl,
        (g) C3-8 cycloalkyl,
        (h) C1-6 alkoxy,
        (i) formyl, or
        (j) carbamoyl,

or a salt thereof.

[Compound I-6]

    
    


A compound of the formula (I) wherein
R is a hydrogen atom;
R1 is cyclopropyl, 2-fluorocyclopropyl or 2,4-difluorophenyl;
R2 is C1-6 alkyl (e.g., methyl), C1-6 alkoxy (e.g., methoxy) or a chlorine atom; or
R1 and R2 are optionally bonded to form —O—CH2—CH(CH3)— wherein the oxygen atom is bonded to the phenyl ring of the quinolone ring; and
R3 is a group of the formula




wherein R22 is

    
    
        (a) cyano,
        (b) nitro,
        (c) C6-14 aryl,
        (d) formyl, or
        (e) carbamoyl,

or a salt thereof.

[Compound I-7]

    
    


A compound of the formula (I) wherein
R is a hydrogen atom;
R1 is cyclopropyl, 2-fluorocyclopropyl or 2,4-difluorophenyl;
R2 is C1-6 alkyl (e.g., methyl), C1-6 alkoxy (e.g., methoxy) or a chlorine atom; and
R3 is 5-pyrimidinyl substituted by 1 or 2 substituents selected from the group consisting of amino, C1-6 alkylamino and di(C1-6 alkyl)amino,
or a salt thereof.
[Compound I-8]
A compound of the formula (I) wherein
R is a hydrogen atom;
R1 is cyclopropyl, 2-fluorocyclopropyl or 2,4-difluorophenyl;
R2 is C1-6 alkyl (e.g., methyl), C1-6 alkoxy (e.g., methoxy) or a chlorine atom; and
R3 is 2-indolyl optionally substituted by 1 or 2 substituents selected from the group consisting of


    
    
        (a) a halogen atom,
        (b) cyano,
        (c) nitro,
        (d) hydroxy,
        (e) C1-6 alkyl optionally substituted by 1 to 3 substituents selected from the group consisting of amino, C1-6 alkoxy-carbonylamino, C1-6 alkylamino and di(C1-6 alkyl)amino,
        (f) C1-6 alkoxy,
        (g) formyl,
        (h) carboxy, and
        (j) amino optionally substituted by 1 or 2 substituents selected from the group consisting of
        
            (i) C1-6 alkoxy-carbonyl,
            (ii) C1-6 alkyl-carbonyl optionally substituted by a substituent selected from the group consisting of
            
                (A) C3-8 cycloalkyloxy optionally substituted by 1 to 3 C1-6 alkyl,
                (B) C1-6 alkylamino,
                (C) di(C1-6 alkyl)amino,
                (D) a cyclic amino group (e.g., morpholino, 1-piperazinyl) optionally substituted by C1-6 alkoxy-carbonyl, and
                (E) a halogen atom,
            
            
            (iii) phenylcarbonyl optionally substituted by 1 to 3 substituents selected from the group consisting of C1-6 alkyl and C1-6 alkoxy,
            (iv) C3-8 cycloalkyl-carbonyl,
            (v) a 5- to 10-membered aromatic heterocyclylcarbonyl group (e.g., pyridylcarbonyl) optionally substituted by C1-6 alkyl optionally substituted by 1 to 3 halogen atoms,
            (vi) benzylcarbonyl optionally substituted by 1 to 3 substituents selected from the group consisting of a halogen atom and C1-6 alkoxy,
            (vii) C6-14 arylsulfonyl optionally substituted by C1-6 alkoxy,
            (viii) C3-8 cycloalkyl-C1-6 alkylsulfonyl optionally substituted by 1 to 3 substituents selected from the group consisting of C1-6 alkyl and oxo (e.g., camphorsulfonyl),
            (ix) a 5- to 10-membered aromatic heterocyclylsulfonyl group (e.g., imidazolylsulfonyl) optionally substituted by 1 to 3 C1-6 alkyl, and
            (x) —C(═N—CN) —SR9 wherein R9 is C1-6 alkyl,

or a salt thereof.

[Compound I-9]

        
        
    
    


A compound of the formula (I) wherein
R is a hydrogen atom;
R1 is cyclopropyl, 2-fluorocyclopropyl or 2,4-difluorophenyl;
R2 is C1-6 alkyl (e.g., methyl), C1-6 alkoxy (e.g., methoxy) or a chlorine atom; and
R3 is a group of the formula




wherein

R23 is a hydrogen atom or C1-6 alkyl, and

R24, R25, R26 and R27 are each independently,

    
    
        (a) a hydrogen atom,
        (b) cyano, or
        (c) nitro,

or a salt thereof.

[Compound I-10]

    
    


A compound of the formula (I) wherein
R is a hydrogen atom;
R1 is cyclopropyl, 2-fluorocyclopropyl or 2,4-difluorophenyl;
R2 is C1-6 alkyl (e.g., methyl), C1-6 alkoxy (e.g., methoxy) or a chlorine atom; and
R3 is a group of the formula




wherein

R28 is a hydrogen atom or hydroxy, and

R29 is a hydrogen atom or C1-6 alkyl,

or a salt thereof.

[Compound I-11]

A compound of the formula (I) wherein
R is a hydrogen atom;
R1 is cyclopropyl, 2-fluorocyclopropyl or 2,4-difluorophenyl;
R2 is C1-6 alkyl (e.g., methyl), C1-6 alkoxy (e.g., methoxy) or a chlorine atom; and
R3 is a group of the formula




wherein

R10, R12 and R14 are each independently,

    
    
        (a) a hydrogen atom or
        (b) C1-6 alkyl, and

R11, R13 and R15 are each independently,

        (a) a hydrogen atom,
        (b) a halogen atom,
        (c) cyano,
        (d) nitro,
        (e) amino,
        (f) C1-6 alkylamino,
        (g) di(C1-6 alkyl)amino,
        (h) C1-6 alkyl optionally substituted by hydroxy, or
        (i) C2-6 alkenyl, or

R10 and R11 are optionally bonded to form —(C═O)—NH—, —C(R31)═N— or —N═N— wherein R31 is a hydrogen atom or C1-6 alkyl, and the nitrogen atom is bonded to the phenyl ring of the fused ring, or

R12 and R13 are optionally bonded to form —(CH2)4—,

or a salt thereof.

[Compound I-12]

    
    


A compound of the formula (I) wherein
R is a hydrogen atom;
R1 is cyclopropyl, 2-fluorocyclopropyl or 2,4-difluorophenyl;
R2 is C1-6 alkyl (e.g., methyl), C1-6 alkoxy (e.g., methoxy) or a chlorine atom; and
R3 is a group of the formula




wherein R10a is

    
    
        (a) a hydrogen atom or
        (b) C1-6 alkyl, and

R11a, R13a and R15a are each independently,

        (a) a hydrogen atom,
        (b) a halogen atom,
        (c) cyano,
        (d) nitro,
        (e) amino,
        (f) C1-6 alkylamino,
        (g) di(C1-6 alkyl)amino,
        (h) C1-6 alkyl optionally substituted by hydroxy, or
        (i) C2-6 alkenyl, and

provided that R10a, R11a, R13a and R15a are not simultaneously hydrogen atom,

or a salt thereof.

[Compound I-13]

A compound of the formula (I) wherein

R is a hydrogen atom;

R1 is cyclopropyl, 2-fluorocyclopropyl or 2,4-difluorophenyl;

R2 is C1-6 alkyl (e.g., methyl), C1-6 alkoxy (e.g., methoxy) or a chlorine atom; and

R3 is a group of the formula

    
    






wherein R31 is a hydrogen atom or C1-6 alkyl,

or a salt thereof.

[Compound I-14]

A compound of the formula (I) wherein
R is a hydrogen atom;
R1 is cyclopropyl, 2-fluorocyclopropyl or 2,4-difluorophenyl;
R2 is C1-6 alkyl (e.g., methyl), C1-6 alkoxy (e.g., methoxy) or a chlorine atom; and
R3 is a group of the formula




wherein R16a is

    
    
        (a) C1-6 alkyl optionally substituted by 1 to 3 substituents selected from the group consisting of cyano, C1-6 alkylamino and di(C1-6 alkyl)amino,
        (b) C2-6 alkenyl optionally substituted by carboxy,
        (c) formyl,
        (d) carboxy,
        (e) carbamoyl,
        (f) —C(R17)═N—OH wherein R17 is a hydrogen atom, cyano or hydroxy, or
        (g) a 5- to 10-membered aromatic heterocyclic group (e.g., tetrazolyl, pyrroryl, oxazolyl, benzimidazolyl, triazolyl) optionally substituted by C1-6 alkyl, C1-6 alkoxy-carbonyl, carboxy or phenyl,

or a salt thereof.

[Compound I-15]

    
    


A compound of the formula (I) wherein
R is a hydrogen atom;
R1 is cyclopropyl, 2-fluorocyclopropyl or 2,4-difluorophenyl;
R2 is C1-6 alkyl (e.g., methyl), C1-6 alkoxy (e.g., methoxy) or a chlorine atom; and
R3 is a group of the formula




wherein

R18a is C1-6 alkyl, and

R19a is (a) a halogen atom,

    
    
        (b) cyano,
        (c) C1-6 alkyl optionally substituted by 1 to 3 substituents selected from the group consisting of
        
            (i) a halogen atom,
            (ii) cyano,
            (iii) hydroxy,
            (iv) amino,
            (v) C1-6 alkylamino,
            (vi) di(C1-6 alkyl)amino, and
            (vii) a cyclic amino group (e.g., 1-piperazinyl) optionally substituted by C1-6 alkyl,
        
        
        (d) C1-6 alkoxy,
        (e) amino optionally substituted by 1 or 2 substituents selected from the group consisting of
        
            (i) C1-6 alkyl-carbonyl optionally substituted by a cyclic amino group (e.g., morpholino),
            (ii) C1-6 alkylsulfonyl, and
            (iii) carbamoyl,
        
        
        (f) carboxy,
        (g) C1-6 alkoxy-carbonyl,
        (h) carbamoyl optionally substituted by C1-6 alkyl optionally substituted by amino, C1-6 alkylamino, di(C1-6 alkyl)amino or C1-6 alkoxy-carbonylamino,
        (i) formyl,
        (j) a 5- to 10-membered aromatic heterocyclic group (e.g., oxazolyl, benzimidazolyl), or
        (k) —CH═N—OR wherein R21 is a hydrogen atom or C1-6 alkyl optionally substituted by C1-6 alkylamino or di(C1-6 alkyl)amino,

or a salt thereof.

[Compound I-16]

    
    


A compound of the formula (I) wherein
R is a hydrogen atom;
R1 is cyclopropyl, 2-fluorocyclopropyl or 2,4-difluorophenyl;
R2 is C1-6 alkyl (e.g., methyl), C1-6 alkoxy (e.g., methoxy) or a chlorine atom; and
R3 is a group of the formula




wherein

R30 is (a) a hydrogen atom,

    
    
        (b) a halogen atom,
        (c) cyano,
        (d) C1-6 alkyl optionally substituted by 1 to 3 substituents selected from the group consisting of a halogen atom and hydroxy,
        (e) C2-6 alkenyl,
        (f) C2-6 alkynyl,
        (g) C1-6 alkoxy,
        (h) formyl, or
        (i) —CH═N—OH,

or a salt thereof.

    
    


Examples of salts of the compound of the formula (I) include pharmaceutically acceptable salts. Suitable pharmaceutically acceptable salts of the compound of the formula (I) are conventional non-toxic salts and include, for example, a salt with a base or an acid addition salt such as a salt with an inorganic base, for example, an alkali metal salt (e.g., sodium salt, potassium salt, etc.), an alkaline earth metal salt (e.g., calcium salt, magnesium salt, etc.), an ammonium salt; a salt with an organic base, for example, an organic amine salt (e.g., trimethylamine salt, triethylamine salt, pyridine salt, picoline salt, ethanolamine salt, triethanolamine salt, dicyclohexylamine salt, N,N′-dibenzylethylenediamine salt, etc.); an inorganic acid addition salt (e.g., hydrochloride, hydrobromide, sulfate, hydrogensulfate, phosphate, etc.); an organic carboxylic or sulfonic acid addition salt (e.g., formate, acetate, trifluoroacetate, maleate, tartrate, citrate, fumarate, methanesulfonate, benzenesulfonate, toluenesulfonate, etc.); and a salt with a basic or acidic amino acid (e.g., arginine, aspartic acid, glutamic acid, etc.).
Compound (I) can be produced, for example, by a method according to the following reaction schemes.




wherein X, R1 and R2 are as defined above, R32 is alkyl and R33 is alkyl.

Step a

Compound (1) can be converted to acid halide by reacting compound (1) with a halogenating agent in the presence or absence of a solvent. The solvent includes aromatic hydrocarbons such as benzene, toluene and xylene; halogenated hydrocarbons such as dichloromethane, chloroform and carbon tetrachloride; ethers such as dioxane, tetrahydrofuran and diethyl ether; N,N-dimethylformamide (DMF); dimethyl sulfoxide (DMSO); and the like. The halogenating agent may be any conventional halogenating agents which can convert hydroxy in carboxy group into a halogen atom, and includes, for example, thionyl chloride, phosphorus oxychloride, phosphorus oxybromide, phosphorus pentachloride, phosphorus pentabromide, and the like. The amounts of compound (1) and the halogenating agent are not particularly limited, but, in case of using no solvent, the halogenating agent is usually used in a large excess amount, and in case of using a solvent, the halogenating agent is usually used in an amount of at least 1 mole, preferably 2 to 4 moles, per 1 mole of compound (1). The reaction temperature and the reaction period of time are not particularly limited, but the reaction is usually carried out at a temperature of from room temperature to about 100° C. for about 30 minutes to about 6 hours.
The obtained acid halide is reacted with magnesium salt of malonic acid monoalkyl ester to give compound (2). Magnesium salt of malonic acid monoalkyl ester can be prepared in situ from potassium salt of malonic acid monoalkyl ester such as potassium ethyl malonate in the presence of magnesium chloride and a basic compound such as triethylamine. The reaction can be carried out in a suitable solvent. The solvent used in the reaction may be any conventional solvents unless they give any undesirable effect on the reaction, and includes, for example, esters such as ethyl acetate; ethers such as diethyl ether, dioxane, tetrahydrofuran, monoglyme and diglyme; alcohols such as methanol, ethanol and isopropanol; aromatic hydrocarbons such as benzene, toluene and xylene; aliphatic hydrocarbons such as n-hexane, heptane, cyclohexane and ligroin; amines such as pyridine and N,N-dimethylaniline; halogenated hydrocarbons such as chloroform, dichloromethane and carbon tetrachloride; aprotic polar solvents such as DMF, DMSO and hexamethylphosphoric triamide (HMPA); and a mixture of these solvents. The reaction is usually carried out at a temperature of from about 0° C. to about 150° C., preferably from about 0° C. to about 120° C., for about 0.5 to about 20 hours. Potassium salt of malonic acid monoalkyl ester is usually used in an amount of at least 1 mole, preferably 1 to 2 moles, per 1 mole of compound (1). Magnesium chloride and the basic compound are usually used in an amount of at least 1 mole, preferably 1 to 2 moles, per 1 mole of compound (1).
Step b
Compound (3) can be prepared by reacting compound (2) with trialkyl orthoformate such as trimethyl orthoformate and triethyl orthoformate in acetic anhydride. The reaction is usually carried out at a temperature of from about 0° C. to about 200° C., preferably from about 0° C. to about 150° C., for about 0.5 to about 20 hours. Trialkyl orthoformate is usually used in an amount of at least 1 mole, preferably 1 to 10 moles, per 1 mole of compound (2).
Step c
Compound (4) can be prepared by reacting compound (3) with compound (6).
The reaction between compound (3) and compound (6) can be carried out in a suitable solvent. The solvent employed in the reaction may be any conventional solvents unless they give any undesirable effect on the reaction, and includes, for example, alcohols such as methanol, ethanol and propanol; ethers such as diethyl ether, dioxane, tetrahydrofuran, monoglyme and diglyme; aromatic hydrocarbons such as benzene, toluene and xylene; aliphatic hydrocarbons such as n-hexane, heptane, cyclohexane and ligroin; halogenated hydrocarbons such as chloroform, methylene chloride and carbon tetrachloride; aprotic polar solvents such as DMF, DMSO and HMPA; and the like. The reaction is usually carried out at a temperature of from about 0° C. to about 150° C., preferably from room temperature to about 100° C., for about 0.1 to about 15 hours. Compound (6) is usually used in an amount of at least 1 mole, preferably 1 to 2 moles, per 1 mole of compound (3).
Step d
Compound (5) can be prepared by cyclization of compound (4).
The cyclization of compound (4) can be carried out in a suitable solvent in the presence of a basic compound. The solvent employed in the reaction may be any conventional solvents unless they give any undesirable effect on the reaction, and includes, for example, ethers such as diethyl ether, dioxane, tetrahydrofuran, monoglyme and diglyme; aliphatic hydrocarbons such as n-hexane, heptane and ligroin; halogenated hydrocarbons such as chloroform, methylene chloride and carbon tetrachloride; aprotic polar solvents such as DMF, DMSO and HMPA; and the Like. The basic compound employed in the reaction includes inorganic bases such as metallic sodium, metallic potassium, sodium hydride, sodium amide, sodium hydroxide, potassium hydroxide, sodium carbonate and potassium carbonate, metal alcoholates such as sodium methylate and sodium ethylate, organic bases such as 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU), N-benzyltrimethylammonium hydroxide and tetrabutylammonium hydroxide, and the like. The reaction is usually carried out at a temperature of from about 0° C. to about 200° C., preferably from room temperature to about 150° C., for about 0.5 to about 15 hours. The basic compound is usually used in an amount of at least 1 mole, preferably 1 to 2 moles, per 1 mole of the compound (4).




wherein X, R1, R2, R3 and R32 are as defined above.

Step a

Compound (Ia) can be prepared by reacting compound (5) and compound (7) or compound (8) in an inert solvent or without using any solvents, in the presence or absence of a basic compound, in the presence of a palladium catalyst.
Examples of inert solvents include water; ethers such as dioxane, tetrahydrofuran, diethyl ether, 1,2-dimethoxyethane, diethylene glycol dimethyl ether and ethylene glycol dimethyl ether; aromatic hydrocarbons such as benzene, toluene and xylene; alcohols such as methanol, ethanol and isopropanol; ketones such as acetone and methyl ethyl ketone; and aprotic polar solvents such as DMF, DMSO, HMPA and acetonitrile. These inert solvents can be used singly or in combinations of two or more.
The palladium catalyst used in the reaction is not particularly limited, but include, for example, tetravalent palladium catalysts such as sodium hexachloropalladate(IV) tetrahydrate and potassium hexachloropalladate(IV); divalent palladium catalysts such as palladium(II) chloride, palladium(II) bromide, palladium(II) acetate, palladium(II) acetylacetonate, dichlorobis(benzonitrile)palladium (II), dichlorobis(acetonitrile)palladium(II), dichlorobis(triphenylphosphine)palladium (II), dichlorotetramine palladium(II), dichloro(cycloocta-1,5-diene)palladium(II), palladium(II) trifluoroacetate, and 1,1′-bis(diphenylphosphino)ferrocene dichloropalladium (II) dichloromethane complex (Pd(dppf)Cl2.CH2Cl2); zerovalent palladium catalysts such as tris(dibenzylideneacetone)dipalladium(0), tris(dibenzylideneacetone)dipalladium(0) chloroform complex and tetrakis(triphenylphosphine)palladium (0), etc. These palladium catalysts are used singly or in combinations of two or more.
In the reaction, the amount of the palladium catalyst is not particularly limited, but is typically in the range from 0.000001 to 20 moles in terms of palladium relative to 1 mole of compound (5). The amount of the palladium catalyst is preferably in the range from 0.0001 to 5 moles in terms of palladium relative to 1 mole of compound (5).
This reaction advantageously proceeds in the presence of a suitable ligand. Examples of ligands of the palladium catalyst include, for example, 2,2′-bis(diphenylphosphino)-1,1′-binaphthyl (BINAP), tri-o-tolylphosphine, bis(diphenylphosphino) ferrocene, triphenylphosphine, tri-t-butylphosphine and 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (Xantphos). These ligands are used singly or in combinations of two or more.
The proportion of the palladium catalyst and ligand is not particularly limited. The amount of the ligand is about 0.1 to about 100 moles per 1 mole of the palladium catalyst, and preferably about 0.5 to about 15 moles per 1 mole of the palladium catalyst.
Various known inorganic and organic bases can be used as basic compounds.
Inorganic bases include, for example, alkali metal hydroxides such as sodium hydroxide, potassium hydroxide, cesium hydroxide and lithium hydroxide; alkali metal carbonates such as sodium carbonate, potassium carbonate, cesium carbonate and lithium carbonate; alkali metal hydrogen carbonates such as lithium hydrogen carbonate, sodium hydrogen carbonate and potassium hydrogen carbonate; alkali metals such as sodium and potassium; phosphates such as sodium phosphate and potassium phosphate; amides such as sodium amide; and alkali metal hydrides such as sodium hydride and potassium hydride.
Organic bases include, for example, alkali metal lower alkoxides such as sodium methoxide, sodium ethoxide, sodium t-butoxide, potassium methoxide, potassium ethoxide and potassium t-butoxide, and amines such as triethylamine, tripropylamine, pyridine, quinoline, piperidine, imidazole, N-ethyldiisopropylamine, dimethylaminopyridine, trimethylamine, dimethylaniline, N-methylmorpholine, 1,5-diazabicyclo[4.3.0]non-5-ene (DBN), 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU), 1,4-diazabicyclo[2.2.2]octane (DABCO), etc.
Such basic compounds can be used singly or in combinations of two or more. More preferable basic compounds used in the reaction include alkali metal carbonates such as sodium carbonate, potassium carbonate, cesium carbonate and lithium carbonate.
The basic compound is usually used in an amount of 0.5 to 10 moles per 1 mole of compound (5), and preferably 0.5 to 6 moles per 1 mole of compound (5).
Compound (7) or compound (8) is usually used in an amount of at least 1 mole per 1 mole of compound (5), and preferably about 1 to about 5 moles per 1 mole of compound (5).
The reaction can be conducted under normal pressure, under inert gas atmosphere including nitrogen, argon, etc., or under increased pressure.
The reaction proceeds usually from room temperature to about 200° C., and preferably from room temperature to about 150° C., and is usually completed in about 1 to about 30 hours. The reaction is also achieved by heating at about 100° C. to about 200° C. for about 5 minutes to about 1 hour using a microwave reactor.
Step b
Compound (Ib) can be prepared by hydrolysis of compound (Ia).
The hydrolysis of compound (Ia) can be carried out under the conditions of conventional hydrolysis, for example, in the presence of a basic compound such as sodium hydroxide, potassium hydroxide, barium hydroxide or potassium carbonate; a mineral acid such as sulfuric acid, hydrochloric acid or nitric acid; or an organic acid such as acetic acid or an aromatic sulfonic acid, in a solvent including water, alcohols such as methanol, ethanol and isopropanol; ketones such as acetone and methyl ethyl ketone; ethers such as dioxane and ethylene glycol diethyl ether; acetic acid; or a mixture thereof. The reaction is usually carried out at a temperature of from room temperature to about 200° C., preferably from room temperature to about 150° C., for about 0.1 to about 30 hours.
Reaction Scheme III
Preparation of Boronate and Boronic Acid




wherein R3 is as defined above, and Z is a bromine atom or an iodine atom.

Step a

Compound (7) can be prepared by reacting compound (9) with bis(pinacolato)diboron (10) in an inert solvent in the presence of a palladium catalyst and a basic compound.
Examples of inert solvents and palladium catalyst are same as those described in Step a in Reaction Scheme II.
The basic compound employed in the reaction includes potassium acetate, triethylamine, N-methylmorpholin, sodium carbonate, potassium carbonate, cesium carbonate, lithium carbonate, potassium phosphate and sodium hydrogen carbonate.
In the reaction, the amount of the palladium catalyst is not particularly limited, but is typically in the range from 0.000001 to 20 moles in terms of palladium relative to 1 mole of compound (9). The amount of the palladium catalyst is preferably in the range from 0.0001 to 5 moles in terms of palladium relative to 1 mole of compound (9).
The basic compound is usually used in an amount of 0.5 to 10 moles per 1 mole of compound (9), and preferably 0.5 to 6 moles per 1 mole of compound (9).
Bis(pinacolato)diboron (10) is usually used in an amount of at least 1 mole per 1 mole of compound (9), and preferably about 1 to about 5 moles per 1 mole of compound (9).
The reaction can be conducted under normal pressure, under inert gas atmosphere including nitrogen, argon, etc., or under increased pressure.
The reaction proceeds usually from room temperature to about 200° C., and preferably from room temperature to about 150° C., and is usually completed in about 1 to about 30 hours.
Step b
Compound (8) can be prepared by reacting compound (9) with trialkyl borate such as trimethyl borate, triethyl borate, tri(isopropyl) borate and tri(n-butyl) borate in an inert solvent in the presence of n-butyllithium or lithium diisopropylamide.
Examples of inert solvents are same as those described in Step a in Reaction Scheme II.
The trialkyl borate is usually used in an amount of at least 1 mole per 1 mole of compound (9), and preferably about 1 to about 5 moles per 1 mole of compound (9).
n-Butyllithium or lithium diisopropylamide is usually used in an amount of at least 1 mole per 1 mole of compound (9), and preferably about 1 to about 5 moles per 1 mole of compound (9).
The reaction is usually carried out at a temperature of from about −70° C. to about 0° C. for about 0.1 to about 15 hours.
Compound (I) of the present invention can easily be converted into a salt thereof by treating with a pharmaceutically acceptable acid or base. The acid includes inorganic acids such as hydrochloric acid, sulfuric acid, phosphoric acid and hydrobromic acid and organic acids such as oxalic acid, maleic acid, fumaric acid, malic acid, tartaric acid, citric acid, benzoic acid, lactic acid, methanesulfonic acid and propionic acid. The base includes sodium hydroxide, potassium hydroxide, calcium hydroxide, sodium carbonate, potassium hydrogen carbonate, and the like.
The compound thus obtained can easily be isolated and purified by conventional methods, such as, for example, extraction with solvents, dilution method, recrystallization, column chromatography and preparative thin layer chromatography.
Compound (I) shows an excellent antimicrobial activity against mycoplasma, Pseudomonas aeruginosa, anaerobic bacteria, resistant cells against various antimicrobials, clinically isolated bacteria, and gram negative and gram positive bacteria such as Clostridium difficile, Enterococcus faecalis and Staphylococcus pyogenes and hence is useful as an antimicrobial agent for the treatment of diseases induced by these microorganisms. Compound (I) also shows low toxicity and less side effects and is characteristic in good absorbability and in sustained activity.
Since compound (I) shows an excellent antimicrobial activity against Clostridium difficile, it is useful for the prevention or treatment of intestinal infections including antibiotics-associated diarrhea (AAD) such as Clostridium difficile-associated diarrhea (CDAD).
The compounds of the present invention are usually used in the form of a usual pharmaceutical preparation. The pharmaceutical preparation can be prepared in admixture with conventional pharmaceutically acceptable diluents or carriers, such as fillers, bulking agents, binding agents, wetting agents, disintegrators, surfactants and lubricating agents. The pharmaceutical preparation includes various preparations suitable for treatment of the diseases, for example, tablets, pills, powders, solutions, suspensions, emulsions, granules, capsules, suppositories, injections such as solutions and suspensions, and the like. In the preparation of tablets, there may be used any conventional carriers, for example, excipients such as lactose, white sugar, sodium chloride, glucose, urea, starches, calcium carbonate, kaolin, crystalline cellulose and silicate, binding agents such as water, ethanol, propanol, simple syrup, glucose solution, starch solution, gelatin solution, carboxymethyl cellulose, shellac, methyl cellulose, potassium phosphate and polyvinylpyrrolidone, disintegrators such as dry starch, sodium alginate, agar powder, laminaran powder, sodium hydrogen carbonate, calcium carbonate, polyoxyethylene sorbitan fatty acid esters, sodium lauryl sulfate, stearic monoglyceride, starches and lactose, disintegration inhibitors such as white sugar, stearin, cacao butter and hydrogenated oils, absorption promoters such as quaternary ammonium salts and sodium lauryl sulfate, wetting agents such as glycerin and starches, adsorbents such as starches, lactose, kaolin, bentonite and colloidal silicates, lubricants such as purified talc, stearates, boric acid powder and polyethylene glycol, and the like. The tablets may also be coated with conventional coating agents, for example, may be in the form of a sugar coated tablet, a gelatin-coated tablets, an enteric coating tablet, a film coating tablet, or a double or multiple layers tablet. In the preparation of pills, there may be used conventional carriers, including excipients such as glucose, lactose, starches, cacao butter, hydrogenated vegetable oils, kaolin and talc, binding agents such as gum arabic powder, tragacanth powder, gelatin and ethanol, disintegrators such as laminaran and agar, and the like. In the preparation of suppositories, there may be used conventional carriers, such as, for example, polyethylene glycol, cacao butter, higher alcohols, higher alcohol esters, gelatin and semi-synthesized glycerides. In the preparation of injections, the solutions, emulsions or suspensions of the compounds are sterilized and are preferably made isotonic with the body liquid. These solutions, emulsions and suspensions are prepared by admixing the active compound with a conventional diluent, such as water, aqueous lactic acid solution, ethyl alcohol, propylene glycol, ethoxylated isostearyl alcohol, polyoxylated isostearyl alcohol or polyoxyethylene sorbitan fatty acid esters. The preparations may also be incorporated with sodium chloride, glucose or glycerin in an amount sufficient to make them isotonic with the body liquid. The preparations may also be incorporated with conventional solubilizers, buffering agents, anesthetizing agents, and further, with coloring agents, preservatives, perfumes, flavors, sweetening agents, and other medicaments. The preparations in the form of a paste, cream or gel may be prepared by using as a diluent such as white petrolatum, paraffin, glycerin, cellulose derivatives, polyethylene glycol, silicone, bentonite, or the like. When the compound of the active ingredient precipitates in the injection, an acid such as, for example, methanesulfonic acid, propionic acid, hydrochloric acid, succinic acid or lactic acid may be added to the injection as required to preserve the injection in a stable solution.
Compound (I) may be contained in any amount in the preparations, and are usually contained in an amount of from 1 to 70% by weight based on the whole weight of the preparations.
The pharmaceutical preparations of the present invention can be administered in any methods. Suitable method for administration may be selected in accordance with the preparation form, age and sex of patients, severity of the diseases, and the like. For instance, tablets, pills, solutions, suspensions, emulsions, granules and capsules are administered in oral route. In case of injection, it is administered intravenously in a single form or together with an auxiliary liquid such as glucose or amino solution. The injections may also be administered in intramuscular, intracutaneous, subcutaneous, or intraperitoneal route. Suppositories are administered in intrarectal route.
The dosage of the pharmaceutical preparations of the present invention may vary according to administration methods, age and sex of patients, severity of the diseases, and the like, usually in the range of about 0.1 to about 100 mg, more preferably in the range of about 0.1 to about 50 mg, of compound (I) per 1 kg body weight of the patient per day. The preparation is usually administered by dividing into 2 to 4 times per day.
The present invention is illustrated by the following Examples, Experimental Examples and Preparation Examples. It is to be understood that the present invention is not limited to these Examples, Experimental Examples or Preparation Examples and various changes and modifications can be made without departing from the scope and spirit of the present invention.
EXAMPLES




In our work, Suzuki coupling was employed as key reaction to construct our final products. For the coupling, the corresponding iodo-intermediates could be prepared through well-known methods that were wildly used to synthesis of quinolones before (General Scheme I).
Example 1
Synthesis of Intermediate 5a (R2=Me)
1.1. Compound 2: A mixture of compound 1 (2 g, 6.71 mmol) and thionyl chloride (9.8 mL) was refluxed for 3 hr, and then concentrated to give acid chloride. To the residue was added dry EtOAc (10 mL) and then the mixture was concentrated.
A mixture of potassium ethyl malonate (1.6 g, 9.40 mmol) and MgCl2 (1.91 g, 20.13 mmol) in dry EtOAc was stirred for 30 min below 50° C. To the mixture was added Et3N (2.83 mL, 20.13 mmol) below 50° C. Then, the mixture was refluxed for 1 hr. To the mixture was added dropwise a solution of the acid chloride in dry EtOAc (10 mL) at 50-70° C. and then the mixture was refluxed for 1.5 hr. Water (30 mL) and 5 N HCl (30 mL) were added to the reaction mixture under ice-cooling. The EtOAc solution was washed with water, dried and concentrated to give compound 2 as a yellow oil, which was used in the next step without purification.
1.2. Compound 3: A mixture of compound 2 (11 g, 29.88 mmol), triethyl orthoformate (7.47 mL, 44.82 mmol) and acetic anhydride (6.77 mL, 71.72 mmol) was heated at 150° C. for 1 hr, and then concentrated to give compound 3, which was used in the next step without purification.

1.3. Compound 4: To compound 3 (obtained above) were added EtOH (50 mL) and cyclopropylamine (2.48 mL, 35.86 mmol). The mixture was stirred for 30 min and concentrated to give compound 4, which was used in the next step without purification.

1.4. Intermediate 5a: Compound 4 (obtained above) was dissolved in dry DMSO (100 mL). K2CO3 (16.52 g, 119.53 mmol) was added to the solution. The reaction mixture was stirred at 100° C. for 1 hr. When TLC (EtOAc/dipropyl ether=1/1) indicated the reaction was completed, the mixture was cooled to room temperature, poured into water, and extracted with EtOAc. The organic layer was washed with brine, dried and concentrated to give a yellow solid which was recrystallized from EtOAc. Intermediate 5a was obtained as a white solid in 75% overall yield. 1H NMR (400 MHz, DMSO) δ 8.60 (s, 1H), 7.70 (d, J=7.8 Hz, 1H), 4.29-4.14 (m, 3H), 2.96 (s, 3H), 1.28 (t, J=7.1 Hz, 3H), 1.14 (q, J=7.0 Hz, 2H), 0.87-0.76 (m, 2H).

The following compounds were synthesized according to General Scheme I.
Example 2
Intermediate 5b (R2═OMe): 1H NMR (400 MHz, DMSO) δ 8.51 (s, 1H), 7.69 (d, J=7.7 Hz, 1H), 4.23 (dd, J=14.0, 6.9 Hz, 2H), 4.03 (s, 1H), 3.80 (s, 3H), 1.28 (t, J=7.0 Hz, 3H), 1.09 (d, J=6.2 Hz, 2H), 0.97 (m, 2H).
Example 3
Intermediate 5c (R2═Cl): 1H NMR (400 MHz, DMSO) δ 8.61 (s, 1H), 7.81 (d, J 7.6 Hz, 1H), 4.23 (m, 3H), 1.28 (t, J=7.1 Hz, 3H), 1.21-1.08 (dd, J=7.1, 2.2 Hz, 2H), 0.99-0.92 (m, 2H).
Example 4
Intermediate 5d: 1H NMR (400 MHz, CDCl3) δ 8.59-8.51 (d, J=3.1 Hz, 1H), 8.03-7.92 (d, J=7.5 Hz, 1H), 4.98-4.73 (dddd, J=62.9, 6.3, 4.9, 3.4 Hz, 1H), 4.44-4.34 (q, J=7.1 Hz, 211), 3.91-3.83 (dt, J=8.6, 5.4 Hz, 1H), 2.95-2.88 (s, 3H), 1.59-1.48 (m, 111), 1.45-1.38 (t, J=7.1 Hz, 3H), 1.35-1.18 (m, 1H).
Example 5
Intermediate 5e: 1H NMR (400 MHz, CDCl3) δ 8.51-8.43 (d, J=2.0 Hz, 1H), 7.94-7.86 (d, J=7.6 Hz, 1H), 4.90-4.65 (dddd, J=62.7, 6.0, 5.1, 3.3 Hz, 1H), 4.37-4.28 (q, J=7.1 Hz, 2H), 3.80-3.76 (s, 3H), 3.75-3.69 (dt, J=8.7, 5.5 Hz, 1H), 1.61-1.47 (m, 2H), 1.46-1.30 (m, 4H).
Example 6
Intermediate 5f: 1H NMR (400 MHz, DMSO) δ 8.65 (s, 1H), 7.48 (d, J=8.16 Hz, 1H), 4.79 (q, J=6.65 Hz, 1H), 4.62 (dd, J=1.82, 11.36 Hz, 1H), 4.44 (dd, J=2.20, 11.36 Hz, 1H), 4.23 (qd, J=2.95, 7.09 Hz, 2H), 1.40 (d, J=6.65 Hz, 3H), 1.28 (t, J=7.09 Hz, 3H).








General Scheme II outlined the preparation of required boronic acids and boronates. They are readily prepared through general methods.
Example 7
Synthesis of Boronic Acid 7




Reaction reagents and conditions: a. 1) NaH, THF, r.t.; 2) nBuLi, B(OiPr)3, −70° C. to 0° C.

7.1 Boronic acid 7: To a solution of compound 6 (10 g, 44.44 mmol) in dry tetrahydrofuran (350 mL) was added sodium hydride (2 g, 66.66 mmol, 80% dispersion) at 0° C. After the mixture was stirred at room temperature for 30 min, the mixture was cooled below −60° C. in a dry ice/acetone bath, and n-butyllithium (70 mL, 112 mmol, 1.6 M in hexane) was added over 30 min. The mixture was kept stirring for another 30 min, then triisopropyl borate (40 mL, 177 mmol) was added dropwise. The reaction mixture was stirred for 10 min, and then warmed to 0° C. slowly in an ice bath. HCl (5 N) was added to the mixture to adjust pH=3-4, and the mixture was stirred for 20 min. Aq. NaOH was added to the mixture to adjust pH=10. After filtration, the organic layer was separated. The aqueous layer was extracted with a mixture of ethyl acetate/THF (4/1; 2×120 mL) and EtOAc (100 mL). The aqueous layer was adjusted to pH=5-6 with HCl. The precipitate thus formed was collected by filtration and dried to give boronic acid 7 (3.5 g, 41%) as a white solid.

Example 8
Synthesis of Boronate 10




8.1 Compound 9: 2-Aminonicotinonitrile 8 (100 g, 0.839 mol) was dissolved in HOAc (800 mL). To the solution was added Na2CO3 (88.97 g, 0.839 mol). Then, Br2 (46.4 mL, 0.923 mol) was added dropwise. The reaction mixture was stirred at room temperature for 50 min. To the mixture was added water (600 mL). The mixture was cooled to about 5° C. The precipitate thus formed was collected by filtration and dried to give compound 9 (207 g, 96%).

8.2 Boronate 10: Compound 9 (50 g, 0.224 mol), bis(pinacolato)diboron (85.6 g, 0.337 mol), KOAc (44.1 g, 0.449 mol) and Pd(dppf)Cl2.CH2Cl2 (2.77 g, 3.4 mmol) were charged into a flask. Dioxane (400 mL) was added. The reaction mixture was stirred at 100° C. for 2 hr under Ar. When LC-MS indicated that the reaction was completed, the mixture was cooled to room temperature. The mixture was filtered through diatomite, concentrated, diluted with a mixture of ethyl acetate and hexane in 3/1 ratio (1000 mL), filtered through silica gel (300-400 mesh), concentrated, crystallized and dried to give boronate 10 (32 g, 66%) as a white solid.

Example 9
Synthesis of Boronate 13




9.1 Compound 12: 3-Chloropyridin-2-amine (100 g, 0.778 mol) was dissolved in acetic acid (1200 mL). To the solution was added Na2CO3 (82.4 q, 0.778 mol). Then, Br: (39.1 mL, 0.856 mmol) was added dropwise. After addition, the reaction mixture was stirred at room temperature for 30 min. To the mixture was added water (800 mL). The mixture was cooled to about 5° C. The resulting solid was collected by filtration and dried to give compound 12 (147 g, 91%) as a white solid.

9.2 Boronate 13: Compound 12 (4 g, 17.2 mmol), bis(pinacolato)diboron (4.79 g, 18.8 mmol), KOAc (3.37 g, 34.2 mmol) and Pd(dppf)Cl2.CH2Cl2 (0.210 g, 0.25 mmol) were charged into a flask. Dioxane (80 mL) was added. The mixture was stirred at 85° C. for 2 hr under Ar. When LC-MS indicated that the reaction was completed, the mixture was cooled to room temperature. The mixture was filtered through diatomite and concentrated. The residue was diluted with ethyl acetate and hexane (3/1, 100 mL), filtered through silica gel (300-400 mesh), concentrated and crystallized by n-hexane to give boronate 13 (3.4 g, 78%) as a white solid.





Example 10
Synthesis of Compound 1-2




10.1 Compound 16: Intermediate 5a (30 g, 65 mmol), boronic acid 7 (17 g, 71.6 mmol) and K2CO3 (27, 195 mmol) were charged into a flask. Dioxane (600 mL) and water (60 mL) were added. The solution was deoxygenated with N2 for 15 min. Pd(dppf)Cl2.CH2Cl2 (2.8 g, 3.24 mmol) was added to the mixture. The reaction mixture was stirred at 85° C. overnight. When the reaction was completed, the reaction mixture was cooled to room temperature. The precipitate was filtered, dissolved in water, filtered, triturated with EtOH, filtered and dried to give compound 16 (16 g, 57%) as an off-white solid. The obtained compound was pure enough for use.

The organic filtrate was concentrated. To the residue were added water, dichloromethane and EtOAc. The precipitate thus formed was collected by filtration and dissolved in HCl (5 N). After filtration to remove Pd residue, the filtrate was basified with aq. NaOH (pH=7-8). The precipitate was collected by filtration and dried to give compound 16 (3 g, 11%) as an off-white solid.
10.2 Compound 1-2: Compound 16 (33 g, 76.1 mmol) was suspended in EtOH (300 mL). Aq. NaOH (4 N, 100 mL) was added to the suspension, and the mixture was stirred at 60° C. for 2 hr. 200 mL of EtOH was evaporated under reduced pressure. To the residue was added HCl (5 N) to adjust pH=4. The resulting precipitate was filtered, triturated with EtOH, filtered and dried to give compound 1-2 (30 g, 97%) as an off-white solid. m.p.>300° C. 1H NMR (400 MHz, DMSO) δ 14.64 (s, 1H), 12.39 (s, 1H), 8.92 (s, 1H), 8.58 (s, 1H), 8.28 (s, 1H), 8.01 (m, 2H), 6.67 (d, J=9.4 Hz, 1H), 4.42 (s, 1H), 2.68 (s, 3H), 1.27 (d, J=6.4 Hz, 2H), 1.12-1.03 (m, 2H). 1C NMR (101 MHz, DMSO) δ 176.92, 165.25, 162.85, 158.16, 155.72, 152.71, 150.92, 149.62, 139.29, 138.79, 137.62, 133.70, 133.52, 131.80, 127.47, 127.38, 123.75, 123.42, 113.89, 108.05, 107.81, 107.29, 41.29, 20.64, 20.62, 10.62. HPLC-MS m/z 406 (MH+). Anal. Calcd for C22H16FN3O4: C, 65.18; H, 3.98; N, 10.37. Found: C, 63.50; H, 4.00; N, 9.91.
Example 11
Synthesis of Compound 2-18




11.1 Compound 17: Boronate 10 (14 g, 56.1 mmol), intermediate 5a (20 g, 46.7 mmol), Cs2CO3 (15.22 g, 46.7 mmol) and Pd(dppf)Cl2.CH2Cl2 (0.98 g, 1.2 mmol) were charged into a flask. Dioxane (500 mL) and water (5 mL) were added. The mixture was stirred at 110° C. overnight under Ar. The mixture was cooled to room temperature. The mixture was filtered, and the solid was washed with dioxane and ethyl acetate. The solid was dissolved in hot CH2Cl2 (1200 mL), and the solution was filtered through diatomite. The operation was repeated twice. The organic layers were combined and concentrated. To the residue was added ethyl acetate (200 mL). The solid was collected by filtration, washed with ethyl acetate (60 mL) and dried to give compound 17 (17.6 g, 90%) as a white solid.

11.2 Compound 2-18: Compound 17 (43 g, 0.101 mol) was dissolved in THF and EtOH (1/1, 500 mL). To the solution was added NaOH (60 mL, 4 N). The mixture was stirred at room temperature for 2 hr. HCl (63 mL, 4 N) was added to acidify the mixture (pH=3-4). The solid was collected by filtration, washed with EtOH (100 mL) and dried to give compound 2-18 (35.7 g, 99%) as a white solid. m.p.>300° C. 1H NMR (400 MHz, DMSO) δ 14.65 (s, 1H), 8.89 (s, 1H), 8.32-8.23 (m, 1H), 8.08 (d, J=2.09 Hz, 1H), 7.94 (d, J=8.87 Hz, 1H), 7.28 (s, 2H), 4.40 (tt, J=3.74, 7.17 Hz, 1H), 2.67 (s, 3H), 1.31-1.19 (m, 2H), 1.10-0.99 (m, 2H). 13C NMR (101 MHz, DMSO) δ 176.95, 176.92, 165.32, 159.60, 158.29, 155.86, 154.07, 152.67, 143.59, 139.32, 133.39, 133.22, 131.73, 127.13, 127.05, 116.93, 116.52, 107.96, 107.71, 107.27, 89.15, 41.32, 20.64, 20.62, 13.0.65. HPLC-MS m/z 379 (MH+). Anal. Calcd for C20H15FN4O3: C, 63.49; H, 4.00; N, 14.81. Found: C, 62.04; H, 4.20; N, 13.97.

Example 12
Synthesis of Compound 3-11




12.1 Compound 18: Boronate 13 (20 g, 75.4 mmol), intermediate 5a (24.1 g, 58.03 mmol), Cs2CO3 (26.5 g, 81.2 mmol) and Pd(dppf)Cl2.CH2Cl2 (1.42 g, 1.7 mmol) were charged into a flask. Dioxane (400 mL) and water (4 mL) were added. The mixture was stirred at 100° C. overnight under Ar. The mixture was cooled to room temperature. The mixture was filtered, and the solid was washed with dioxane and ethyl acetate. The solid was dissolved in hot CH2Cl2 (1200 mL), and the solution was filtered through diatomite. The operation was repeated twice. The organic layers were combined and concentrated. To the residue was added ethyl acetate (200 mL). The solid was collected by filtration, washed with ethyl acetate (60 mL) and dried to give compound 18 (21 g, 85%) as a white solid.

12.2 Compound 19: Compound 18 (39 g, 91.91 mmol) was dissolved in THF and EtOH (1/1, 600 mL). To the mixture was added NaOH (4 N, 60 mL). The mixture was stirred at room temperature for 2 hr. HCl (4 N, 62 mL) was added to acidify the solution (pH=3-4). The solid was collected by filtration, washed with EtOH (100 mL) and dried to give compound 19 (34 g, 98%) as a white solid.

12.3 Compound 3-11: Chloroacetaldehyde (40% in water, 80 mL) was added to a solution of compound 19 (34 g, 91.9 mmol) in EtOH (600 mL). The mixture was refluxed for 3 hr. When LC-MS indicated that the reaction was completed, the mixture was cooled to 5° C. and filtered. The solid was dried to give compound 3-11 (21 g). The mother liquid was basified (pH=7-8) with aq. NaOH. The precipitate was collected by filtration, washed with EtOH and dried to give compound 3-11 (11.5 g) as a white solid. In total, 32.5 g of compound 3-11 was obtained in 93% yield. m.p.: 307-311° C. 1H NMR (400 MHz, DMSO) δ 14.53 (s, 1H), 8.98-8.84 (m, 2H), 8.28 (d, J=1.16 Hz, 1H), 7.98 (d, J=8.83 Hz, 1H), 7.90 (d, J=0.89 Hz, 1H), 7.77 (s, 1H), 4.43 (tt, J=3.70, 7.10 Hz, 1H), 3.50-3.36 (m, 1H), 2.72 (s, 3H), 1.26 (d, J=6.80 Hz, 2H), 1.07 (d, J=18.24 Hz, 2H). 13C NMR (101 MHz, DMSO) δ 176.91, 176.88, 165.23, 158.22, 155.77, 152.84, 139.98, 139.17, 139.16, 132.44, 132.15, 131.98, 131.54, 127.86, 127.78, 127.38, 120.72, 118.97, 116.37, 108.15, 107.91, 107.37, 41.38, 20.54, 20.52, 10.72. HPLC-MS: m/z 412 (MH+). Anal. Calcd for C21H15ClFN3O3: C, 61.25; H, 3.67; N, 10.20. Found: C, 58.59; H, 3.86; N, 9.76.

Compounds listed in the following Tables were synthesized according to General Scheme III.







TABLE 1













 













Compound




MS 



No.
R3 =
R2 =
R1 =
NMR
(MH+)
HPLC





1-1 




OMe
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.63  (s, 1H), 12.41 (s, 1H), 8.82 (s, 1H), 8.69  (s, 1H), 8.38 (s, 1H), 8.05 (d, J = 9.6 Hz,  1H), 7.99 (d, J = 9.1 Hz, 1H), 6.66 (dd, J = 9.5, 1.6 Hz, 1H), 4.24 (s, 1H), 3.42 (s, 3H),  1.19 (d, J = 7.2 Hz, 4H).
422
98%


 


1-2 




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.64  (s, 1H), 12.39 (s, 1H), 8.92 (s, 1H), 8.58 (s, 1H), 8.28 (s, 1H), 8.01 (m, 2H), 6,67 (d,  J = 9.4 Hz, 1H), 4,42 (s, 1H), 2.68 (s, 3H), 1.27 (d, J = 6.4 Hz, 2H), 1.12-1.03 (m, 2H). 
406
98%


 


1-3 




OMe




1H NMR (400 MHz, DMSO) δ 14.49  (s, 1H), 12.41 (s, 1H), 8.85 (d, J = 1.3 Hz, 1H), 8.67 (s, 1H), 8.36 (s, 1H), 8.05 (d,  J = 9.6 Hz, 1H), 8.00 (d, J = 9.1 Hz, 1H),  6.77-6.54 (m, 1H), 5.24-4.97 (m, 1H),  4.29-4.10 (m, 1H), 3.44 (s, 3H),  1.89-1.59 (m, 2H).
440
98%


 


1-4 




Me




1H NMR (400 MHz, DMSO) δ 14.50  (s, 1H), 12.39 (s, 1H), 8.90 (d, J = 3.0 Hz, 1H), 8.58 (s, 1H), 8.27 (s, 1H), 8.02 (m, 2H),  6.74-6.61 (m, 1H), 5.17 (dd, J = 64.3,  3.1 Hz, 1H), 4.39 (m, 1H), 2.60 (s, 3H),  1.84-1.50 (m, 2H). 
424
98%


 


1-5 




Cl
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.22  (s, 1H), 12.42 (s, 1H), 8.94 (s, 1H), 8.61  (d, J = 2.0 Hz. 1H), 8.31 (d, J = 2.0 Hz, 1H),  8.20 (d, J = 8.5 Hz, 1H), 8.03 (d, J = 9.6 Hz,  1H), 6.67 (d, J = 9.5 Hz, 1H), 4.51-4.34  (m, 1H), 1.29-1.19 (m, 2H), 1.17-1.05  (m, 2H).
426
98%


 


1-7 




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.65  (s, 1H), 11.27 (s, 1H), 8.91 (s, 1H), 8.04  (d, J = 9.5 Hz, 1H), 7.98 (d, J = 8.8 Hz, 1H),  7.78 (s, 2H), 6.69 (d, J = 9.5 Hz, 1H), 4.49-4.30  (m, 1H), 2.65 (s, 3H), 1.25 (d, J = 6.7 Hz,  2H), 1.08 (s, 2H).
439
98%


 


1-8 




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.66  (s, 1H), 11.99 (s, 1H), 8.91 (s, 1H), 8.03 (d,  J = 9.1 Hz, 1H), 7.98 (d, J = 8.8 Hz, 1H),  7.60 (s, 1H), 7.57 (d, J = 11.5 Hz, 1H),  6.66 (d, J = 9.6 Hz, 1H), 4.51-4.29 (m, 1H),  1.25 (d, J = 6.3 Hz, 2H), 1.15-0.94 (m, 2H). 
423
98%


 


1-9 




OMe
Cyclopropyl
1H NMR (400 MHz, DMSO) δ  14.64 (s, 1H), 11.30 (s, 1H), 8.82 (s, 1H),  8.15-8.03 (m, 1H), 8.00-7.93 (d, J = 9.1 Hz,  1H), 7.93-7.80 (d, J = 12.9 Hz, 2H), 6.79-6.51 (d, J = 9.4 Hz, 1H), 4.26-4.15  (m, 1H), 3.51-3.38 (s, 3H), 1.31-1.09 (m, 4H). 
455
93%


 


1-10




OMe
Cyclopropyl
1H NMR (400 MHz, DMSO) δ  14.69-14.59 (s, 1H), 12.08-11.94 (s, 1H),  8.90-8.74 (s, 1H), 8.13-8.01 (d, J = 1.8 Hz, 1H),  7.99-7.91 (d, J = 9.1 Hz, 1H), 7.77-7.71 (s, 1H),  7.68-7.59 (d, J = 11.6 Hz, 1H), 6.71-6.62 (d,  J = 9.6 Hz, 1H), 4.30-4.17 (ddd, J = 11.2,  7.5, 4.7 Hz, 1H), 3.47-3.39 (s, 3H), 1.22-1.11  (m, 4H)
439
95%


 


1-11




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ  14.68 (s, 1H), 9.92 (s, 1H), 8.91 (s, 1H), 8.09  (d, J = 9.6 Hz, 1H), 7.99 (d, J = 8.8 Hz, 1H),  7.81 (s, 1H), 7.62-7.53 (m, 4H), 7.52-7.47  (m, 1H), 7.46 (s, 1H), 6.65 (d, J = 9.5 Hz, 1H),  4.65-4.23 (m, 1H), 2.70 (s, 3H), 1.24 (d,  J = 7.0 Hz, 2H), 1.07 (s, 2H).
481
98%


 


1-12




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ  14.68 (s, 1H), 12.23 (s, 1H), 8.92 (s, 1H), 8.10  (d, J = 9.5 Hz, 1H), 8.00 (d, J = 8.7 Hz, 1H),  7.87 (s, 1H), 7.70 (s, 1H), 6.70 (d, J = 9.3 Hz,  1H), 4.43 (s, 1H), 2.64 (s, 3H), 1.23 (s, 2H),  1.07 (d, J = 12.5 Hz, 2H). 
489
98%


 


1-13




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.66  (s, 1H), 10.55 (s, 1H), 8.91 (s, 1H), 8.04 (d, J = 9.5 Hz, 1H), 7.99 (d, J = 8.7 Hz, 1H),  7.84 (s, 1H), 7.74 (s, 1H), 6.68 (d, J = 9.4 Hz, 1H), 4.75 (s, 1H), 4.40 (m, 1H),  2.64 (s, 3H), 1.25 (d, J = 6.9 Hz, 2H), 1.08  (s, 2H). 
429
90%


 


1-14




Me
Cyclopropyl
1H NMR (400 MHz. DMSO) δ 14.70  (s, 1H), 11.06 (s, 1H), 8.91 (s, 1H), 8.05- 7.87 (m, 2H), 7.31 (s, 1H), 7.16 (s, 1H),  6.60 (d, J = 9.5 Hz, 1H), 4.40 (dd, J = 7.0, 3.4 Hz, 1H), 3.94 (s, 3H), 2 65 (s, 3H),  1.25 (d, J = 7.1 Hz, 2H), 1.08 (s, 2H).
435
90%


 


1-15




Me
Cyclopropyl
1H NMR (400 MHz. DMSO) δ 14.65  (s, 1H), 10.97 (s, 1H), 8.92 (s, 1H), 8.28-8.06  (m, 2H), 8.01 (d, J = 8.8 Hz, 1H), 7.95  (s, 1H), 6.74 (d, J = 8.5 Hz, 1H), 4.49-4.33  (m, 1H), 2.64 (s, 3H), 1.25 (d, J = 6.8 Hz, 2H),  1.10 (s, 2H).  
473
90%


 


1-16




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.72  (s, 1H), 11.95 (s, 1H), 8.91 (s, 1H), 7.99 (d, J = 7.9 Hz, 2H), 7.76 (s, 1H), 7.54 (d, J = 8.4 Hz,  1H), 7.47 (d, J = 8.4 Hz, 1H), 6.59 (d,  J = 9.5 Hz, 1H), 4.40 (s, 1H), 2.63 (s, 3H), 1.25  (d, J = 6.1 Hz, 2H), 1.07 (s, 2H).
405
98%


 


1-17




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.66  (s, 1H), 10.76 (s, 1H), 8.92 (s, 1H), 8.03 (d, J = 9.7 Hz, 1H), 7.99 (d, J = 8.8 Hz, 1H),  7.93 (s, 1H), 7.83 (s, 1H), 6.68 (d, J = 9.4 Hz,  1H), 2.65 (s, 3H), 1.25 (m, 2H), 1.07 (m, 2H). 
482; 484
96%


 


1-18




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.63  (s, 1H), 11.86 (s, 1H), 8.92 (s, 1H), 8.16 (m, 3H), 8.00 (d, J = 8.7 Hz, 1H), 6.80 (s, 1H),  4.42 (s, 1H), 2.65 (s, 3H), 1.26 (m, 2H),  1.09 (m, 2H). 
430
96%


 


1-19




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.69  (s, 1H), 11.10 (s, 1H), 8.90 (s, 1H), 7.97 (t, J = 9.04 Hz, 2H), 7.58 (s, 1H), 7.39 (s, 1H), 6.59  (d, J = 9.48 Hz, 1H), 4.39 (dt, J = 3.29,  6.75 Hz, 1H), 3.36 (s, 3H), 2.63 (s, 3H), 1.25  (d, J = 6.45 Hz, 2H), 1.06 (s, 2H).
419
96%


 


1-20




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.64  (s, 1H), 8.93 (s, 1H), 8.21 (s, 1H), 8.18 (s, 1H), 8.15 (d, J = 9.7 Hz, 1H), 8.02 (d, J =  8.9 Hz, 1H), 6.81 (d, J = 9.7 Hz, 1H), 6.24  (s, 2H), 4.41 (m, 2H),  2.65 (s, 4H), 1.25 (m, 2H), 1.10 (m, 2H). 
461
90%


 


1-21




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.75  (s, 1H), 12.18 (s, 1H), 8.91 (s, 1H), 8.14 (s, 1H), 7.96 (d, J = 8.8 Hz, 1H), 7.78  (d, J = 7.7 Hz, 1H), 7.60 (d, J = 7.8 Hz, 1H),  7.41 (d, J = 7.9 Hz, 1H), 7.28  (d, J = 7.4 Hz, 1H), 4.43 (s, 1H), 2.71  (s, 3H), 1.24 (s, 2H), 1.05 (s, 2H).
405
98%


 


1-22




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.75  (s, 1H), 8.91 (s, 1H), 8.16 (s, 1H), 7.96 (d, J = 8.2 Hz, 1H), 7.90 (s, 1H), 7.85  (d, J = 7.3 Hz, 1H), 7.66 (d, J = 8.5 Hz, 1H),  7.38 (d, J = 6.7 Hz, 1H), 4.42 (s, 1H),  3.74 (s, 3H), 2.69 (s, 3H), 1.23 (s, 2H), 1.05 (s, 2H).
419
95%


 


1-23




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.72  (s, 1H), 12.04 (s, 1H), 8.93 (s, 1H), 8.04 (d, J = 8.2 Hz, 1H), 7.88 (t, J = 7.5 Hz, 1H), 7.48  (d, J = 8.1 Hz, 1H), 7.35 (d, J = 9.7 Hz, 1H),  7.17 (d, J = 7.1 Hz, 1H), 6.49 (d, J = 9.7 Hz,  1H), 4.39 (s, 1H), 2.50 (s, 3H), 1.16 (m, 4H).
405
96%


 


1-24




Me
Cyclopropyl
1H NMR (400 MHz. DMSO) δ 14.82  (s, 1H), 10.88 (s, 1H), 8.95 (s, 1H), 8.20-7.94  (m, 2H), 7.86 (d, J = 30.6 Hz, 1H), 7.44  (d, J = 7.5 Hz, 1H), 7.36 (s, 1H), 6.57 (s, 1H), 4.41 (s, 1H), 2.67 (s, 3H),  1.47-0.92 (m, 4H)  
405
90%


 


1-25




Me
Cyclopropyl
1H NMR (400 MHz. DMSO) δ 14.66  (s, 1H), 12.12 (s, 1H), 8.94 (s, 1H), 6.06 (d, J = 8.5 Hz, 1H), 7.58 (s, 1H), 7.45  (d, J = 7.0 Hz, 1H), 7.13 (s, 1H), 7.02  (d, J = 8.0 Hz, 1H), 6.65 (s, 1H),  4.40 (m, 1H), 2.62 (s, 3H), 1.28-1.04  (m, 4H). 
405
90%


 


1-26




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.70  (s, 1H), 11.88 (s, 1H), 8.92 (s, 1H), 8.01 (d, J = 8.8 Hz, 2H), 7.86 (d, J = 7.8 Hz, 1H), 7.29  (s, 1H), 7.22 (d, J = 7.6 Hz, 1H), 6.80  (d, J = 9.6 Hz, 1H), 4.40 (s, 1H), 2.62  (s, 3H), 1.24 (d, J = 5.6 Hz, 2H), 1.07 (s, 2H).
405
94%


 


1-27




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.80  (s, 1H), 11.57 (s, 1H), 11.48 (s, 1H), 8.97 (s, 1H), 8.04 (d, J = 8.5 Hz, 1H), 7.82 (s, 1H), 760  (d, J = 8.1 Hz, 1H), 7.49 (d, J = 6.2 Hz, 1H),  5.86 (s, 1H), 4.45 (s, 1H), 2.68 (s, 3H), 1.30  (d, J = 6.7 Hz, 2H), 1.13 (s, 2H). 
421
98%


 


1-28




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.75  (s, 1H), 10.73 (s, 1H), 8.90 (s, 1H), 7.97 (d, J = 8.4 Hz, 1H), 7.89 (s, 1H), 7.43 (s, 1H), 7.28  (d, J = 7.6 Hz, 1H), 4.40 (s, 1H), 2.62 (s, 3H), 1.24 (s, 2H), 1.06 (s, 2H). 
466
95%


 


1-29




OMe
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.69  (s, 1H), 11.96 (s, 1H), 8.81 (s, 1H), 8.01 (d, J = 9.6 Hz, 1H), 7.95 (d, J = 9.1 Hz, 1H), 7.87  (s, 1H), 7.68 (d, J = 8.6 Hz, 1H), 7.49  (d, J = 8.6 Hz, 1H), 6.57 (dd, J = 9.5, 1.7 Hz, 1H),  4.32-4.10 (m, 1H), 3.38 (s, 3H), 1.18 (m, 4H).
421
98%


 


1-30




Cl
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.41  (s, 1H), 11.96 (s, 1H), 8.91 (s, 1H), 8.20 (d, J = 8.8 Hz, 1H), 7.95 (d, 9.1 Hz, 1H), 7.80  (s, 1H), 7.68 (d, J = 8.6 Hz, 1H), 7.49 (d, J = 8.6 Hz, 1H), 6.62  (dd, J = 9.5, 1.7 Hz, 1H), 4.32-4.10 (m, 1H),  1.30 (m, 2H), 1.18 (m, 2H).
425
96%


 


1-31




OMe
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.67  (s, 1H), 11.89 (s, 1H), 8.82 (s, 1H), 8.17- 7.90 (m, 2H), 7.85 (d, J = 8.0 Hz, 1H),  7.48 (s, 1H), 7.35 (d, J = 7.9 Hz, 1H), 6.60 (d, J = 11.2 Hz, 1H), 4.28-4.14 (m, 1H), 3.41  (s, 4H), 1.18 (m, 4H).
421
90%


 


1-32




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.69  (s, 1H), 11.78 (s, 1H), 8.91 (s, 1H), 7.98 (d, J = 8.77 Hz, 1H), 7.72 (s, 1H), 7.54 (s, 1H),  7.50-7.44 (m, 1H), 6.48 (s, 1H), 2.63 (s, 3H), 2.44 (s, 3H), 1.28-1.21 (m, 2H), 1.12-1.02 (m, 2H). 
419
96%


 


1-33




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.62  (s, 1H), 13.15 (s, 1H), 8.92 (s, 1H), 8.87 (s, 1H), 8.77 (d, J = 1.74 Hz, 1H), 8.38  (d, J = 1.97 Hz, 1H), 8.02 (d, J = 8.86 Hz, 1H), 4.42 (tt, J = 3.74, 7.15 Hz, 1H), 2.66  (s, 3H), 1.25 (q, J = 6.85 Hz, 2H), 1.08 (s, 2H).
431
96%


 


1-34




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 9.11  (s, 1H), 8.92 (s, 1H), 8.31 (d, J = 8.86 Hz, 1H), 8.16 (d, J = 8.54 Hz, 1H), 8.03  (d, J = 8.91 Hz, 1H), 6.51 (s, 1H), 4.44 (tt, J = 3.64, 7.02 Hz, 2H), 2.69 (s, 3H),  2.51 (s, 3H), 1.24 (d, J = 6.83 Hz, 2H),  1.10 (s, 2H).
420
95%


 


1-35




OMe
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.75-14.55  (m, 1H), 9.83-9.67 (d, J = 3.2 Hz, 1H),  8.89-8.73 (s, 1H), 7.96-7.86 (d, J = 9.1 Hz, 1H),  7.58-7.47 (s, 1H), 7.42-7.34 (s, 1H), 4.30-4.14  (tt, J = 7.3, 4.5 Hz, 1H), 3.52-3.39  (s, 3H), 3.11-2.95 (t, J = 7.5 Hz, 2H),  2.62-2.56 (dd, J = 8.5, 6.3 Hz, 2H), 1.21-1.12  (m, 4H).
457
99%


 


1-36




OMe
Cyclopropyl
1H NMR (400 MHz, CDCl3) δ 14.52-14.39  (s, 1H), 8.87-8.82 (s, 1H), 8.01-7.92  (m, 1H), 7.75-7.69 (s, 1H), 7.39-7.34  (t, J = 1.7 Hz, 1H), 7.21-7.18 (s, 1H), 6.79-6.69  (dd, J = 17.3, 11.0 Hz, 1H), 5.70-5.62  (d, J = 17.3 Hz, 1H), 5.54-5.44  (d, J = 11.0 Hz, 1H), 4.09-3.99  (d, J = 3.7 Hz, 1H), 3.45-3.36 (s, 3H), 3.03-2.95 (dd, J = 8.5, 6.5 Hz, 2H), 
449
85%






2.68-2.59 (dd, J = 8.7, 6.5 Hz, 2H),








1.26-1.21 (dd, J = 5.2, 1.8 Hz, 2H), 1.11-1.03 








(dt, J = 4.0, 1.9 Hz, 2H).




 


1-37




OMe
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.73-14.60  (s, 1H), 10.38-10.26 (s, 1H), 8.84-8.76 (s, 1H),  7.96-7.88 (d, J = 9.1 Hz, 1H), 7.36-7.28  (d, J = 11.2 Hz, 1H), 7.25-7.19 (s, 1H), 4.29-4.18  (ddd, J = 11.3, 7.3, 4.4 Hz, 1H), 3.47-3.43 (s, 3H), 3.07-2.98 (t, J = 7.4 Hz, 2H), 2.60-2.53  (dd, J = 8.5, 6.5 Hz. 2H), 1.21-1.08  (d, J = 5.3 Hz, 4H).
441
85%


 


1-38




OMe
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.70  (s, 1H), 9.62 (s, 1H), 8.79 (s, 1H), 7.89 (d, J = 9.2 Hz, 1H), 7.20 (d, J = 8.5 Hz, 2H),  4.39-4.16 (m, 1H), 3.42 (s, 3H), 3.03-2.88  (m, 2H), 2.54 (m, 5H), 1.16 (m, 4H). 
436
99%


 


1-39




OMe
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 15.13-14.27  (m, 1H), 10.76-10.64 (s, 5H), 8.98-8.88 (s, 1H),  8.19-8.14 (d, J = 2.2 Hz, 1H), 8.00-7.94  (d, J = 8.7 Hz, 1H), 7.75-7.70 (d, J = 2.1 Hz, 1H),  4.49-4.32 (tt, J = 7.3, 3.8 Hz, 1H), 3.03-2.95 (m, 2H), 2.69-2.84 (s, 3H), 2.62-2.56 (t, J = 7.5 Hz, 2H), 1.28-1.22 (m, 2H), 1.09-1.03 (m, 2H).
408
90%


 


1-40




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.60  (s, 1H), 12.01 (s, 1H), 8.92 (s, 1H), 8.53 (s, 1H), 8.08-7.98 (m, 2H), 7.72 (s, 1H), 6.85  (d, J = 9.75 Hz, 1H), 4.41 (s, 1H), 3.34 (s, 1H),  2.65 (s, 3H), 2.54 (s, 3H), 1.24 (d, J = 6.54 Hz,  2H), 1.09 (s, 2H).
406
96%


 


1-41




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.85-14.51  (s, 1H), 9.00-8.91 (m, 2H), 8.60-8.53 (s, 1H),  8.18-8.09 (t, J = 8.4 Hz, 2H), 8.09-8.02 (m, 1H),  7.95-7.84 (s, 1H), 7.79-7.68 (s, 1H),  4.51-4.31 (s, 1H), 2.79-2.61 (s, 3H), 1.36-1.20  (d, J = 6.9 Hz, 2H), 1.16-1.04 (s, 2H).
389
100% 


 


1-42




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 15.01-14.88  (d, J = 2.6 Hz, 1H), 8.95-8.82 (d, J = 2.5 Hz, 1H),  8.05-7.94 (d, J = 6.7 Hz, 1H), 7.89-7.77  (d, J = 9.4 Hz, 1H), 7.62-7.40 (m, 3H),  6.33-6.21 (s, 1H), 5.59-5.49 (s, 2H), 4.48- 4.35  (s, 1H), 2.86-2.76 (s, 3H), 1.30-1.15 
392
100% 






(d, J = 7.0 Hz, 2H), 1.00-0.88 (s, 2H).




 


1-43




Me
Cyclopropyl
1H NMR (400 MHz, MeOD) δ 9.05-8.91  (s, 1H), 8.87-8.77 (s, 1H), 8.43-8.36 (s, 1H),  8.14-8.06 (d, J = 7.3 Hz, 1H), 8.02-7.88  (d, J = 21.7 Hz, 2H), 7.74-7.62 (d, J = 8.7 Hz,  1H), 7.59-7.51 (s, 1H), 4.35-4.15 (s, 1H),  2.73-2.53 (m, 3H), 1.05 -0.93 (s, 2H), 
389
97%






0.85-0.71 (d, J = 8.0 Hz, 2H).




 


1-44




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.72-14.59  (s, 1H), 9.01-8.91 (s, 1H), 8.88-8.80 (s, 1H),  8.66-8.56 (d, J = 8.6 Hz, 1H), 8.25-8.16  (d, J = 8.0 Hz, 1H), 8.14-8.09 (s, 1H), 8.08-8.01  (d, J = 8.6 Hz, 1H), 7.95-7.89 (d, J = 8.7 Hz, 1H),  7.88-7.79 (d, J = 7.7 Hz, 1H), 4.51-4.35 (s, 1H),  2.75-2.67 (s, 3H), 1.30-1.19 (d, J = 6.8 Hz, 2H),  1.16-1.07 (s, 2H).
405
97.5%  


 


1-45




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.85-14.58  (s, 1H), 9.00-8.88 (s, 1H), 8.19-8.07  (d, J = 8.3 Hz, 1H), 8.07-7.94 (m, 4H),  7.68-7.58 (d, J = 6.0 Hz, 2H), 7.57-7.48 (d,  J = 8.2 Hz, 1H), 4.49-4.33 (s, 1H), 2.72-2.59  (s, 3H), 1.33-1.19 (d, 
388
98%






J = 7.4 Hz, 2H), 1.16-1.00 (s, 2H).




 


1-46




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 9.69-9.59  (s, 1H), 9.01-8.92 (d, J = 2.5 Hz, 1H),  8.69-8.58 (d, J = 2.4 Hz, 1H), 8.47-8.34  (d, J = 7.6 Hz, 1H), 8.14-8.04 (d, J = 8.1 Hz,  1H), 7.95-7.80 (t, J = 8.7 Hz, 2H),  7.57-7.46 (d, J = 7.9 Hz, 1H),  4.48-4.34 (s, 1H), 2.52-2.50  (s, 3H), 1.29-1.01 (m, 4H).
389
98%


 


1-47




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.96-14.46  (s, 1H), 12.04-11.50 (s, 1H), 8.98-8.89 (s, 1H),  8.34-8.17 (d, J = 12.3 Hz, 1H), 8.17-8.01 (m, 2H),  7.97-7.90 (d, J = 8.1 Hz, 1H), 4.48-4.36  (dd, J = 7.3, 4.1 Hz, 1H), 2.66-2.56 (s, 3H), 1.31-1.17 (d, J = 7.1 Hz, 2H), 1.15-1.03 (s, 2H). 
422
99%


 


1-48




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 9.19-9.11  (s, 1H), 8.98-8.92 (s, 1H), 8.45-8.39 (s, 1H),  8.13-8.00 (dd, J = 16.7, 8.4 Hz, 2H), 7.80-7.69  (t, J = 7.7 Hz, 1H), 7.66-7.55 (t, J = 7.7 Hz, 1H),  7.38-7.29 (d, J = 8.3 Hz, 1H), 4.47-4.34 (s, 1H),  2.65-2.54 (s, 3H), 1.28-1.07 (m, 4H). 
405
98%


 


1-49




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.69-14.45  (s, 1H), 10.31-10.19 (s, 1H), 9.06-8.94  (d, J = 3.6 Hz, 2H), 8.73-8.62 (d, J = 8.2 Hz, 1H),  8.61-8.43 (m, 2H), 8.32-8.21 (t, J = 7.5 Hz, 1H),  8.21-8.11 (m, 2H), 7.83-7.71 (d, J = 8.3 Hz, 1H),  4.67-4.52 (s, 3H), 4.50-4.39 (d, J = 7.6 Hz, 1H),  2.52-2.50 (m, 3H), 1.32-1.03 (m, 4H). 
404
100% 


 


1-50




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.72-14.45  (s, 1H), 9.88-9.78 (s, 1H), 9.58-9.48 (s, 1H),  9.02-8.92 (s, 1H), 8.70-8.60 (d, J = 9.0 Hz, 1H), 8.59-8.51 (d, J = 8.2 Hz, 1H), 8.46-8.36  (t, J = 7.9 Hz, 1H), 8.24-8.06 (t, J = 9.7 Hz, 2H), 4.78-4.67 (s, 2H), 4.53-4.40 (s, 1H),  2.82-2.71 (s, 3H), 1.37-1.18 (d, J = 6.4 Hz, 2H),  1.16-1.07 (m, 2H).
404
98%


 


1-51




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 9.10-9.01  (d, J = 4.0 Hz, 1H), 8.98-8.91 (d, J = 2.6 Hz,  1H), 8.30-8.19 (d, J = 8.4 Hz, 1H), 8.14-8.07  (s, 1H), 8.05-7.97 (t, J = 7.7 Hz, 1H), 7.96-7.89  (d, J = 8.4 Hz, 1H), 7.78-7.68 (d, J = 6.8 Hz, 1H),  7.65 7.57 (m, 1H), 4.45-4.33 (s, 1H), 2.48-2.40  (d, J = 2.8 Hz, 3H), 1.28-1.03 (m, 4H). 
389
93.6%  


 


1-52




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.78-14.66  (s, 1H), 9.06-8.97 (s, 1H), 8.96-8.88 (s, 1H),  8.54-8.46 (d, J = 8.1 Hz, 1H), 8.26-8.14  (d, J = 8.3 Hz, 1H), 8.14-8.06 (s, 1H), 8.06-7.98  (d, J = 8.6 Hz, 1H), 7.74-7.58 (d, J = 8.3 Hz,  2H), 4.51-4.29 (s, 1H), 2.73-2.60 (s, 3H), 
389
100% 






1.29-1.18 (d, J = 7.0 Hz, 2H), 1.15-1.07 (s, 2H).




 


1-53




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 8.96-8.88  (d, J = 2.4 Hz, 1H), 8.85-8.78 (s, 1H),  8.57-8.47 (d, J = 8.2 Hz, 1H), 8.25-8.13  (d, J = 8.3 Hz, 1H), 8.03-7.95 (d, J = 8.3 Hz, 1H),  7.86-7.77 (m, 2H), 7.69-7.54 (d, J = 8.7 Hz, 1H), 4.44-4.31 (s, 1H), 2.48-2.42 (s, 3H), 1.29-1.16  (d, J = 7.6 Hz, 2H), 1.15-1.02 (s, 2H). 
389
98%


 


1-54




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 9.17-9.09  (s, 1H), 9.01-8.91 (d, J = 2.7 Hz, 1H),  8.26-8.17 (d, J = 8.5 Hz, 1H), 8.15-8.06  (d, J = 8.5 Hz, 1H), 7.94-7.84 (s, 1H), 2.48-2.42  (m, 2H), 7.72-7.59 (d, J = 9.2 Hz, 2H),  7.56-7.45 (d, J = 8.3 Hz, 1H), 4.45- 4.35  (s, 1H), 2.52-2.45 (s, 3H), 1.29-1.03 (dd, J = 16.6, 7.5 Hz, 4H).
389
98%


 


1-55




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 15.08-14.78  (s, 1H), 8.95-8.83 (s, 2H), 8.48-8.37  (d, J = 6.0 Hz, 1H), 8.33-8.19 (d,  J = 8.2 Hz, 1H), 8.14-8.02 (d, J = 8.5 Hz, 1H), 7.94-7.76 (m, 2H), 7.68-7.59  (d, J = 7.1 Hz, 1H), 7.58-7.49 (t,  J = 7.2 Hz, 1H), 4.47-4.34 (s, 1H),  2.73-2.56 (s, 3H), 1.31-0.99 (m, 4H).
405
95%


 


1-56




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 9.00-8.91  (s, 1H), 8.85-8.75 (d, J = 6.1 Hz, 1H),  8.73-8.64 (d, J = 8.6 Hz, 1H), 8.13-8.05  (d, J = 8.4 Hz, 1H), 7.97-7.86 (d, J = 8.1 Hz, 1H),  7.80-7.71 (s, 1H), 7.65-7.58 (d, J = 5.8 Hz, 1H), 7.57-7.48 (d, J = 8.4 Hz, 1H), 4.46-4.35  (s, 1H), 2.57-2.52 (s, 3H), 1.28-1.04 (m, 4H).
405
96%


 


1-57




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.95-14.35  (m, 1H), 9.01-8.90 (t, J = 2.0 Hz, 1H),  8.80-8.63 (m, 2H), 8.13-8.06 (m, 1H),  8.04-7.95 (t, J = 7.8 Hz, 1H), 7.84-7.75  (d, J = 6.5 Hz, 1H), 7.52-7.41 (ddd, J = 10.0,  5.1, 2.5 Hz, 1H), 7.38-7.29 (d, J = 8.4 Hz, 1H),  4.46-4.32 (d, J = 6.9 Hz, 1H), 2.49-2.44 (s, 3H),  1.29-0.99 (m, 4H). 
405
93.3%  


 


1-58




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 8.98-8.89  (s, 1H), 8.73-8.64 (d, J = 6.6 Hz, 1H), 8.58-8.52  (s, 1H), 8.35-8.26 (d, J = 8.2 Hz, 1H),  8.12-7.99 (t, J = 10.7 Hz, 2H), 7.83-7.75  (d, J = 8.3 Hz, 1H), 7.65-7.53 (s, 1H),  4.46-4.36 (s, 1H), 2.65-2.59 (s, 3H), 1.29-1.19 
405
96.2%  






(d, J = 7.8 Hz, 2H), 1.14-1.07 (s, 2H).




 


1-59




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 8.96-8.87  (s, 1H), 8.75-8.64 (d, J = 7.2 Hz, 2H),  8.28-8.19 (s, 1H), 8.10-7.99 (d, J = 8.5 Hz, 2H),  7.90-7.80 (d, J = 9.0 Hz, 1H), 7.63-7.52 (s, 1H),  4.48-4.34 (s, 1H), 2.65-2.57 (s, 3H), 1.30-1.18  (d, J = 7.1 Hz, 2H), 1.14-1.02 (s, 2H). 
405
99%


 


1-60




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 9.77- 9.61  (s, 1H), 9.00-8.90 (d, J = 3.1 Hz, 1H), 8.75-8.62  (d, J = 5.8 Hz, 1H), 8.57-8.42 (d, J = 8.2 Hz, 1H),  8.31-8.21 (s, 1H), 8.22-8.13 (d, J = 5.3 Hz, 1H),  8.11-8.01 (d, J = 8.7 Hz, 1H), 7.94-7.81  (d, J = 8.4 Hz, 1H), 4.49-4.34 (s, 1H), 2.68-2.59
369
93.6%  






(s, 3H), 1.34-1.18 (d, J = 7.6 Hz, 2H),








1.15-1.00 (s, 2H).




 


1-61




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 9.19-9.10  (s, 1H), 9.03-8.95 (s, 1H), 8.37-8.27  (d, J = 6.9 Hz, 1H), 8.18-8.05 (m, 4H),  7.81-7.73 (d, J = 8.4 Hz, 1H), 4.52-4.42  (t, J = 5.2 Hz, 1H), 2.74-2.65 (s, 3H), 1.36-1.27  (d, J = 7.1 Hz, 2H), 1.19-1.10 (s, 2H).
405
1005


 


1-62




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.82-14.70  (s, 1H), 11.54-11.41 (s, 1H), 9.03-8.93 (s, 1H),  8.44-8.33 (d, J = 8.2 Hz, 1H), 8.14-8.01 (d,  J = 8.0 Hz, 1H), 7.84-7.75 (s, 1H), 7.58-7.51  (d, J = 7.6 Hz, 1H), 7.39-7.26 (s, 1H), 6.76-6.64  (d, J = 6.6 Hz, 1H), 4.52-4.40 (s, 1H), 2.70-2.61  (s, 3H), 1.37-1.22 (d, J = 6.8 Hz, 2H),  1.19-1.04 (s, 2H).
405
100% 


 











1-63




1H NMR (400 MHz, DMSO) δ 15.18  (s, 1H), 12.31 (s, 1H), 9.09 (s, 1H), 8.82 (d, J = 2.0 Hz, 1H), 8.45 (d, J = 1.7 Hz, 1H),  8.03 (t, J = 9.3 Hz, 2H), 7.76  (d, J = 8.4 Hz, 1H), 6.63 (d, J = 9.4 Hz, 1H),  5.00 (d, J = 6.7 Hz, 1H),  4.58 (d, J = 10.8 Hz, 1H), 4.45  (d, J = 10.0 Hz, 1H), 2.54 (s, 1H),  1.52 (d, J = 6.7 Hz, 3H). 
390
98%


 


1-64




1H NMR (400 MHz, DMSO) δ 14.96  (s, 1H), 12.35 (s, 1H), 9.10 (s, 1H), 8.68 (s, 1H), 8.34 (s, 1H), 8.01 (d, J = 9.53 Hz, 1H),  7.79 (d, J = 9.70 Hz, 1H), 6.64  (d, J = 9.45 Hz, 1H), 5.01  (d, J = 6.68 Hz, 1H), 4.60-4.54  (m, 1H), 4.46 (d, J = 9.78 Hz, 1H),  1.49 (d, J = 6.71 Hz, 3H). 
408
96%


 


1-65




1H NMR (400 MHz, DMSO) δ 9.27 (s, 1H), 8.95 (s, 1H), 8.87 (d, J = 15.4 Hz, 1H), 8.41-8.22 (m, 3H), 8.01  (t, J = 7.3 Hz, 1H), 7.85  (t, J = 7.3 Hz, 1H), 7.73 (d, J = 8.2 Hz, 1H), 4.45 (m, 1H),  2.77 (s, 3H), 1.31 (d, J = 6.2 Hz, 2H),  1.11 (s, 2H).
371
97%
















TABLE 2













 













Com-








pound




MS



No.
R3 =
R2 =
R1 =
NMR
(MH+)
HPLC





2-1




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 8.28  (s, 1H), 7.98 (s, 1H), 7.80 (s, 1H),  7.33 (d, J = 8.90 Hz, 1H), 7.16 (d,  J = 9.30 Hz, 1H), 3.66 (d, J = 3.58 Hz,  1H), 1.96 (s, 3H), 0.58 (d, J = 5.78. Hz,  1H), 0.37 (d, J = 1.61, Hz, 2H).
357
94%


 


2-2




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 8.93  (s, 1H), 8.48 (d, J = 2.77 Hz, 1H), 8.13  (s, 1H), 8.01 (d, J = 8.72 Hz, 1H), 7.61  (s, 1H), 4.50-4.30 (m, 1H), 3.49 (d,  J = 5.30 Hz, 5H), 3.38-3.29 (m, 5H),  2.66 (d, J = 15.95 Hz, 3H), 1.43 (s, 9H),  1.28-1.21 (m, 2H), 1.08 (s, 2H).
523
98%


 


2-3




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 8.92  (s, 1H), 8.79 (d, J = 5.61 Hz, 2H), 8.01  (d, J = 8.93 Hz, 1H), 7.50 (d, J = 5.50 Hz,  2H), 4.40 (s, 1H), 2.61 (s, 3H), 1.24 (d,  J = 5.97 Hz, 2H), 1.07 (s, 2H).
339
98%


 


2-4




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 9.00  (s, 2H), 8.92 (s, 1H), 8.49 (d, J = 2.73 Hz,  1H), 8.12 (s, 1H), 7.98 (t, J = 11.57 Hz, 1H),  7.56 (s, 1H), 4.44-4.34 (m, 1H), 3.64 (s, 5H),  3.26 (s, 4H), 2.62 (s, 3H), 1.23 (d, J = 6.27 Hz,  2H), 1.07 (s, 2H).
423
95%


 


2-5




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 8.93 (s, 1H),  8.71 (t, J = 26.47 Hz, 1H), 8.04 (d,  J = 8.68 Hz, 2H), 7.61 (d, J= 45.28 Hz, 1H),  4.44-4.38 (m, 1H), 2.55 (s, 2H), 2.34 (d,  J = 9.33 Hz, 3H), 1.23 (s, 2H) 1.06 (dd,  J = 4.45, 8.57 Hz, 2H).
353
95%


 


2-6




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.55 (s, 1H),  8.92 (s, 1H), 8.83 (t, J = 8.69 Hz, 1H), 8.65  (dt, J = 8.70, 17.42 Hz, 1H), 8.05 (d,  J = 8.87 Hz, 1H), 7.73-7.52 (m, 1H), 4.41  (tt J = 3.77, 7.16 Hz, 1H), 2.64 (s, 3H),  1.31-1.16 (m, 2H), 1.10-0.97 (m, 2H).
357
98%


 


2-7




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 8.93  (s, 1H), 8.85-8.61 (m, 2H), 8.03 (d, J = 6.60 Hz, 1H), 7.96 (s, 2H), 7.69 (dd, J = 5.19,  7.64 Hz, 1H), 4.41 (ddd, J = 3.87, 7.26, 10.97 Hz, 2H), 2.75-2.72 (m, 5H), 1.33-1.20  (m, 3H), 1.13-1.03 (m, 2H).
339
98%


 


2-8




Me
Cyclopropyl
1H NMR (400 MHz, MeOD) δ 8.79 (s, 1H),  7.92-7.71 (m, 2H), 7.55 (t, J = 17.62 Hz, 1H),  6.84 (t, J = 36.31 Hz, 1H), 4.16-4.04 (m, 1H),  3.02 (s, 5H), 1.09-1.01 (m, 2H), 0.81 (q,  J = 7.23 Hz, 2H). 
355
98%


 


2-9




Me
Cyclopropyl
1H NMR (400 MHz, MeOD) δ 8.06 (t,  J = 38.62 Hz, 2H), 7.68 (dd, J = 8.35, 33.76 Hz, 2H), 7.47 (d, J = 8.87 Hz, 1H), 7.13-6.77  (m, 2H), 4.33 (s, 1H), 3.97 (d, J = 7.85 Hz, 3H),  2.20-1.90 (m, 2H), 1.35-1.22 (m, 1H), 1.05 (s, 1H). 
369
98%


 


2-10




Me
Cyclopropyl
1H NMR (400 MHz, MeOD) δ 9.06 (s, 1H),  8.33 (s, 1H), 8.01 (d, J = 9.18 Hz, 1H), 7.67  (t, J = 24.14 Hz, 2H), 7.17 (s, 1H), 4.37 (s, 1H),  3.94 (s, 3H), 2.66 (s, 3H), 1.32 (d, J = 6.60 Hz,  2H), 1.07 (s, 2H). 
369
98%


 


2-11




Me
Cyclopropyl
1H NMR (400 MHz, MeOD) δ 9.05 (s, 1H),  8.29 (s, 2H), 8.09 (d, J = 7.83 Hz, 1H), 7.94  (d, J = 23.80 Hz, 2H), 7.39-7.20 (m, 2H), 7.09  (s, 1H), 4.36 (s, 1H), 2.77 (s, 3H), 1.30 (s, 2H),  1.09 (s, 2H).
466
98%


 


2-12




Me
Cyclopropyl
1H NMR (400 MHz, MeOD) δ 9.02 (s, 1H),  8.40 (d, J = 92.33 Hz, 2H), 8.16-8.03 (m, 2H),  7.98-7.80 (m, 1H), 7.75-7.50 (m, 2H), 4.34  (s, 1H), 3.82 (d, J = 24.28 Hz, 4H), 3.45 (s, 4H),  2.70 (d, J = 23.16 Hz, 3H), 1.27 (dd, J = 11.61,  24.61 Hz, 3H), 1.09 (s, 2H).
424
98%


 


2-13




Me
Cyclopropyl
1H NMR(400 MHz, DMSO) δ 14.68 (s, 1H),  8.91 (s, 1H), 8.69 (s, 1H), 7.97 (d, J = 8.46 Hz, 1H),  7.79 (s, 1H), 7.63 (s, 1H), 4.40 (s, 1H), 3.82 (d,  J = 6.95 Hz, 2H), 3.21 (s, 2H), 2.63 (d, J = 43.98 Hz,  3H), 1.22 (d, J = 5.36 Hz, 2H), 1.05 (s, 2H). 
380
97%


 


2-14




Me
Cyclopropyl
1H HMR (400 MHz, DMSO) δ 14.69 (s, 2H),  8.91 (s, 1H), 8.49 (s, 2H), 8.24 (s, 2H), 7.98 (d,  J = 8.62 Hz, 1H), 4.41 (s, 1H), 2.65 (d,  J = 31.48 Hz, 3H), 1.24 (d, J = 6.48 Hz, 2H),  1.07 (s, 2H). 
399
99%


 


2-15




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.67 (s, 1H),  8.91 (s, 1H), 8.13 (d, J = 25.11 Hz, 1H), 8.07  (s, 1H), 7.95 (dd, J = 8.95, 25.35 Hz, 2H), 7.06  (d, J = 8.71 Hz, 1H), 4.41 (s, 1H), 2.65 (d,  J = 25.72 Hz, 3H), 1.22 (d, J = 5.45 Hz, 2H),  1.05 (s, 2H).
354
99%


 


2-16




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 8.91 (s, 1H),  8.74 (s, 1H), 8.54 (t, J = 24.30 Hz, 2H), 7.99  (d, J = 8.68 Hz, 1H), 4.41 (s, 1H), 3.10 (d,  J = 17.91 Hz, 3H), 2.70 (s, 3H), 1.25 (d,  J = 5.66 Hz, 2H), 1.07 (s, 2H). 
413
99%


 


2-17




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.63 (s, 1H),  9.79 (s, 2H), 8.92 (s, 1H), 8.61 (s, 1H), 8.01  (d, J = 13.11 Hz, 2H), 4.67 (d, J = 32.94 Hz,  4H), 4.40 (s, 1H), 2.62 (s, 3H), 1.23 (s, 3H),  1.07 (s, 2H).
380
97%


 


2-18




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.65 (s, 1H),  8.89 (s, 1H), 8.27 (s, 1H), 8.07 (t, J = 6.62 Hz,  1H), 7.94 (d, J = 8.87 Hz, 1H), 7.28 (s, 2H),  4.40 (tt, J = 3.75, 7.16 Hz, 1H), 3.31 (s, 1H), 2.67 (s, 3H), 1.31-1.19 (m, 2H), 1.10-1.00  (m, 2H).
379
99%


 


2-19




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 9.28 (s, 1H),  8.93 (s, 1H), 8.70 (s, 1H), 8.36 (s, 1H), 8.03  (d, J = 8.65 Hz, 1H), 4.41 (s, 2H), 2.65  (s, 3H), 2.44 (s, 3H), 1.25 (d, J = 6.79 Hz,  2H), 1.10 (s, 2H).
420
97%


 


2-20




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 8.91 (s, 1H),  8.19 (d, J = 11.25 Hz, 3H), 7.99 (d,  J = 8.83 Hz, 1H), 7.62 (s, 1H), 4.41 (s, 2H),  2.69 (s, 3H), 1.25 (d, J = 5.80 Hz, 2H), 1.05 (s, 2H). 
397
99%


 


2-21




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.72 (s, 1H),  8.89 (s, 1H), 8.11-7.87 (m, 2H), 7.74 (s, 1H),  6.71 (s, 2H), 4.39 (s, 1H), 2.63 (d, J = 29.40 Hz,  3H), 1.20 (t, J = 25.86 Hz, 2H), 0.99 (d,  J = 41.43 Hz, 2H).
388
98%


 


2-22




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.71 (s, 1H),  8.90 (s, 1H), 8.26 (s, 1H), 7.95 (d, J = 8.81 Hz,  1H), 7.86 (s, 1H), 6.89 (s, 2H), 4.39 (s, 1H),  2.66 (s, 3H), 1.24 (d, J = 5.61 Hz, 2H), 1.06  (s, 2H).
422
98%


 


2-23




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.71 (s, 1H),  8.98 (s, 1H), 8.13-8.02 (m, 2H), 7.92 (d,  J = 14.79 Hz, 3H), 4.47 (s, 1H), 2.71 (d,  J = 23.60 Hz, 3H), 2.31 (s, 3H), 1.29 (d,  J = 5.54 Hz, 2H), 1.15 (d, J = 22.69 Hz, 2H). 
366
99%


 


2-24




OMe
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.67 (s, 1H),  8.79 (s, 1H), 8.11 (s, 1H), 7.90 (s, 1H), 7.82  (s, 1H), 6.73 (s, 2H), 4.22 (s, 1H), 3.46 (s, 3H),  3.31 (s, 2H), 1.16 (s, 4H).
404
98%


 


2-25




OMe
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.66 (s, 1H),  8.80 (s, 1H), 8.39 (s, 1H), 8.13-7.81 (m, 2H),  6.91 (s, 2H), 4.23 (s, 1H), 3.31 (s, 3H), 1.17  (d, J = 6.99 Hz, 3H).
436
99%


 


2-26




OMe
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.74 (d,  J = 61.68 Hz, 1H), 8.76 (d, J = 28.90 Hz, 1H), 8.39 (s, 1H), 7.97 (s, 1H), 7.92 (d,  J = 9.13 Hz, 1H), 4.23 (s, 1H), 3.46 (s, 3H), 1.17 (d, J = 7.13 Hz, 4H).
395
96%


 


2-27




Me
Cyclopropyl
1H NMR (400 MHz, DMSO), 8.89 (s, 1H),  7.95-7.93 (m, 2H), 7.83 (s, 1H), 7.60-6.57  (d, 1H), 4.39 (s, 1H), 2.63 (d, J = 29.40 Hz,  3H), 1.20 (t, J = 25.86 Hz, 2H), 0.99 (d,  J = 41.43 Hz, 2H). 
372
98%


 


2-28




OMe
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 9.95 (s, 1H),  8.94-8.66 (m, 1H), 8.49-8.39 (m, 1H), 8.26  (d, J = 1.30 Hz, 1H), 7.91 (dd, J = 19.79,  31.75 Hz, 2H), 4.27-4.17 (m, 1H), 3.50-3.42  (m, 3H), 1.17 (dt, J = 7.59, 17.65 Hz, 3H).
398
98%


 


2-29




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 9.95 (s, 1H), 8.92 (d, J = 13.25 Hz, 1H), 8.32 (d, J = 1.05 Hz,  1H), 8.17 (d, J = 1.69 Hz, 1H), 8.00 (t,  J = 18.18 Hz, 1H), 7.83 (d, J = 33.09 Hz, 1H),  4.40 (dt, J = 3.59, 10.71 Hz, 1H), 2.68 (d,  J = 12.78 Hz, 3H), 1.25 (q, J = 6.89 Hz, 2H), 
382
98%






1.14-0.93 (m, 2H).




 


2-30




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.64 (s, 2H),  8.90 (s, 1H), 7.97 (d, J = 8.81 Hz, 1H), 7.64  (d, J = 1.21 Hz, 1H), 7.34 (s, 1H), 4.40 (td,  J = 3.75, 7.19 Hz, 1H), 3.90 (s, 3H), 2.78-2.61  (m, 3H), 1.23 (q, J = 7.19 Hz, 2H), 1.16-0.97 (m, 2H).
384
95%


 


2-31




Me




1H NMR (400 MHz, DMSO) δ 14.64 (s, 2H),  8.90 (s, 1H), 7.97 (d, J = 8.81 Hz, 1H), 7.64  (d, J = 1.21 Hz, 1H), 7.34 (s, 1H), 4.40 (td,  J = 3.75, 7.19 Hz, 1H), 3.90 (s, 3H), 2.78-2.61  (m, 3H), 1.23 (q, J = 7.19 Hz, 2H), 1.16-0.97  (m, 2H).
406
99%


 


2-32




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.62 (s, 1H),  8.90 (s, 1H), 7.99 (d, J = 1.60 Hz, 1H), 7.95  (t, J = 10.20 Hz, 1H), 7.70-7.53 (m, 1H), 4.39  (td, J = 3.61, 7.03 Hz, 1H), 2.62 (d,  J = 19.25 Hz, 3H), 1.84 (ddd, J = 5.42, 8.33,  13.56 Hz, 1H), 1.21 (t, J = 6.56 Hz, 1H), 1.05  (d, J = 8.64 Hz, 1H), 1.03-0.96 (m, 2H), 
394
98%






0.78-0.65 (m, 2H).




 


2-33




Me




1H NMR (400 MHz, DMSO) δ 8.88 (d,  J = 3.01 Hz, 1H), 8.18 (s, 1H), 8.13 (s, 1H), 8.09 (s, 1H), 7.99 (d, J = 8.77 Hz, 1H), 7.54  (s, 1H), 5.29-5.01 (m, 1H), 4.50-4.31 (m, 1H),  2.71-2.57 (m, 2H), 1.76 (ddd, J = 9.04, 15.14,  17.62 Hz, 1H), 1.53 (d, J = 26.94 Hz, 1H).
415
98%


 


2-34




Cl
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 8.92 (s, 1H), 8.11  (d, J = 8.56 Hz, 1H), 8.02 (d, J = 0.96 Hz, 1H),  7.81 (d, J = 1.67 Hz, 1H), 4.44-4.39 (m, 2H),  1.32- 1.17 (m, 2H), 1.17-1.04 (m, 2H). 
408
94%


 


2-35




OMe
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 8.80 (s, 1H),  7.99 (s, 1H), 7.92 (d, J = 9.3 Hz, 1H), 7.69  (d, J = 12.0 Hz, 1H), 4.29-4.14 (m, 1H), 3.47  (s, 3H), 1.24-1.04 (m, 4H).
387
99%


 


2-36




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.67 (s, 1H),  8.92 (s, 1H), 8.37 (s, 1H), 8.30 (d, J = 2.3 Hz,  1H), 8.11-7.88 (m, 3H), 7.51 (s, 1H), 4.55-4.30  (m, 3H), 3.20 (m, 2H), 2.68 (s, 3H), 1.25 (d,  J = 6.4 Hz, 2H), 1.08 (d, J = 7.0 Hz, 2H).
441
98%


 


2-37




OMe




1H NMR (400 MHz, DMSO) δ 14.52 (s, 1H),  8.82 (d, J = 1.51 Hz, 1H), 8.38 (s, 1H), 8.11  (s, 1H), 7.94 (d, J = 9.20 Hz, 1H), 7.36 (s, 2H),  5.10 (ddd, J = 5.42, 8.45, 64.07 Hz, 1H),  4.24 -4.12 (m, 1H), 1.86-1.55 (m, 2H).
413
98%


 


2-38




OMe




1H NMR (400 MHz, DMSO) δ 14.55 (s, 1H),  8.82 (d, J = 1.46 Hz, 1H), 8.15 (d, J = 36.97 Hz,  1H), 7.92 (d, J = 9.24 Hz, 1H), 7.80 (s, 1H), 6.75  (s, 2H), 5.10 (ddd, J = 5.43, 8.45, 64.08 Hz, 1H),  4.29-4.12 (m, 1H), 1.93-1.53 (m, 2H).
422
98%


 


2-39




Me




1H NMR (400 MHz, DMSO) δ 14.39 (s, 1H),  8.80 (s, 1H), 8.16-8.08 (m, 2H), 7.98-7.86  (m, 2H), 7.69-7.59 (m, 1H), 7.37 (dd,  J = 5.20, 11.82 Hz, 1H), 7.26 (s, 2H), 1.67 (s, 3H).
451
99%


 


2-40




Me
Cyclopropyl
1H NMR (400 MHz, CDCl3) δ 14.60-14.29  (s, 1H), 8.96-8.89 (s, 1H), 8.05-7.96 (m, 2H),  7.48-7.40 (m, 4H), 7.40-7.33 (dt, J = 8.5, 2.8 Hz,  1H), 7.33-7.29 (s, 1H), 4.88-4.75 (s, 2H), 4.17-3.98  (s, 1H), 2.73-2.62 (s, 3H), 1.28-1.20 (m, 2H),  1.02-0.93 (s, 2H).
430
99%


 


2-41




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.83-14.68  (s, 1H), 8.99-8.81 (s, 1H), 7.96-7.89 (d,  J = 8.9 Hz, 1H), 7.88-7.81 (s, 1H), 7.36-7.20  (s, 1H), 6.19-6.08 (s, 2H), 4.47-4.31 (s, 1H), 2.75-2.60 (s, 3H), 1.36-1.10 (m, 6H), 1.10-0.94 (t, J = 3.1 Hz, 2H).
382
93%


 


2-42




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.83-14.67  (s, 3H), 8.97-8.85 (s, 3H), 8.00-7.85 (m, 6H),  7.72-7.60 (t, J = 1.7 Hz, 3H), 6.97-6.81 (dd,  J = 17.3, 11.0 Hz, 3H), 6.45-6.27 (s, 6H),  5.85-5.70 (m, 4H), 5.44-5.26 (dd, J = 11.0,  1.2 Hz, 3H), 4.47-4.33 (s, 1H), 2.76-2.60 
380
99%






(s, 9H), 1.30-1.18 (m, 6H), 1.12-0.98 (m, 5H),








1.32 -1.20 (m, 7H).




 


2-43




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 8.95-8.90 (s, 1H),  8.36-8.31 (m, 1H), 8.13-8.07 (d, J = 2.0 Hz, 1H),  8.02-7.97 (d, J = 8.8 Hz, 1H), 4.49-4.36 (m, 3H),  2.90-2.79 (s, 5H), 2.76-2.67 (s, 3H), 1.33-1.20  (q, J = 6.9 Hz, 2H), 1.10-0.98 (m, 2H). 
397
98%


 


2-44




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 8.93-8.91 (s, 1H),  8.24-8.20 (m, 1H), 8.01-7.96 (d, J = 8.8 Hz, 1H),  7.93-7.67 (t, J = 2.8 Hz, 1H), 4.49-4.38 (tt, J = 7.2,  3.9 Hz, 1H), 4.24-4.14 (t, J = 5.5 Hz, 2H), 2.85-2.77  (s, 6H), 1.29 -1.20 (m, 2H), 1,09-0.98 (m, 2H). 
411
97%


 


2-45




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 8.94-8.89 (s, 1H),  8.15-8.09 (d, J = 2.1 Hz, 1H), 8.02-7.96 (d,  J = 8.9 Hz, 1H), 7.92-7.88 (s, 1H), 4.46-4.37 (m, 1H),  4.57-4.46 (s, 2H), 2.71-2.65 (s, 3H), 1.25-1.18  (d, J = 6.7 Hz, 2H), 1.10-0.98 (m, 2H). 
384
90%


 


2-46




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.71 (s, 1H),  8.89 (s, 1H), 8.35 (s, 2H), 7.94 (d, J = 8.67 Hz, 1H),  7.09 (s, 2H), 4.39 (s, 1H), 2.70 (s, 3H), 1.24 (d,  J = 5.31 Hz, 2H), 1.03 (s, 2H).
354
99%


 


2-47




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.72 (s, 1H),  8.89 (s, 1H), 8.41 (s, 2H) 7.95 (d, J = 8.41 Hz, 1H),  7.60 (d, J = 28.12 Hz, 1H), 4.40 (s, 1H), 2.88 (s, 3H),  2.70 (s, 3H), 1.25 (d, J = 5.56 Hz, 2H), 1.03 (s, 2H). 
369
99%


 


2-48




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.73 (s, 1H),  8.89 (s, 1H), 8.39 (s, 2H), 7.95 (d, J = 8.73 Hz, 1H),  7.64 (s, 1H), 4.39 (s, 1H), 2.70 (s, 3H), 2.53 (d,  J = 9.32 Hz, 3H), 1.24 (d, J = 6.11 Hz, 2H), 1.17  (t, J = 6.98 Hz, 2H), 1.03 (s, 2H). 
383
97%


 


2-49




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.72 (s, 2H),  8.90 (s, 1H), 8.48 (s, 2H), 7.96 (d, J = 8.59 Hz, 1H),  4.39 (s, 1H), 3.24 (d, J = 22.01 Hz, 6H), 2.70 (s, 3H),  1.25 (d, J = 6.03 Hz, 2H), 1.04 (d, J = 7.73 Hz, 2H).
383
98%


 


2-50




Cl
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 8.92 (s, 1H),  8.35 (s, 2H), 8.13 (d, J = 8.6 Hz, 1H), 7.15  (s, 2H), 4.41 (m, 3.8 Hz, 1H), 1.37-1.17  (m, 2H), 1.18-1.02 (m, 2H).
375
99%


 


2-51




Me




1H NMR (400 MHz, DMSO) δ 8.87 (d,  J = 3.2 Hz, 1H), 8.35 (d, J = 1.0 Hz, 2H), 7.97  (d, J = 8.9 Hz, 1H), 7.08 (s, 2H), 5.33-4.97  (m, 2H), 4.37 (m, 1H), 2.65 (s, 3H),  1.89-1.41 (m, 2H). 
373
99%


 


2-52




MeO




1H NMR (400 MHz, DMSO) δ 14.54 (s, 1H),  8.82 (d, J = 1.2 Hz, 1H), 8.44 (s, 2H), 7.93 (d,  J = 9.2 Hz, 1H), 7.10 (s, 2H), 5.09 (m, 1H),  4.37-3.96 (m, 1H), 3.50 (s, 3H), 1.98-1.52  (m, 2H). 
389
98%


 


2-53




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.65 (s, 1H),  8.91 (d, J = 4.9 Hz, 1H), 8.76 (s, 2H), 8.15-7.85  (m, 1H), 4.63-4.29 (m, 1H), 2.50 (s, 3H),  1.29-1.15 (m, 2H), 1.06 (d, J = 7.0 Hz, 2H).
384
99%


 


2-54




MeO
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 8.86 (s, 1H), 8.52 (s, 2H), 8.00 (d, J = 9.2 Hz, 1H), 7.18 (s, 2H), 4.29 (m, 1H), 3.55 (s, 3H), 1.27-1.11 (m, 4H). 
371
99%


 


2-55




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.67 (s, 1H),  8.79 (s, 1H), 8.19 (s, 1H), 7.90 (d, J = 9.3 Hz,  1H), 7.81 (s, 1H), 6.91 (t, J = 5.6 Hz, 1H),  4.29-4.11 (m, 1H), 3.53-3.41 (m, 5H),  1.26-1.06 (m, 7H).
432
98%


 











2-56




1H NMR (400 MHz, DMSO) +δ 9.06  (s, 1H), 8.38 (s, 1H), 8.13 (d, J = 1.75 Hz,  1H), 7.72 (d, J = 9.80 Hz, 1H), 7.29 (s, 2H),  5.06-4.90 (m, 1H), 4.58 (d, J = 10.62 Hz, 1H),  4.44 (d, J = 9.71 Hz, 1H), 1.48 (d, J = 6.75 Hz,  3H). 
381
95%


 


2-57




1HNMR (400 MHz, DMSO) δ 14.95  (s, 1H), 8.91 (s, 1H), 8.37-8.33 (d,  J = 2.5 Hz, 1H), 8.24-8.19 (d, J = 8.3 Hz,  1H), 8.14-8.10 (d, J = 2.5 Hz, 1H),  7.58-7.51 (d, J = 8.3 Hz, 1H), 7.22 (s, 2H),  4.42-4.36 (tt, 7.1, 3.7 Hz, 1H), 2.71 (s, 3H),  1.30-1.25 (m, 2H), 1.05-0.94 (m, 2H).
361
95%


 


2-58




1H NMR (400 MHz, DMSO) δ 14.95  (s, 1H), 8.89 (s, 1H), 8.32 (d, J = 3.5 Hz, 1H), 8.21 (d, J = 8.2 Hz, 1H), 8.06 (s, 1H),  7.79 (s, 1H), 7.53 (d, J = 8.2 Hz, 1H), 6.61  (s, 2H), 4.39 (s, 1H), 2.72 (s, 3H), 1.27  (d, J = 6.1 Hz, 2H), 1.03 (s, 2H). 
370
99%


 


2-59




1H NMR (400 MHz, DMSO) δ 15.00  (s, 1H), 9.06 (s, 1H), 8.17 (s, 1H), 7.80  (s, 1H), 7.72 (d, J = 9.8 Hz, 1H), 6.86  (t, J = 5.7 Hz, 1H), 4.98 (d, J = 6.7 Hz, 1H), 4.57 (d, J = 10.2 Hz, 1H), 4.48-4.32  (m, 1H), 3.55-3.37 (m, 2H), 1.48 (d, J = 6.8 Hz, 2H), 1.17 (t, J = 7.1 Hz, 2H). 
418
98%


 


2-60




1H NMR (400 MHz, DMSO) δ 14.55  (s, 1H), 8.82 (d, J = 1.6 Hz, 1H), 8.18  (s, 1H), 7.92 (d, J = 9.3 Hz, 1H), 7.80  (s, 1H), 6.92 (t J = 5.7 Hz, 1H), 5.10  (ddd, J = 64.1, 8.4, 5.4 Hz, 1H), 4.32-4.06  (m, 1H), 3.58-3.37 (m, 5H), 1.93-1.51 (m, 2H), 1.19 (t, J = 7.1 Hz, 3H).
450
98%
















TABLE 3













 













Com-








pound




MS



No.
R3 =
R2 =
R1 =
NMR
(MH+)
HPLC





3-1 




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.59 (s, 1H),  9.08 (s, 1H), 8.94 (s, 1H), 8.33 (d, J = 1.3 Hz, 1H), 8.16 (d, J = 1.7 Hz, 1H) 8.06  (t, J = 8.5 Hz, 2H), 7.85 (d, J = 9.4 Hz,  1H), 4.49-4.38 (m, 1H), 2.70 (s, 3H), 1.25 (d,  J = 6.6 Hz, 2H), 1.09 (s, 2H).
378
98%


 


3-2




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.83 (s, 1H),  9.38 (s, 1H), 8.91 (d, J = 25.3 Hz, 1H), 8.79  (s, 1H), 8.13 (s, 1H), 8.06 (d, J = 8.8 Hz, 1H),  8.01 (s, 1H), 4.44 (s, 1H), 2.75 (s, 3H), 1.25  (s, 2H), 1.09 (s, 2H).
379
95%


 


3-3




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.70 (s, 1H),  9.41 (s, 1H), 9.00 (s, 1H), 8.80 (s, 1H), 8.36  (s, 1H), 3.17 (s, 1H), 8.07 (s, 2H), 7.86 (s,  1H), 7.61 (s, 1H), 4.49 (s, 1H), 2.79 (s, 3H),  1.31 (s, 3H), 1.17 (s, 2H).
456
98%


 


3-4




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.57 (d, J =  5.1 Hz, 1H), 9.05 (d, J = 6.5 Hz, 1H), 8.94 (s,  1H), 8.44 (s, 1H), 8.23 (s, 1H), 8.11 (s, 1H),  8.05 (d, J = 8.8 Hz, 1H), 7.54 (d, J = 6.4 Hz,  1H), 4.43 (s, 1H), 2.68 (s, 3H), 1.24 (d, J =  5.0 Hz, 2H), 1.11 (s, 2H).
378
97%


 


3-5




OMe
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.64 (s, 1H),  9.13 (d, J = 6.3 Hz, 1H), 8.90 (s, 1H), 8.53 (s,  1H), 8.31 (d, J = 11.7 Hz, 2H), 8.09 (d, J =  9.1 Hz, 1H), 7.72 (d, J = 6.8 Hz, 1H), 4.30 (s,  1H), 3.57 (s, 3H), 1.25 (s, 4H).
394
95%


 


3-6




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 9.30 (s, 1H),  8.93 (s, 1H), 8.64 (s, 1H), 8.04 (t, J = 9.2 Hz,  2H), 7.75 (d, J = 9.2 Hz, 1H), 4.42 (s, 1H),  2.69 (s, 3H), 1.24 (s, 2H), 1.09 (s, 2H).
379
97%


 


3-7




OMe
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.61 (s, 1H,  9.33 (s, 1H), 8.83 (s, 1H), 8.64 (s, 1H), 8.06  (d, J = 9.2 Hz, 1H), 8.01 (d, J = 9.1 Hz, 1H),  7.86 (d, J = 9.3 Hz, 1H), 4.24 (s, 1H), 3.48  (s, 3H), 1.19 (d, J = 5.2 Hz, 4H).
395
98%


 


3-8




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.60 (s, 1H),  9.11 (s, 1H), 8.93 (s, 1H), 8.22 (d, J = 1.2 Hz,  1H), 8.17 (s, 1H), 8.03 (d, J = 8.9 Hz, 1H),  7.84 (d, J = 1.1 Hz, 1H), 4.43 (tt, J = 7.1, 3.7  Hz, 1H), 2.70 (s, 3H), 1.26 (d, J = 6.8 Hz, 2H),  1.09 (s, 2H).
379
98%


 


3-9




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.60 (s, 1H),  9.07 (s, 1H), 8.93 (s, 1H), 8.22 (s, 1H), 8.02  (d, J = 8.9 Hz, 1H), 7.81 (s, 1H), 7.80 (s, 1H),  4.49-4.37 (m, 1H), 2.70 (d, J = 21.5 Hz, 3H),  1.27 (t, J = 9.8 Hz, 2H), 1.14-1.05 (m, 2H).
446
97%


 


3-10




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.62 (s, 1H),  8.94 (s, 2H), 8.35 (s, 1H), 8.23 (s, 1H), 8.05 (d, J = 8.7 Hz, 1H), 7.75 (s, 1H), 4.43 (s,  1H), 2.69 (s, 3H), 2.66 (s, 3H), 1.24 (s, 2H), 1.08 (s, 2H).
392
98%


 


3-11




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.61 (s, 1H)  8.92 (s, 1H), 8.79 (d, J = 1.2 Hz, 1H), 8.16 (d,  J = 1.1 Hz, 1H), 8.01 (d, J = 8.8 Hz, 1H), 7.76  (d, J = 1.1 Hz, 1H), 7.58 (s, 1H), 4.42 (tt, J =  7.2, 3.8 Hz, 1H), 2.70 (d, J = 20.2 Hz, 3H),  1.26 (d, J = 6.9 Hz, 2H), 1.15-1.03 (m, 2H).
412
99%


 


3-12




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 9.40 (s, 1H),  8.94 (s, 1H), 8.88 (s, 1H), 8.18 (d, J = 9.3  Hz, 1H), 8.05 (d, J = 8.8 Hz, 1H), 7.89 (d,  J = 9.3 Hz, 1H), 4.43 (s, 1H), 2.69 (s, 3H),  1.24 (d, J = 6.1 Hz, 2H), 1.12 (s, 2H).
423
96%


 


3-13




OMe
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.60 (s, 1H),  8.90 (s, 1H), 8.83 (s, 1H), 6.22 (d, J = 1.0 Hz,  1H), 7.98 (d, J = 9.2 Hz, 1H), 7.75 (d, J = 1.0  Hz, 1H), 7.66 (s, 1H), 4.29-4.18 (m, 1H), 3.51  (d, J = 13.2 Hz, 3H), 1.25-1.14 (m, 4H).
428
100%


 


3-14




OMe
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.59 (s, 1H),  9.19 (s, 1H), 8.83 (s, 1H), 8.28 (s, 1H), 8.01  (d, J = 9.2 Hz, 1H), 7.92 (s, 1H), 7.81 (s, 1H),  4.25 (dt, J = 11.0, 5.7 Hz, 1H), 3.50 (d, J =  12.8 Hz, 3H), 1.19 (m, 4H).
462
98%


 


3-15




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 9.61 (s, 1H),  8.93 (s, 1H), 8.51 (s, 1H), 8.13 (s, 1H), 8.04  (d, J = 8.8 Hz, 1H), 7.97 (d, J = 9.2 Hz, 1H),  7.62 (d, J = 9.2 Hz, 1H), 7.55 (s,1H), 4.42 (s,  1H), 2.69 (s, 3H), 1.24 (s, 2H) 1.10 (s, 2H).
421
98%


 


3-16




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.87-13.95 (m,  2H), 9.60 (s, 1H), 8.94 (s, 1H), 8.44 (s, 1H),  8.05 (t, J = 9.5 Hz, 2H), 7.71 (d, J = 9.4 Hz, 1H),  4.46- 4.39 (m, 1H), 2.71 (m, 3H), 2.46 (s, 3H),  1.25 (d, J = 6.3 Hz, 2H), 1.11 (s, 2H).
459
98%


 


3-17




Cl
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.44-13.91 (m,  1H), 9.16 (s, 1H), 8.95 (s, 1H), 8.37 (s, 1H),  8.23 (d, J = 8.6 Hz, 1H), 8.08 (s, 1H), 7.81 (s,  1H), 4.43 (m, 1H), 1.23 (m, 2H), 1.16 (s, 2H).
398
98%


 


3-18




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.62 (s, 1H),  8.92 (s, 1H), 8.68 (s, 1H), 8.19 (d, J = 2.9 Hz,  1H), 8.01 (d, J = 8.8 Hz, 1H), 7.73 (d, J = 1.0  Hz, 1H), 7.32 (d, J = 11.7 Hz, 1H), 4.42 (m,  1H), 2.72 (s, 3H), 1.25 (d, 2H), 1.12-1.04 (m,  2H). 
396
98%


 


3-19




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 9.29 (s, 1H),  8.94 (s, 1H), 8.54 (s, 1H), 8.36 (s, 1H), 8.05  (d, J = 8.9 Hz, 1H), 8.00 (s, 1H), 4.49-4.38  (m, 1H), 2.74 (s, 3H), 1.25 (d, J = 6.9 Hz,  2H), 1.11 (s, 2H).
423
98%


 


3-20




Cl
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 8.95 (s, 1H),  8.88 (t, J = 4.2 Hz, 1H), 8.22 (t, J = 2.4 Hz,  1H), 8.20 (d, J = 8.5 Hz, 1H), 7.82 (s, 1H),  7.68 (s, 1H), 4.48- 4.36 (m, 1H), 1.26-1.19 (m, 2H), 1.14 (m, 2H).
432
98%


 


3-21




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.60 (s, 1H),  9.32 (d, J = 1.2 Hz, 1H), 8.93 (s, 1H), 8.71 (s,  1H), 8.06 (s, 1H), 8.02 (d, J = 8.8 Hz, 1H), 4.43  (tt, J = 7.0, 3.6 Hz, 1H), 2.70 (d, J = 17.8 Hz,  3H), 1.30-1.20 (m, 2H), 1.15-1.05 (m, 2H).
413
98%


 


3-22




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.57 (s, 1H),  9.22 (s, 1H), 8.93 (s, 1H), 8.71 (s, 1H), 8.02  (d, J = 8.8 Hz, 1H), 7.85 (d, J = 10.8 Hz, 1H),  4.47-4.37 (m, 1H), 2.72 (s, 3H), 1.29-1.22 (m,  2H), 1.10 (s, 2H). 
397
99%


 


3-23




OMe
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.57 (s, 1H),  9.26 (s, 1H), 8.84 (s, 1H), 8.72 (s, 1H), 8.01  (d, J = 9.1 Hz, 1H), 7.92 (d, J = 10.9 Hz, 1H),  4.26-4.16 (m, 1H), 3.51 (s, 3H), 1.20 (d, J =  5.5 Hz, 4H).
413
95%


 


3-24




OMe




1H NMR (400 MHz, DMSO) δ 14.47 (s, 1H),  8.89 (t, J = 1.3 Hz, 1H), 8.86 (d, J = 1.8 Hz,  1H), 8.23 (d, J = 1.3 Hz, 1H), 8.00 (d, J = 9.1  Hz, 1H), 7.75 (d, J = 1.2 Hz, 1H), 7.63 (t, J =  1.3 Hz, 1H), 5.31-4.93 (dtd, J = 64.0, 5.5, 3.3  Hz, 1H), 4.26- 4.12 (dt, J = 8.9, 5.4 Hz, 1H),  3.54 (s, 3H), 1.93-1.49 (m, 2H).
446
98%


 


3-25




Me




1H NMR (400 MHz, CDCl3) δ 14.07 (s, 1H),  8.55 (s, 1H), 8.14 (d, J = 8.4 Hz, 1H), 8.00 (d,  J = 17.0 Hz, 1H), 7.66 (dd, J = 11.6, 4.8 Hz,  2H), 7.49 (d, J = 4.4 Hz, 1H), 7.13-7.03 (m,  2H), 7.01 (d, J = 0.8 Hz, 1H), 5.22 (s, 1H),  1.72 (s, 3H).
484
98%


 


3-26




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.64 (s, 1H),  9.09 (s, 1H), 8.93 (s, 1H), 8.58 (s, 1H), 8.02  (d, J = 8.8 Hz, 1H), 7.54 (s, 1H), 4.46-4.36  (m, 1H), 2.70 (s, 3H), 2.64 (s, 3H), 1.25 (d,  J = 6.2 Hz, 2H), 1.09 (s, 2H).
393
98%


 


3-27




Me




1H NMR (400 MHz, DMSO) δ 14.48 (s, 1H),  8.90 (d, J = 3.0 Hz, 1H), 8.76 (s, 1H), 8.16 (s,  1H), 8.03 (d, J = 8.8 Hz, 1H), 7.75 (s, 1H),  7.57 (s, 1H), 5.16 (d, J = 64.5 Hz, 1H), 4.44- 4.33 (m, 1H), 2.65 (s, 3H), 1.83-1.68 (m, 1H),  1.62 (m, 1H).
430
98%


 


3-28




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.59 (s, 1H),  9.63 (s, 1H), 8.94 (s, 1H), 8.81 (s, 1H), 8.30  (s, 1H), 8.04 (d, J = 8.9 Hz, 1H), 4.50-4.37  (m, 1H), 2.73 (s, 3H), 1.24 (t, J = 9.6 Hz, 2H),  1.12 (s, 2H).
447
98%


 


3-29




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 9.33 (s, 1H),  8.94 (s, 1H), 8.74 (s, 1H), 8.63 (s, 2H), 8.05  (d, J = 8.8 Hz, 1H), 7.84 (s, 1H), 4.51 (s,  2H), 4.46-4.36 (m, 1H), 2.71 (s, 3H), 1.26  (d, J = 6.8 Hz, 2H), 1.09 (s, 2H).
408
95%


 


3-30




OMe
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.58 (s, 1H),  9.37 (s, 1H), 8.84 (s, 1H), 8.72 (s, 1H), 8.13  (s, 1H), 8.00 (d, J = 9.0 Hz, 1H), 4.29-4.18  (m, 1H), 3.51 (s, 3H), 1.20 (d, J = 5.4 Hz,  4H).
429
96%


 


3-31




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 9.43 (s, 1H),  8.99 (s, 1H), 8.89 (s, 1H), 8.14-8.01 (m, 2H),  7.54 (d, J = 9.8 Hz, 1H), 4.49 (s, 2H), 2.77  (s, 3H), 1.30 (s, 2H), 1.14 (s, 2H).
379
88%


 


3-32




OMe
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 9.42 (s, 1H),  8.92 (s, 1H), 8.83 (s, 1H), 8.00 (s, 2H), 7.57  (d, J = 9.3 Hz, 1H), 4.23 (s, 1H), 3.51 (s,  3H), 1.18 (s, 4H).
395
95%


 


3-33




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 8.98 (s, 1H),  8.74 (s, 1H), 8.48 (s, 1H), 8.23 (s, 1H), 8.04  (d, J = 8.9 Hz, 1H), 4.39 (s, 2H), 2.64 (s,  3H), 1.29 (s, 2H), 1.07 (s, 2H).
379
99%


 


3-34




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 15.02-14.73  (m, 1H), 9.01 (s, 1H), 8.10 (s, 3H), 7.54 (s,  1H), 4.51 (s, 1H), 1.33 (s, 2H), 1.18 (s, 2H).
379
95%


 


3-35




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.68 (s, 1H),  14.19 (s, 1H), 8.93 (s, 1H), 8.53 (s, 1H), 8.44  (s, 1H), 8.40 (s, 1H), 8.01 (d, J = 8.5 Hz, 1H),  4.42 (s, 1H), 2.64 (s, 3H), 1.22 (m, 2H), 1.12  (m, 2H).
423
98%


 


3-36




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 12.67 (s, 1H),  8.97 (s, 1H), 8.10 (s, 1H) 8.01 (d, J = 8.7 Hz,  1H), 7.02 (s, 1H), 6.48 (s, 1H), 4.46 (s, 1H),  2.70 (s, 2H), 1.30 (s, 2H), 1.12 (s, 2H). 
393
98%


 


3-37




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.83 (s, 1H),  13.45 (b, 1H), 8.98 (s, 1H), 8.26 (s, 1H), 8.04  (d, J = 8.6 Hz, 1H), 7.90 (s, 1H), 7.78 (d, J =  8.5 Hz, 1H), 7.42 (d, J = 8.4 Hz, 1H), 4.46 (s,  1H), 2.68 (s, 3H), 1.31 (d, J = 5.7 Hz, 2H),  1.14 (s, 2H).
378
92%


 


3-38




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.69 (s, 1H),  13.83 (s, 1H), 8.91 (s, 1H), 8.31 (s, 1H), 7.98  (d, J = 8.8 Hz, 1H), 7.83 (s, 1H), 7.53 (s, 1H),  4.46-4.34 (m, 1H), 2.63 (s, 3H), 1.25 (d, J =  6.9 Hz, 2H), 1.09 (s, 2H).
412
98%


 


3-39




OMe
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.74 (s, 1H),  14.27 (s, 1H), 8.90 (s, 1H), 8.62 (d, J = 10.6  Hz, 3H), 8.07 (d, J = 9.1 Hz, 1H), 4.31 (s, 1H),  3.44 (s, 3H), 1.26 (s, 4H).
439
95%


 


3-40




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.77 (s, 1H),  13.23 (s, 1H), 8.91 (s, 1H), 8.49 (s, 1H), 7.98  (d, J = 8.3 Hz, 1H), 7.79 (d, J = 8.0 Hz, 1H),  7.67 (s, 1H), 7.25 (d, J = 7.9 Hz, 1H), 4.40 (s,  1H), 2.61 (s, 2H), 1.25 (s, 2H), 1.09 (s, 2H).
378
98%


 


3-41




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.72 (s, 1H),  9.52 (s, 1H), 8.92 (s, 1H), 8.30 (s, 1H), 8.27 (d,  J = 8.4 Hz, 1H), 8.01 (d, J = 8.8 Hz, 1H), 7.58  (d, J = 8.1 Hz, 1H), 4.40 (s, 1H), 2.62 (s, 3H),  1.25 (d, J = 5.9 Hz, 2H), 1.08 (s, 2H).
395
95%


 


3-42




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.77 (s, 1H),  11.96 (s, 1H), 8.92 (s, 1H), 8.24 (s, 1H), 8.06  (s, 1H), 7.99 (d, J = 8.7 Hz, 1H), 7.61 (s, 1H),  6.57 (s, 1H), 4.41 (s, 1H), 2.64 (s, 3H), 1.26  (d, J = 6.1 Hz, 2H), 1.09 (s, 2H).
378
98%


 


3-43




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.76-14.48 (s,  1H), 8.97-6.90 (d, J = 2.7 Hz, 2H), 8.63-8.55  (s, 1H), 8.07-7.97 (t, J = 9.2 Hz, 2H), 7.69- 7.58 (m, 1H), 4.48-4.39 (s, 2H), 2.73-2.65 (s,  3H), 1.27-1.20 (m, 2H), 1.14-1.06 (s, 2H).
403
95%


 


3-44




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 10.02-9.98 (s,  1H), 9.48-9.43 (s, 1H), 8.95-8.90 (s, 1H),  8.67-8.62 (s, 1H), 8.12-8.07 (d, J = 9.2 Hz,  1H), 8.07-8.01 (d, J = 8.9 Hz, 1H), 7.82-7.75  (dd, J = 9.4, 1.7 Hz, 1H), 4.48-4.36 (s, 1H),  2.72-2.67 (s, 3H), 1.25-1.21 (t, J = 3.8 Hz,  2H), 1.14-1.06 (m, 2H).
406
90%


 


3-45




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 9.93 (s, 1H),  8.83 (s, 1H). 8.40 (s, 1H), 8.09-8.05 (dd, J =  9.2, 1.0 Hz, 1H), 8.05-8.00 (d, J = 8.7 Hz,  1H), 7.81-7.72 (dd, J = 9.3, 1.7 Hz, 1H),  5.35-5.16 (s, 1H), 4.53-4.33 (m, 1H), 2.75- 2.64 (s, 3H), 1.28-1.20 (d, J = 6.2 Hz, 2H),  1.15-1.03 (d, J = 3.8 Hz, 2H).
402
98%


 


3-46




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.70-14.56 (s,  1H), 9.23-9.15 (m, 1H), 8.99-8.89 (s, 1H),  8.72-8.65 (s, 1H), 8.08-7.99 (d, J = 8.8 Hz, 1H),  7.84-7.77 (s, 1H), 7.16-7.04 (m, 1H), 6.93-6.82  (m, 1H) 5.82-5.69 (dd, J = 11.2, 1.6 Hz, 1H),  4.49-4.36 (t, J = 3.5 Hz, 1H), 2.75-2.68 (s, 3H),  1.33-1.19 (t, J = 6.5 Hz, 2H), 1.16-1.03 (s, 2H).
405
97%


 


3-47




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.76-14.48 (s,  1H), 8.96-8.91 (s, 4H), 8.86-8.79 (s, 4H), 8.64- 8.56 (d, J = 2.3 Hz, 4H), 8.06-7.99 (d, J = 8.8  Hz, 4H), 7.86-7.79 (d, J = 9.4 Hz, 4H), 7.52- 7.43 (s, 3H), 4.48-4.37 (s, 1H), 2.74-2.67 (s,  12H), 1.29-1.20 (d, J = 6.8 Hz, 9H), 1.11-1.01  (t, J = 3.0 Hz, 6H).
422
96%


 


3-48




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.76-14.48 (s,  1H), 8.95-8.89 (s, 1H), 8.84-8.78 (s, 1H), 8.63- 8.58 (s, 1H), 8.05-8.00 (d, J = 8.8 Hz, 1H),  7.90-7.84 (d, J = 9.4 Hz, 1H), 7.53-7.45 (d, J =  9.3 Hz, 1H), 4.47-4.40 (s, 1H), 2.73-2.68 (s,  3H), 1.27-1.21 (d, J = 6.6 Hz, 2H), 1.12-1.02  (s, 2H). 
446
90%


 


3-49




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 8.93 (s, 1H),  8.66 (s, 1H), 8.06-7.99 (d, J = 8.7 Hz, 1H),  7.99-7.95 (s, 1H), 7.94-7.88 (d, J = 9.3 Hz,  1H), 7.55-7.47 (dd, J = 9.3, 1.6 Hz, 1H), 4.52- 4.32 (m, 1H), 2.77-2.61 (s, 3H), 1.33-1.17 (d,  J = 6.6 Hz, 2H), 1.19-1.05 (t, J = 3.3 Hz, 2H).
412
98%


 


3-50




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 8.93 (s, 1H),  8.60 (s, 1H), 8.06-8.00 (d, J = 8.7 Hz, 1H),  8.00-7.96 (s, 1H), 7.92-7.86 (d, J = 9.3 Hz,  1H), 7.56-7.48 (d, J = 9.4 Hz, 1H), 4.55-4.26  (m, 1H), 2.81-2.60 (s, 3H), 1.37-1.21 (d, J =  6.5 Hz, 2H), 1.15-1.05 (m, 2H).
456, 458
97%


 


3-51




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.71-14.62  (s, 1H), 8.96-8.88 (s, 1H), 8.83-8.75 (s, 1H),  8.25-8.16 (d, J = 7.5 Hz, 2H), 8.15-8.07 (s,  1H), 8.07-7.97 (d, J = 8.8 HZ, 1H), 7.77- 7.71 (s, 1H), 7.57-7.42 (m, 4H), 4.50-4.33 (s,  1H), 2.82-2.71 (s, 3H), 1.31-1.22 (d, J = 6.7  Hz, 2H), 1.15-1.04 (s, 2H). 
454
99%


 


3-52




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.71-14.60  (s,1H), 8.95-8.88 (s,1H), 8.73-8.65 (s, 1H),  8.10-7.96 (m, 2H), 7.74-7.68 (s, 1H), 7.40- 7.32 (s, 1H), 7.11-7.02 (m, 1H), 6.96-6.83  (m, 1H), 5.70-5.60 (dd, J = 11.2, 2.0 Hz,  1H), 4.47-4.38 (t, J = 3.5 Hz, 1H), 2.78-2.69  (s, 3H), 1.31-1.20 (d, J = 6.9 Hz, 2H), 1.14- 1.01 (s, 2H).
405
93%


 


3-53




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.71-14.60  (s, 1H), 8.95-8.88 (s, 1H), 8.73-8.65 (s, 1H),  8.10-7.96 (m, 2H), 7.74-7.68 (s, 1H), 7.40- 7.32 (s, 1H), 7.11-7.02 (m, 1H), 6.96-6.83  (m, 1H), 5.70-5.60 (dd, J = 11.2, 2.0 Hz, 1H),  4.47-4.38 (t, J = 3.5 Hz, 1H), 2.78-2.69 (s,  3H), 1.31-1.20 (d, J = 6.9 Hz, 2H), 1.14-1.01  (s, 2H).
403
95%


 


3-54




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.76-14.39  (s, 1H), 9.20-9.07 (d, J = 7.0 Hz, 1H), 8.95- 8.90 (s, 1H), 8.67-8.60 (s, 1H), 8.08-8.00 (m,  2H), 7.32-7.24 (m, 1H), 4.47-4.36 (s, 1H),  2.75-2.61 (s, 3H), 1.30-1.19 (m, 2H), 1.15- 1.03 (q, J = 3.8, 3.1 Hz, 2H). 
379
98%


 


3-55




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.76-14.36  (s, 1H), 9.68-9.65 (d, J = 1.5 Hz, 1H), 8.95- 8.92 (s, 1H), 8.84-8.81 (s, 1H), 8.63-8.59 (d,  J = 1.5 Hz, 1H), 8.06-8.01 (d, J = 8.8 Hz,  1H), 4.46-4.39 (s, 1H), 2.76-2.69 (s, 3H),  1.30-1.20 (m, 2H), 1.14-1.05 (s, 2H). 
404
98%


 


3-56




OMe




1H NMR (400 MHz, DMSO) δ 14.73-14.06  (s, 1H), 9.21-9.18 (m, 1H), 6.87-8.83 (d, J =  1.86 Hz, 1H), 8.32-8.27 (d, J = 1.33 Hz, 1H),  8.20-8.16 (s, 1H), 8.04-7.97 (d, J = 9.06 Hz,  1H), 7.87-7.80 (d, J = 1.20 Hz, 1H), 5.31-4.87  (m, 1H), 4.32-4.12 (m, 1H), 3.67-3.47 (s, 3H),  1.95-1.56 (m, 2H).
437
98%


 


3-57




OMe
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.61 (s, 1H),  8.83 (s, 1H), 8.77 (s, 1H), 8.23 (d, J = 2.1 Hz,  1H), 7.99 (d, J = 9.2 Hz, 1H), 7.73 (d, J = 1.0  Hz, 1H), 7.40 (d, J = 11.8 Hz, 1H), 4.46-4.08  (m, 1H), 3.51 (d, J = 10.5 Hz, 3H), 1.19 (d,  J = 6.9 Hz, 4H).
412
90%


 


3-58




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.83-14.57 (s,  1H), 9.82-9.48 (s, 2H), 9.01-8.84 (d, J = 2.6 Hz,  1H), 8.05-7.90 (dd, J = 8.5, 2.7 Hz, 1H), 7.65- 7.57 (d, J = 7.5 Hz, 1H), 7.51-7.46 (s, 1H),  7.45-7.36 (d, J = 7.7 Hz, 1H), 4.72-4.50 (s, 4H),  4.47-4.28 (d, J = 6.8 Hz, 1H), 2.64-2.53 (d, J =  2.7 Hz, 3H), 1.31-1.14 (d, J = 6.1 Hz, 2H),  1.14-0.96 (s, 2H).
379
95%


 


3-59




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 8.95-8.83 (d, J =  2.4 Hz, 1H), 7.98-7.86 (d, J = 8.8 Hz, 1H), 7.25- 7.15 (s, 1H), 7.14-7.01 (d, J = 7.9 Hz, 1H), 6.97- 6.81 (d, J = 7.9 Hz, 1H), 3.65-3.50 (m, 2H),  4.45-4.29 (dp, J = 9.2, 4.7, 3.9 Hz, 1H), 3.16- 2.99 (t, J = 8.4 Hz, 2H), 2.65-2.56 (s, 3H), 1.28- 1.16 (d, J = 6.6 Hz, 3H), 1.12-0.97 (m, 2H).
379
99%


 


3-60




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 15.01-14.39 (m,  1H), 12.95-12.53 (s, 2H), 9.03-8.82 (t, J = 1.9  Hz, 1H), 8.73-8.47 (s, 2H), 8.10-7.90 (d, J = 8.4  Hz, 1H), 7.62-7.44 (m, 1H), 4.51-4.23 (m, 1H),  7.44-7.31 (s, 1H), 7.31-7.11 (d, J = 8.6 Hz, 1H),  2.65-2.55 (s, 3H), 1.30-1.16 (m, 2H), 1.16-0.96  (s, 2H).
393
90%


 


3-61




Me
Cyclopropyl
1H NMR (400 MHz, MeOD) δ 9.17-9.06 (d, J =  2.8 Hz, 1H), 8.30-8.15 (m, 1H), 7.94-7.80 (m,  2H), 7.65-7.49 (dt, J = 7.5, 3.3 Hz, 2H), 4.47- 4.32 (d, J = 6.9 Hz, 1H), 2.96-2.81 (d, J = 2.8  Hz, 3H), 1.43-1.27 (dd, J = 10.8, 4.5 Hz, 2H),  1.21-1.05 (s, 2H).
378
100%


 


3-62




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.63-14.42 (s,  1H), 8.99-8.89 (s, 1H), 8.33-8.25 (d, J = 7.8 Hz,  1H), 8.25-8.18 (d, J = 8.0 Hz, 1H), 8.14-8.05 (d,  J = 8.7 Hz, 1H), 7.71-7.56 (dt, J = 22.8, 7.4 Hz,  2H), 4.51-4.31 (s, 1H), 2.85-2.70 (s, 3H), 1.30- 1.20 (d, J = 7.0 Hz, 2H), 1.13-0.97 (s, 2H).
395
100%


 


3-63




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 15.01-14.28 (s,  2H), 9.04-8.32 (t, J = 2.3 Hz, 1H), 8.05-7.98 (d,  J = 8.3 Hz, 1H), 7.98-7.92 (dd, J = 10.5, 2.5 Hz,  1H), 7.90-7.83 (s, 1H), 7.56-7.47 (d, J = 8.2 Hz,  1H), 4.46-4.34 (t, J = 6.3 Hz, 1H), 2.87-2.78 (t,  J = 2.1 Hz, 3H), 2.64-2.55 (s, 3H), 1.29-1.16  (m, 2H), 1.16-1.03 (s, 2H).
392
100%


 


3-64




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 15.01-14.28 (s,  2H), 9.04-8.82 (t, J = 2.3 Hz, 1H), 8.05-7.98 (d,  J = 8.3 Hz, 1H), 7.98-7.92 (dd, J = 10.5, 2.5 Hz,  1H), 7.90-7.83 (s, 1H), 7.56-7.47 (d, J = 8.2 Hz,  1H), 4.46-4.34 (t, J = 6.3 Hz, 1H), 2.87-2.78 (t,  J = 2.1 Hz, 3H), 2.64-2.55 (m, 6H), 1.29-1.16  (m, 2H), 1.16-1.03 (s, 2H).
421
100%


 


3-65




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 15.05-14.35 (m,  1H), 10.46-9.91 (m, 1H), 9.02-8.80 (s, 1H),  8.80-8.47 (d, J = 15.2 Hz, 1H), 8.12-7.64 (m,  3H), 7.44-7.25 (dd, J = 23.7, 8.0 Hz, 1H), 4.84- 4.63 (d, J = 8.8 Hz, 2H), 4.49-4.32 (s, 1H),  3.01-2.77 (d, J = 17.9 Hz, 6H), 1.37-1.13 (d, J =  6.9 Hz, 2H), 1.17-0.86 (s, 2H).
449
96%


 


3-66




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.97-14.24 (s,  2H), 9.14-8.97 (m, 2H), 8.98-8.88 (s, 2H), 8.07- 7.89 (dd, J = 24.1, 8.9 Hz, 6H), 7.86-7.79 (s,  1H), 7.52-7.37 (t, J = 9.6 Hz, 3H), 4.57-4.31 (t,  J = 6.8 Hz, 5H), 2.66-2.55 (s, 7H), 1.60-1.40  (m, 7H), 1.30-1.16 (m, 2H), 1.16-0.98 (s, 2H).
406
97%


 


3-67




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.97-14.24 (s,  2H), 9.14-8.97 (m, 2H), 8.98-8.88 (s, 2H), 8.07- 7.89 (dd, J = 24.1, 8.9 Hz, 6H), 7.86-7.79 (s,  1H), 7.52-7.37 (t, J = 9.6 Hz, 3H), 4.57-4.31 (t,  J = 6.8 Hz, 5H), 2.66-2.55 (s, 3H), 1.60-1.40  (m, 7H), 1.30-1.16 (m, 2H), 1.16-0.96 (s, 2H).
392
100%


 


3-68




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 8.95-8.91 (s,  1H), 8.65-8.59 (s, 1H), 8.31-8.25 (s, 1H), 8.23- 8.17 (s, 1H), 8.05-7.98 (m, 1H), 4.48-4.35 (s,  1H), 2.68-2.61 (s, 3H), 1.30-1.22 (s, 2H), 1.16- 1.06 (s, 2H).
423
97%


 


3-69




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.96-14.48 (m,  1H), 10.94-10.65 (d, J = 25.6 Hz, 2H), 9.01- 8.77 (m, 1H), 8.05-7.81 (d, J = 8.6 Hz, 1H),  7.18-7.00 (d, J = 7.8 Hz, 1H), 7.00-6.78 (m,  2H), 4.47-4.25 (td, J = 6.9, 3.6 Hz, 1H), 2.67- 2.54 (s, 3H), 1.27-1.10 (d, J = 6.3 Hz, 2H), 1.14-0.88 (s, 2H).
394
94%


 


3-70




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 15.02-14.18 (s,  1H), 9.00-8.67 (m, 2H), 8.12-7.68 (m, 3H),  7.49-7.25 (dd, J = 16.6, 8.2 Hz, 1H), 5.04-4.75  (m, 1H), 4.62-4.23 (m, 9H), 3.77-3.55 (m, 2H),  3.57-3.23 (d, J = 7.0 Hz, 1H), 2.70-2.53 (s,  3H), 1.37-1.15 (t, J = 8.0 Hz, 2H), 1.15-0.84  (td, J = 16.0, 7.8 Hz, 9H).
494
90%


 


3-71




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.45-14.13 (s,  1H), 11.09-10.85 (s, 1H), 8.73-8.58 (d, J = 2.7  Hz, 1H), 7.85-7.61 (m, 2H), 7.31-7.15 (m, 1H),  7.07-6.83 (m, 2H), 4.27-4.07 (s, 1H), 3.82-3.71  (d, J = 2.5 Hz, 3H), 1.27-1.08 (m, 2H), 1.08- 0.86 (s, 2H). 
408
93%


 


3-72




OMe
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 15.07-14.72 (s,  1H), 9.21-8.97 (s, 1H), 8.95-8.73 (m, 1H),  8.41-8.14 (m, 1H), 8.12-7.95 (s, 1H), 3.40-3.18  (m, 4H), 7.95-7.79 (d, J = 8.6 Hz, 1H), 7.79- 7.60 (dd, J = 8.5, 3.9 Hz, 2H), 4.34-4.10 (d,  J = 6.3 Hz, 1H), 1.30-1.02 (s, 4H).
376
95%


 


3-73




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.85-14.61 (s,  1H), 10.68-10.51 (s, 1H), 9.04-8.78 (m, 1H),  8.01-7.81 (m, 1H), 7.36-7.11 (m, 2H), 7.11- 6.87 (dd, J = 7.8, 2.7 Hz, 1H), 4.47-4.29 (s,  1H), 3.72-3.47 (s, 2H), 1.27-1.08 (m, 2H),  1.08-0.86 (s, 2H).
393
97%


 


3-74




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.85-14.61 (s,  1H), 10.68-10.51 (s, 1H), 9.04-6.78 (m, 1H),  8.01-7.81 (m, 1H), 7.36-7.11 (m, 2H), 7.11- 6.87 (dd, J = 7.8, 2.7 Hz, 1H), 4.47-4.29 (s,  1H), 3.72-3.47 (s, 2H), 2.66-2.57 (d, J = 2.7  Hz, 3H), 2.55-2.45 (d, J = 3.4 Hz, 4H).
424
97%


 


3-75




OMe
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.80-14.62 (m,  1H), 8.38-8.18 (m, 1H), 8.03-7.83 (m, 1H),  8.96-8.82 (m, 1H), 7.77-7.59 (m, 1H), 7.37- 7.22 (m, 1H), 4.48-4.29 (m, 1H), 3.24-3.08 (m,  2H), 3.94-3.70 (m, 2H), 1.32-1.12 (m, 2H),  1.12-0.86 (m, 2H).
394
100%


 


3-76




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 15.11-14.26 (d,  J = 53.0 Hz, 1H), 10.22-9.45 (m, 1H), 9.01-8.84  (m, 1H), 8.77-8.58 (s, 1H), 8.09-7.92 (d, J = 8.5  Hz, 1H), 7.88-7.68 (s, 1H), 7.51-7.33 (s, 1H),  4.84-4.58 (s, 2H), 4.53-4.25 (s, 1H), 2.96-2.72  (s, 6H), 2.72-2.56 (s, 3H), 1.34-1.17 (d, J = 6.5  Hz, 2H), 1.17-0.93 (d, J = 10.1 Hz, 2H).
435
94%


 


3-77




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.87-14.59 (s,  1H), 12.20-12.00 (s, 1H), 9.01-8.79 (s, 1H), 8.09- 7.83 (d, J = 8.6 Hz, 1H), 7.74-7.59 (s, 1H), 7.39- 7.20 (m, 2H), 4.48-4.31 (s, 1H), 2.72-2.56 (s, 3H),  1.36-1.12 (d, J = 6.9 Hz, 2H), 1.12-0.79 (s, 2H).
411
98%


 


3-78




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.85-14.61 (s, 1H),  10.68-10.51 (s, 1H), 9.04-8.78 (m, 1H), 8.01-7.81  (m, 1H), 7.36-7.11 (m, 2H), 7.11-6.87 (dd, J = 7.8,  2.7 Hz, 1H), 4.47-4.29 (s, 1H), 3.72-3.47 (s, 2H),  1.27-1.08 (m, 2H), 1.08-0.86 (s, 2H). 
393
95%


 


3-79




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.82-14.60 (s, 1H),  11.50-11.28 (s, 1H), 8.99-8.81 (s, 1H), 8.09-7.90  (m, 2H), 7.66-7.53 (d, J = 1.1 Hz, 1H), 6.91-6.78 (s, 1H), 6.17-5.99 (d, J = 15.7 Hz, 1H), 5.38-5.23  (d, J = 9.0 Hz, 1H), 4.48-4.31 (dd, J = 8.4, 4.4 Hz,  1H), 3.61-3.41 (s, 1H), 2.71-2.56 (s, 3H), 1.32- 1.16 (s, 2H), 1.14-0.97 (s, 2H).
421
97%


 


3-80




MeO
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.82-14.60 (s, 1H),  11.50-11.28 (s, 1H), 8.99-8.81 (s, 1H), 8.09-7.90 (m,  2H), 7.66-7.53 (d, J = 1.1 Hz, 1H), 6.91-6.78 (s, 1H),  6.17-5.99 (d, J = 15.7 Hz, 1H), 5.38-5.23 (d, J = 9.0  Hz, 1H), 4.48-4.31 (dd, J = 8.4, 4.4 Hz, 1H), 3.61- 3.41 (s, 1H), 2.71-2.56 (s, 3H), 1.14-0.97 (s, 4H).
437
90%


 


3-81




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.85-14.61 (s, 1H),  10.95-10.69 (s, 1H), 9.06-8.79 (s, 2H), 8.05-7.90 (d,  J = 8.7 Hz, 1H), 7.28-7.09 (s, 1H), 6.65-6.63 (s, 1H), 4.46 -4.29 (tt, J = 7.4, 4.0 Hz, 1H), 2.72-2.54 (s, 3H),  1.32-1.14 (d, J = 5.8 Hz, 2H), 1.14-0.97 (d, J = 3.8  Hz, 2H).
394
94%


 


3-82




OMe
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.89-14.50 (s, 2H),  11.09-10.63 (s, 1H), 9.21-8.97 (s, 1H), 8.97-8.73 (s,  1H), 8.07-7.85 (m, 1H), 3.48-3.31 (m, 5H), 7.42- 7.26 (m, 1H), 7.04-6.87 (m, 1H), 4.31-4.13 (p, J =  5.6 Hz, 1H), 2.72-2.54 (s, 3H), 1.27-1.01 (d, J =  5.6 Hz, 4H).
410
98%


 


3-83




OMe
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 15.05-14.39 (s, 1H),  13.02-12.32 (s, 1H), 8.97-8.77 (s, 1H), 8.47-8.20 (s,  1H), 7.85-7.39 (m, 2H), 7.33-6.98 (d, J = 8.0 Hz,  1H), 4.47-4.23 (s, 1H), 2.74-2.52 (s, 3H), 1.34-1.13  (m, 2H), 1.13-0.71 (s, 2H).
428
100%


 


3-84




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.75 (d, J = 8.7 Hz,  1H), 8.91 (s, 1H), 8.13 (s, 1H), 7.99 (t, J = 11.1 Hz,  1H), 7.78 (t, J = 13.2 Hz, 1H), 7.72 (s, 1H), 7.33 (d,  J = 8.5 Hz, 1H), 7.07 (s, 1H), 4.40 (m, 1H), 2.61 (s,  3H), 1.24 (d, J = 5.7 Hz, 2H), 1.08 (s, 2H).
378
98%


 


3-85




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.70 (s, 1H), 8.90  (s, 1H), 8.21 (d, J =8.0 Hz, 1H), 7.98 (d, J = 8.1 Hz,  1H), 7.94 (s, 1H), 7.90 (s, 1H), 7.56 (s, 1H), 7.38 (d,  J = 7.9 Hz, 1H), 4.38 (s, 1H), 2.65 (s, 3H), 1.17 (m,  2H), 1.06 (m, 2H).
394
98%


 











3-86




1H NMR (400 MHz, DMSO) δ 15.38-14.22 (s, 1H),  9.14-9.08 (s, 1H), 9.00-8.94 (s, 1H), 8.32-8.24 (s,  1H), 7.93-7.90 (s, 1H), 7.90-7.86 (s, 1H), 7.83-7.76  (d, J = 9.72 Hz, 1H), 5.07-4.96 (d, J = 6.74 Hz, 1H),  4.65-4.56 (d, J = 11.26 Hz, 1H), 4.53-4.43 (d, J =  9.86 Hz, 1H), 1.54-1.46 (d, J = 6.76 Hz, 3H).
414
99%


 


3-87




1H NMR (400 MHz, DMSO) δ 14.87 (s, 1H), 8.93  (s, 1H), 8.77 (s, 1H), 8.27 (d, J = 8.2 Hz, 1H), 8.15  (s, 1H), 7.73 (d, J = 0.9 Hz, 1H), 7.63 (m, 2H), 4.46- 4.36 (m, 1H), 2.76 (s, 3H), 1.29 (d, J = 6.5 Hz, 2H), 1.08 (t, J = 7.4 Hz, 2H).
394
99%
















TABLE 4













 











Com-






pound


MS



No.
R3 =
NMR
(MH+)
HPLC





4-1




1H NMR (400 MHz, DMSO) δ 14.49 (s, 1H), 11.38 (s, 1H),  8.70 (s, 1H), 7.78 (d, J = 9.1 Hz, 1H), 7.42 (d, J = 7.9 Hz, 1H),  7.26 (d, J = 8.1 Hz, 1H), 7.00-6.92 (m, 1H), 6.86 (t, J = 7.5  Hz, 1H), 6.51 (s, 1H), 4.24-4.16 (m, 1H), 2.56 (s, 3H), 1.03  (dd, J = 12.0, 4.6 Hz, 2H), 0.86 (d, J = 7.4 Hz, 2H).
377
95%


 


4-2




1H NMR (400 MHz, DMSO) δ 14.70 (s, 1H), 11.59 (s, 1H),  8.92 (s, 1H), 8.00 (d, J = 9.1 Hz, 1H), 7.64 (d, J = 7.5 Hz,  1H), 7.48 (d, J = 8.0 Hz, 1H), 7.19 (t, J = 7.5 Hz, 1H), 7.08  (t, J = 7.3 Hz, 1H), 6.73 (s, 1H), 4.42 (s, 1H), 2.78 (s, 3H),  1.27 (d, J = 6.1 Hz, 2H), 1.07 (s, 2H).
377
100%


 


4-3




1H NMR (400 MHz, DMSO) δ 14.66 (s, 1H), 8.93 (s, 1H),  8.05 (d, J = 8.6 Hz, 1H), 7.65 (d, J = 7.7 Hz, 1H), 7.57 (d,  J = 8.0 Hz, 1H), 7.30-7.24 (m, 1H), 7.14 (t, J = 7.3 Hz,  1H), 6.68 (s, 1H), 4.41 (s, 1H), 3.58 (s, 3H), 2.65 (s, 3H),  1.24 (s, 4H).
391
98%


 


4-4




1H NMR (400 MHz, DMSO) δ 14.82 (s, 1H), 11.36 (s, 1H),  8.90 (s, 1H), 7.95 (d, J = 7.8 Hz, 1H), 7.57 (s, 3H), 7.46 (s,  1H), 7.07 (d, J = 8.5 Hz, 1H), 6.53 (s, 1H), 4.39 (s, 1H),  2.62 (s, 3H), 1.24 (s, 2H), 1.09 (d, J = 18.8 Hz, 2H).
377
87%


 


4-5




1H NMR (400 MHz, DMSO) δ 14.71 (s, 1H), 11.55 (s, 1H),  8.92 (s, 1H), 8.00 (d, J = 9.0 Hz, 1H), 7.30 (d, J = 8.4 Hz,  1H), 7.09 (t, J = 7.4 Hz, 1H), 6.87 (d, J = 6.9 Hz, 1H), 6.75  (s, 1H), 4.42 (s, 1H), 2.79 (s, 3H), 2.09 (s, 1.28 (d, J = 6.0  Hz, 2H), 1.07 (s, 2H).
391
90%


 


4-6




1H NMR (400 MHz, DMSO) δ 14.71 (s, 1H), 11.43 (s, 1H),  8.91 (s, 1H), 7.99 (d, J = 8.7 Hz, 1H), 7.37 (d, J = 6.6 Hz,  1H), 7.13 (s, 1H), 6.84 (d, J = 8.7 Hz, 1H), 6.63 (s, 1H),  4.41 (s, 1H), 3.78 (s, 4H), 2.77 (s, 3H), 1.26 (d, J = 5.7 Hz,  2H), 1.07 (s, 2H).
407
92.3%


 


4-9




1H NMR (400 MHz, DMSO) δ 14.65 (s, 1H), 12.23 (d, J =  30.1 Hz, 1H), 8.93 (s, 1H), 8.20 (d, J = 11.8 Hz, 1H), 7.65  (s, 1H), 7.53 (s, 2H), 6.87 (d, J = 26.1 Hz, 1H), 4.38 (d, J =  31.7 Hz, 1H), 2.74 (d, J = 19.6 Hz, 3H), 1.24 (d, J = 8.9 Hz,  2H), 1.07 (s, 2H).
402
92.8%


 


4-10




1H NMR (400 MHz, DMSO) δ 14.67 (s, 1H), 11.70 (s, 1H),  8.92 (s, 1H), 8.00 (d, J = 8.9 Hz, 1H), 7.52-7.44 (m, 1H),  7.41 (d, J = 9.8 Hz, 1H), 7.04 (t, J = 9.3 Hz, 1H), 6.72 (s,  1H), 4.42 (s, 1H), 2.77 (s, 3H), 1.26 (d, J = 6.4 Hz, 2H), 1.07  (s, 2H).
395
89.7%


 


4-11




1H NMR (400 MHz, DMSO) δ 14.68 (s, 1H), 11.98 (s, 1H),  8.93 (s, 1H), 8.02 (d, J = 9.1 Hz, 1H), 7.47 (d, J = 7.3 Hz,  1H), 7.19 (q, J = 7.8 Hz, 2H), 6.76 (s, 1H), 4.42 (s, 1H), 2.78  (s, 3H), 1.27 (d, J = 6.2 Hz, 2H), 1.08 (s, 2H).
411
97%


 


4-12




1H NMR (400 MHz, DMSO) δ 14.64 (s, 1H), 12.30 (s, 1H),  8.93 (s, 1H), 8.04 (d, J = 8.3 Hz, 1H), 7.86 (d, J = 6.8 Hz,  1H), 7.64 (s, 1H), 7.36 (s, 1H), 6.91 (s, 1H), 4.43 (s, 1H),  2.78 (s, 3H), 1.28 (s, 2H), 1.09 (s, 2H).
402
99%


 


4-13




1H NMR (400 MHz, DMSO) δ 14.66 (s, 1H), 11.93 (s, 1H),  8.92 (s, 1H), 8.01 (d, J = 9.1 Hz, 1H), 7.33 (d, J = 8.3 Hz,  1H), 7.17 (d, J = 6.5 Hz, 1H), 6.87 (t, J = 8.9 Hz, 1H), 6.80  (s, 1H), 4.42 (s, 1H), 2.78 (s, 3H), 1.27 (d, J = 6.4 Hz, 2H),  1.07 (s, 2H).
395
87%


 


4-14




1H NMR (400 MHz, DMSO) δ 14.70 (s, 1H), 11.43 (s, 1H),  8.92 (s, 1H), 8.00 (d, J = 8.8 Hz, 1H), 7.46 (s, 1H), 6.98 (s,  2H), 6.67 (s, 1H), 4.42 (s, 1H), 2.77 (s, 3H), 1.26 (d, J = 6.3  Hz, 2H), 1.09 (s, 2H).
391
92.7%


 


4-15




1H NMR (400 MHz, DMSO) δ 11.07 (s, 1H), 9.02 (s, 1H),  8.04 (s, 1H), 7.55 (s, 2H), 7.29 (s, 1H), 6.96 (s, 1H), 6.67  (s, 1H), 2.85 (s, 3H), 2.47 (s, 3H), 1.34 (s, 2H), 1.09 (s,  2H).
391
99%


 


4-16




1H NMR (400 MHz, DMSO) δ 14.64 (s, 1H), 12.41 (s, 1H),  8.93 (s, 1H), 8.69 (s, 1H), 8.07 (d, J = 13.8 Hz. 2H), 7.67 (s,  1H), 7.05 (s, 1H), 4.42 (s, 1H), 2.78 (s, 3H), 1.26 (s, 2H),  1.08 (s, 2H).
422
100%


 


4-17




1H NMR (400 MHz, DMSO) δ 14.70 (s, 1H), 11.70 (s, 1H),  8.92 (s, 1H), 8.00 (d, J = 9.0 Hz, 1H), 7.65 (s, 1H), 7.24 (d,  J = 10.1 Hz, 1H), 6.96 (t, J = 9.1 Hz, 1H), 6.76 (s, 1H), 4.42  (s, 1H), 2.77 (s, 3H), 1.26 (d, J = 5.7 Hz, 2H), 1.07 (s, 2H).
395
88%


 


4-18




1H NMR (400 MHz, DMSO) δ 14.68 (s, 1H), 12.08 (s, 1H),  8.92 (s, 1H), 8.01 (d, J = 8.9 Hz, 1H), 7.47 (d, J = 6.4 Hz,  1H), 7.04 (d, J = 9.3 Hz, 2H), 6.79 (s, 1H), 4.42 (s, 1H),  2.76 (s, 3H), 1.26 (d, J = 6.2 Hz, 2H), 1.08 (s, 2H).
395
89.1%


 


4-19




1H NMR (400 MHz, DMSO) δ 14.65 (s, 1H), 12.66 (s, 1H),  11.98 (s, 1H), 8.93 (s, 1H), 8.12 (s, 1H), 8.03 (d, J = 8.8 Hz,  1H), 7.70 (q, J = 8.2 Hz, 2H), 6.83 (s, 1H), 4.43 (s, 1H), 2.78  (s, 3H), 1.27 (d, J = 6.2 Hz, 2H), 1.08 (s, 2H).
421
100%


 


4-20




1H NMR (400 MHz, DMSO) δ 14.68 (s, 1H), 11.78 (s, 1H),  8.92 (s, 1H), 8.01 (d, J = 9.0 Hz, 1H), 7.66 (d, J = 8.6 Hz,  1H), 7.51 (s, 1H), 7.10 (d, J = 8.4 Hz, 1H), 6.77 (s, 1H),  4.42 (s, 1H), 2.77 (s, 3H), 1.26 (d, J = 6.1 Hz, 2H), 1.07 (s,  2H).
411
90%


 


4-21




1H NMR (400 MHz, DMSO) δ 14.49 (s, 1H), 12.71 (s, 1H),  8.92 (s, 1H), 8.15 (s, 1H), 8.04 (d, J = 9.4 Hz, 2H), 7.43 (s,  1H), 7.29 (s, 1H), 4.42 (s, 1H), 2.79 (s, 3H), 1.27 (s, 2H),  1.08 (s, 2H).
422
97%


 


4-22




1H NMR (400 MHz, MeOD) δ 8.96 (s, 1H), 7.93 (d, J =  9.1 Hz, 1H), 7.55 (d, J = 12.6 Hz, 2H), 7.47 (s, 1H), 7.34 (d, J = 8.1 Hz, 1H), 6.77 (s, 1H), 6.57 (d, J = 7.9 Hz,  1H), 6.51 (s, 1H), 4.29 (s, 1H), 2.78 (s, 3H), 1.38-1.24  (m, 2H), 1.20 (s, 2H).
393
90%


 


4-23




1H NMR (400 MHz, DMSO) δ 14.68 (s, 1H), 11.82 (s,  1H), 8.92 (s, 1H), 8.01 (d, J = 8.5 Hz, 1H), 7.70 (s, 1H), 7.50 (d, J = 8.3 Hz, 1H), 7.19 (d, J = 9.4 Hz, 1H), 6.73  (s, 1H), 4.42 (s, 1H), 2.76 (s, 3H), 1.26 (d, J = 6.1 Hz,  2H), 1.07 (s, 2H).
411
90%


 


4-24




1H NMR (400 MHz, DMSO) δ 14.63 (s, 1H), 11.61 (s,  1H), 8.95 (d, J = 9.5 Hz, 1H), 8.41 (s, 1H), 7.99 (s,  1H), 7.67 (d, J = 9.1 Hz, 1H), 6.52 (s, 1H), 4.43 (s, 1H),  2.78 (s, 3H), 1.25 (s, 2H), 1.08 (s, 2H). 
422
90%


 


4-25




1H NMR (400 MHz, DMSO) δ 14.82 (s, 1H), 11.31 (s,  1H), 8.91 (s, 1H), 7.97 (d, J = 8.4 Hz, 1H), 7.71 (d, J =  7.8 Hz, 1H), 7.48 (s, 1H), 7.41 (s, 1H), 6.99 (d, J = 7.9  Hz, 1H), 6.53 (s, 1H), 4.40 (s, 1H), 2.63 (s, 3H), 1.24 (s,  2H), 1.08 (s, 2H).
377
100%


 


4-26




1H NMR (400 MHz, DMSO) δ 14.70 (s, 1H), 12.37 (s,  1H), 8.93 (s, 1H), 8.19 (t, J = 9.0 Hz, 2H), 8.01 (d, J =  8.0 Hz, 1H), 7.34 (s, 1H), 7.00 (s, 1H), 4.43 (s, 1H),  2.75 (s, 3H), 1.24 (s, 2H), 1.11 (s, 2H).
422
99%


 


4-27




1H NMR (400 MHz, DMSO) δ 14.73 (s, 1H), 11.45 (s,  1H), 9.17 (s, 1H), 8.92 (s, 1H), 7.99 (d, J = 8.6 Hz,  1H), 7.77 (s, 1H), 7.35 (d, J = 8.5 Hz, 1H), 7.24 (s,  1H), 6.64 (s, 1H), 4.42 (s, 1H), 2.77 (s, 2H), 1.46 (d,  J = 29.9 Hz, 9H), 1.25 (s, 2H), 1.06 (s, 2H).
492
100%


 


4-28 




1H NMR (400 MHz, DMSO) δ 14.67 (s, 1H), 11.94 (s,  1H), 9.97 (s, 2H), 8.93 (s, 1H), 8.02 (d, J = 8.7 Hz,  1H), 7.65 (s, 1H), 7.60 (d, J = 8.6 Hz, 1H), 7.19-7.13  (m, 1H), 6.84 (s, 1H), 4.42 (s, 2H), 2.76 (s, 3H), 1.14- 1.00 (m, 4H). 
392
94%


 


4-29 




1H NMR (400 MHz, DMSO) δ 14.67 (s, 1H), 11.94 (s,  1H), 9.97 (s, 2H), 8.93 (s, 1H), 8.02 (d, J = 8.7 Hz,  1H), 7.65 (s, 1H), 7.60 (d, J = 8.6 Hz, 1H), 7.19-7.13  (m, 1H), 6.84 (s, 1H), 4.42 (s, 2H), 2.76 (s, 3H), 1.14- 1.00 (m, 4H).
391
100%


 


4-30 




1H NMR (400 MHz, DMSO) δ 14.73 (s, 1H), 11.38 (s,  1H), 9.33 (s, 1H), 8.91 (s, 1H), 7.98 (d, J = 9.1 Hz,  1H), 7.81 (s, 1H), 7.48 (d, J = 8.3 Hz, 1H), 7.09 (d, J =  8.7 Hz, 1H), 6.64 (s, 1H), 4.42 (s, 1H), 2.78 (s, 3H), 1.51 (s, 10H), 1.25 (d, J = 8.9 Hz, 2H),  1.08 (dd, J = 14.0, 6.3 Hz, 2H).
492
97%


 


4-31 




1H NMR (400 MHz, DMSO) δ 14.31 (s, 1H), 11.68 (s,  1H), 8.94 (s, 1H), 8.17 (d, J = 8.7 Hz, 1H), 7.66 (d, J =  7.8 Hz, 1H), 7.49 (d, J = 8.1 Hz, 1H), 7.21 (t, J = 7.5  Hz, 1H), 7.08 (t, J = 7.4 Hz, 1H), 6.80 (s, 1H), 4.44 (s,  1H), 1.25 (d, J = 6.4 Hz, 2H), 1.12 (s, 2H).
397
100%


 


4-32 




1H NMR (400 MHz, DMSO) δ 14.72 (s, 1H), 11.74 (s,  1H), 9.35 (s, 2H), 8.92 (s, 1H), 8.00 (d, J = 9.0 Hz,  1H), 7.66 (d, J = 8.5 Hz, 1H), 7.34 (s, 1H), 6.94 (d, J =  8.3 Hz, 1H), 6.76 (s, 1H), 4.42 (s, 1H), 2.78 (s, 3H),  1.27 (d, J = 5.6 Hz, 3H), 1.06 (s, 2H).
392
97%


 


4-33 




1H NMR (400 MHz, DMSO) δ 14.73 (s, 1H), 11.56 (s,  1H), 9.17 (s, 1H), 8.93 (s, 1H), 8.00 (d, J = 7.7 Hz,  1H), 7.46 (s, 2H), 7.12 (d, J = 20.9 Hz, 2H), 5.18-4.56 (m,  1H), 4.44 (s, 1H), 2.80 (s, 3H), 1.24 (s, 2H), 1.07 (s, 2H).
492
91%


 


4-34 




1H NMR (400 MHz, DMSO) δ 14.70 (s, 1H), 11.77 (s,  1H), 8.93 (s, 1H), 8.01 (d, J = 6.4 Hz, 1H), 7.23-7.03  (m, 2H), 6.88(s, 1H), 6.76 (d, J = 6.4 Hz, 1H), 4.43 (m,  1H), 2.77(s, 3H), 1.24 (d, J = 6.6 Hz, 2H), 1.12 (s, 2H).
392
99%


 


4-35 




1H NMR (400 MHz, DMSO) δ 14.28 (s, 1H), 11.79 (s,  1H), 8.94 (s, 1H), 8.17 (d, J = 8.8 Hz, 1H), 7.56-7.38  (m, 2H), 7.06 (t, J = 8.8 Hz, 1H), 6.79 (s, 1H), 4.44 (s,  1H), 1.24 (d, J = 6.6 Hz, 2H), 1.12 (s, 2H).
415
91%


 


4-36 




1H NMR (400 MHz, DMSO) δ 14.28 (s, 1H), 12.16 (s,  1H), 8.95 (s, 1H), 8.18 (d, J = 8.0 Hz, 1H), 7.49 (d, J =  4.2 Hz, 1H), 7.05 (d, J = 8.5 Hz, 2H), 6.85 (s, 1H), 4.43  (s, 1H), 1.24 (s, 2H), 1.13 (s, 2H).
415
95%


 


4-37 




1H NMR (400 MHz, DMSO) δ 14.26 (s, 1H), 12.07 (s,  1H), 8.95 (s, 1H), 8.19 (d, J = 8.5 Hz, 1H), 7.49 (d, J =  7.6 Hz, 1H), 7.29-7.07 (m, 2H), 6.81 (s, 1H), 4.44 (s,  1H), 1.25 (s, 2H), 1.13 (s, 2H).
431
95%


 


4-38 




1H NMR (400 MHz, DMSO) δ 14.28 (s, 1H), 12.04 (s,  1H), 8.95 (s, 1H), 8.19 (d, J = 8.7 Hz, 1H), 7.34 (d, J =  8.0 Hz, 1H), 7.20 (s, 1H), 6.93-6.81 (m, 2H), 4.44 (s,  1H), 1.24 (s, 2H), 1.13 (s, 2H).  
415
87%


 


4-39 




1H NMR (400 MHz, DMSO) δ 14.71 (s, 1H), 11.66 (s,  1H), 10.06 (s, 1H), 8.92 (s, 1H), 8.02 (s, 3H), 7.46 (s,  1H), 7.31 (s, 1H), 7.19 (s, 1H), 7.06 (s, 1H), 6.90 (s,  1H), 4.42 (s, 1H), 3.85 (s, 3H), 2.79 (s, 3H), 1.26 (s,  2H), 1.07 (s, 2H). 
526
95.6%


 


4-40 




1H NMR (400 MHz, DMSO) δ 14.71 (s, 1H), 11.62 (s,  1H), 10.05 (s, 1H), 8.93 (s, 1H), 7.99 (d, J = 9.2 Hz,  1H), 7.70 (d, J = 7.5 Hz, 2H), 7.28-6.87 (m, 6H), 4.42  (s, 1H), 3.75 (s, 3H), 2.68 (s, 3H), 1.25 (d, J = 9.3 Hz,  2H), 1.05 (d, J = 18.8 Hz, 2H)
562
96%


 


4-41 




1H NMR (400 MHz, DMSO) δ 14.73 (s, 1H), 11.66 (s,  1H), 9.62 (s, 1H), 8.93 (s, 1H), 6.02 (d, J = 8.7 Hz,  1H), 7.72 (s, 1H), 7.21 (s, 1H), 7.12 (s, 1H), 7.04 (s,  1H), 4.44 (s, 1H) 3.05 (s, 1H), 2.82 (d, J = 25.3 Hz,  3H), 1.12 (d, J = 24.4 Hz, 10H).
462
87%


 


4-42 




1H NMR (400 MHz, DMSO) δ 11.87 (s, 1H), 9.18 (s,  1H), 8.08-7.63 (m, 2H), 7.48 (s, 2H), 7.20 (s, 2H), 6.95  (s, 2H), 4.54 (s, 1H), 4.24 (s, 2H), 2.81 (s, 3H), 1.29 (s,  2H), 1.06 (s, 2H).
406
97%


 


4-43 




1H NMR (400 MHz, DMSO) δ 14.78 (s, 1H), 11.70 (s,  1H), 8.98 (s, 1H), 8.06 (d, J = 9.0 Hz, 1H), 7.49 (s,  1H), 7.43 (d, J = 7.4 Hz, 1H), 7.20 (s, 1H), 7.00 (d, J =  6.8 Hz, 1H), 6.91 (s, 1H), 4.49 (s, 3H), 2.84 (s, 3H),  1.46 (s, 9H), 1.30 (s, 2H), 1.13 (s, 2H).
506
98%


 


4-44 




1H NMR (400 MHz, DMSO) δ 14.76 (s, 1H), 12.92 (s,  1H), 8.92 (s, 1H), 8.79 (s, 1H), 8.07 (s, 1H), 7.99 (d, J =  8.6 Hz, 1H), 7.77 (d, J = 8.3 Hz, 1H), 7.37 (d, J = 8.0  Hz, 1H), 4.40 (s, 1H), 2.62 (s, 3H), 1.25 (d, J = 5.7 Hz,  2H), 1.10 (s, 2H). 
422
100%


 


4-45 




1H NMR (400 MHz, DMSO) δ 11.65 (s, 1H), 9.57 (s,  1H), 8.82 (s, 1H), 7.93 (d, J = 8.3 Hz, 1H), 7.71 (d, J = 5.5 Hz, 1H), 7.19 (s, 1H), 7.09 (s, 1H), 7.00 (s, 1H),  4.32 (s, 1H), 2.72 (d, J = 18.9 Hz, 3H), 1.89-1.77 (m,  5H), 1.65 (s, 1H), 1.45 (d, J = 10.5 Hz, 2H), 1.35-1.16  (m, 6H), 0.97 (s, 2H).
502
89%


 


4-46 




1H NMR (400 MHz, DMSO) δ 14.69 (s, 1H), 11.94 (s,  1H), 9.39 (s, 1H), 8.92 (s, 1H), 8.00 (d, J = 7.8 Hz,  1H), 7.72 (s, 1H), 7.28 (s, 1H), 7.15 (s, 1H), 6.81 (s,  1H), 4.43 (s, 1H), 4.27-4.13 (m, 2H), 2.79 (s, 3H), 2.33  (s, 1H), 2.17 (s, 1H), 1.59 (d, J = 14.2 Hz, 2H), 1.26 (s,  5H), 1.07 (s, 2H), 0.85 (dd, J = 54.3, 14.6 Hz, 14H).
588
86.3%


 


4-47 




1H NMR (400 MHz, DMSO) δ 14.73 (s, 1H), 11.74 (s,  1H), 10.60 (s, 1H), 9.30 (s, 1H), 8.92 (s, 1H), 8.61 (d,  J = 7.6 Hz, 1H), 8.11 (d, J = 7.9 Hz, 1H), 8.01 (d, J =  8.8 Hz, 1H), 7.59 (d, J = 6.7 Hz, 1H), 7.37 (d, J = 7.8  Hz, 1H), 7.24 (d, J = 8.0 Hz, 1H), 6.97 (s, 1H), 4.43  (s, 1H), 2.79 (s, 3H), 1.25 (s, 2H), 1.07 (s, 2H).
565
96%


 


4-48 




1H NMR (400 MHz, DMSO) δ 14.70 (s, 1H), 11.74 (s,  1H), 9.76 (s, 1H), 8.93 (s, 1H), 8.01 (d, J = 8.7 Hz,  1H), 7.29 (d, J = 6.6 Hz, 1H), 7.23- 7.01 (m, 3H), 4.43  (s, 1H), 3.49 (d, J = 14.6 Hz, 1H), 3.06 (d, J = 14.8 Hz,  1H), 2.37 (dd, J = 27.4, 15.5 Hz, 2H), 2.04 (s, 1H), 1.91  (d, J = 17.7 Hz, 2H), 1.51 (d, J = 11.3 Hz, 1H), 1.41 (d,  J = 10.3 Hz, 1H), 1.25 (s, 2H), 1.09 (d, J = 11.8 Hz,  3H), 0.98 (s, 2H), 0.77 (d, J = 22.2 Hz, 3H).
606
88%


 


4-49 




1H NMR (400 MHz, DMSO) δ 14.69 (s, 1H), 11.58 (s,  1H), 10.29 (s, 1H), 8.91 (s, 1H), 8.40 (s, 1H), 8.05 (dd,  J = 15.6, 8.6 Hz, 2H), 7.97 (s, 2H), 7.83 (d, J = 8.2 Hz,  1H), 7.72- 7.56 (m, 2H), 7.18 (d, J = 8.0 Hz, 1H), 7.04  (t, J = 8.0 Hz, 1H), 6.98 (d, J = 7.5 Hz, 1H), 6.81 (s,  1H), 4.35 (s, 1H), 2.54 (s, 3H), 1.23 (s, 2H), 1.04 (s, 2H).
582
100%


 


4-50 




1H NMR (400 MHz, DMSO) δ 14.72 (s, 1H), 11.68 (s,  1H), 10.26 (s, 1H), 8.92 (s, 1H), 8.00 (s, 1H), 7.74 (s,  1H), 7.29 (s, 1H), 7.19 (s, 1H), 7.03 (s, 1H), 6.93 (s, 2H),  4.43 (s, 1H), 2.79 (s, 3H), 2.31 (s, 6H), 2.10 (s, 3H), 1.24  (s, 2H), 1.07 (s, 2H).
538
90%


 


4-51 




1H NMR (400 MHz, DMSO) δ 14.73 (s, 1H), 11.62 (s,  1H), 10.08 (s, 1H), 8.93 (s, 1H), 8.00 (d, J = 7.6 Hz,  1H), 7.76 (d, J = 8.6 Hz, 2H), 7.18 (d, J = 7.7 Hz, 2H),  7.02 (d, J = 18.7 Hz, 2H), 4.44 (s, 1H), 3.63 (s, 3H),  2.76 (s, 3H), 1.24 (s, 2H), 1.08 (s, 2H).
536
99%


 


4-52 




1H NMR (400 MHz, DMSO) δ 14.72 (s, 1H), 11.68 (s,  1H), 9.29 (s, 1H), 8.93 (s, 1H), 8.81 (s, 1H), 8.31 (s,  1H), 8.03 (d, J = 8.9 Hz, 1H), 7.15 (s, 2H), 7.02 (dd, J = 24.0, 8.3 Hz, 2H), 6.94 (s, 1H), 4.44 (s, 1H), 3.91 (s,  3H), 2.80 (s, 3H), 1.25 (d, J = 15.5 Hz, 2H), 1.08 (s, 2H).
575
96%


 


4-53 




1H NMR (400 MHz, DMSO) δ 14.71 (s, 1H), 11.72 (s,  1H), 10.04 (s, 1H), 8.94 (s, 1H), 8.02 (d, J = 10.3 Hz,  1H), 7.71 (d, J = 7.0 Hz, 1H), 7.24 (s, 1H), 7.15 (d, J =  7.3 Hz, 1H), 7.04 (s, 1H), 4.44 (s, 1H), 3.98 (s, 2H),  3.76 (s, 2H), 3.43 (s, 2H), 3.07 (d, J = 24.3 Hz, 4H),  2.78 (s, 3H), 2.69 (d, J = 10.9 Hz, 1H), 1.26 (s, 2H),  1.08 (s, 2H).
533
99%


 


4-54 




1H NMR (400 MHz, DMSO) δ 14.71 (s, 1H), 11.72 (s,  1H), 10.03 (s, 1H), 8.94 (s, 1H), 8.02 (d, J = 8.9 Hz,  1H), 7.70 (s, 1H), 7.24 (s, 1H), 7.14 (s, 1H), 7.03 (s,  1H), 5.33 (s, 1H), 4.43 (s, 1H), 4.03 (s, 2H), 3.03 (s,  4H), 2.78 (s, 3H), 2.00 (d, J = 7.6 Hz, 2H), 1.24 (s,  9H), 1.08 (s, 2H), 0.85 (s, 2H). 
632
96%


 


4-55 




1H NMR (400 MHz, DMSO) δ 14.71 (s, 1H), 11.72 (s,  1H), 10.04 (s, 1H), 9.57 (s, 1H), 8.94 (s, 1H), 8.02 (d,  J = 8.9 Hz, 1H), 7.71 (d, J = 7.8 Hz, 1H), 7.26 (d, J =  7.6 Hz, 1H), 7.15 (d, J = 9.1 Hz, 1H), 7.03 (d, J = 9.6 Hz, 1H), 4.44 (s, 1H), 2.99 (s,  1H), 2.82 (s, 3H), 2.78 (s, 2H), 2.54 (s, 2H), 1.26 (s,  2H), 1.08 (s, 2H). 
491
91%


 


4-56 




1H NMR (400 MHz, DMSO) δ 14.71 (s, 1H), 11.87 (s,  1H), 10.45 (s, 1H), 8.93 (s, 1H), 8.02 (d, J = 8.8 Hz,  1H), 7.47 (d, J = 7.2 Hz, 1H), 7.23 (s, 1H), 7.07 (d, J =  7.9 Hz, 1H), 6.68 (s, 1H), 4.42 (s, 1H), 2.78 (s, 3H),  2.68 (s, 3H), 1.26 (s, 2H), 1.08 (s, 2H).
490
96%


 


4-57 




1H NMR (400 MHz, DMSO) δ 14.78 (s, 1H), 11.75 (s,  1H), 9.64 (s, 1H, 8.92 (s, 1H), 7.99 (d, J = 8.7 Hz,  1H), 7.83 (s, 1H), 7.70 (s, 1H), 7.63 (d, J = 7.8 Hz,  1H), 7.18 (d, J = 8.6 Hz, 1H), 4.48 (s, 2H), 4.40 (s,  1H), 2.72 (d, J = 27.2 Hz, 7H), 2.62 (s, 3H), 1.25 (s,  2H), 1.08 (s, 2H).
M-(Me)2N 389
100%


 


4-58 




1H NMR (400 MHz, DMSO) δ 14.79 (s, 1H), 9.84 (s,  1H), 8.92 (s, 1H), 7.97 (d, J = 8.2 Hz, 1H), 7.77 (d, J =  8.7 Hz, 1H), 7.62 (s, 1H), 7.56 (s, 1H), 7.20 (d, J = 8.0  Hz, 1H), 6.63 (s, 1H), 4.64 (s, 2H), 4.39 (s, 1H), 3.57  (s, 2H), 2.88 (s, 6H), 2.65 (d, J = 22.8 Hz, 3H), 1.24 (s,  1H), 1.08 (s, 2H).
448
100%


 


4-59 




1H NMR (400 MHz, DMSO) δ 14.76 (s, 1H), 11.62 (s,  1H), 9.68 (s, 1H), 8.92 (s, 1H), 7.9 (s, 1H), 6.95 (s, 2H),  6.77 (s, 1H), 6.46 (s, 1H), 4.43 (s, 1H), 2.80 (s, 3H), 1.27  (s, 2H), 1.07 (s, 4H).
393
99%


 


4-60 




1H NMR (400 MHz, DMSO) δ 14.77 (s, 1H), 11.29 (s,  1H), 8.91 (s, 1H), 7.97 (d, J = 9.0 Hz, 1H), 7.13 (s, 1H),  6.97 (s, 1H), 6.61 (s, 1H), 4.42 (s, 1H), 3.80 (d, J = 13.7  Hz, 7H), 2.78 (s, 3H), 1.26 (s, 2H), 1.06 (s, 2H).
437
99%


 


4-61 




1H NMR (400 MHz, DMSO) δ 14.74 (s, 1H), 11.29 (s,  1H), 8.91 (s, 1H), 8.81 (s, 1H), 7.98 (d, J = 9.1 Hz, 1H),  7.27 (d, J = 8.8 Hz, 1H), 6.93 (s, 1H), 6.71 (d, J = 8.4  Hz, 1H), 6.53 (s, 1H), 4.41 (s, 2H), 2.77 (s, 3H), 1.25 (s,  2H), 1.06 (s, 2H).
393
98%


 


4-62 




1H NMR (400 MHz, DMSO) δ 14.75 (s, 1H), 11.50 (s,  1H), 9.79 (s, 1H), 8.91 (s, 1H), 7.97 (d, J = 8.7 Hz, 1H),  7.07 (d, J = 6.7 Hz, 1H), 6.86 (s, 1H), 6.60 (s, 2H), 4.41  (s, 1H), 2.76 (s, 3H), 1.23 (s, 2H), 1.08 (s, 2H).
393
100%


 


4-63 




1H NMR (400 MHz, DMSO) δ 12.18 (s, 1H), 10.24 (s,  1H), 8.93 (s, 1H), 8.04 (d, J = 8.8 Hz, 1H), 7.87 (d, J =  8.8 Hz, 2H), 7.78 (d, J = 7.0 Hz, 1H), 7.46 (d, J = 7.3  Hz, 2H), 7.35 (s, 1H), 4.43 (s, 1H), 2.77 (s, 3H), 1.27  (s, 2H), 1.09 (s, 2H).
405
85%


 


4-64 




1H NMR (400 MHz, DMSO) δ 14.55 (s, 1H), 13.88 (s,  1H), 8.94 (s, 1H), 8.10 (d, J = 8.4 Hz, 1H), 8.01 (dd, J =  14.5, 7.6 Hz, 2H), 7.62 (s, 1H), 4.44 (s, 1H), 2.71 (s,  3H), 1.24 (s, 2H), 1.08 (s, 2H).
447
89%


 


4-65 




1H NMR (400 MHz, DMSO) δ 14.44 (s, 1H), 11.53 (s,  1H), 8.84 (s, 1H), 8.16 (d, J = 9.1 Hz, 1H), 7.95 (d, J =  7.2 Hz, 1H), 7.69 (d, J = 9.7 Hz, 1H), 7.58 (t, J = 10.6  Hz, 1H), 7.42 (d, J = 7.4 Hz, 2H), 7.16 (t, J = 7.5 Hz,  1H), 7.04 (t, J = 7.4 Hz, 1H), 6.62 (s, 1H), 5.77 (s,  1H), 1.77 (d, J = 17.9 Hz, 3H).  
449
94.06%


 


4-66 




1H NMR (400 MHz, DMSO) δ 14.79 (s, 1H), 11.42 (s,  1H), 8.70 (s, 1H), 8.04 (d, J = 8.2 Hz, 1H), 7.57 (d, J =  8.2 Hz, 1H), 7.42 (d, J = 8.0 Hz, 1H), 7.25 (s, 1H), 6.96  (d, J = 8.1 Hz, 1H), 6.86 (d, J = 7.7 Hz, 1H), 6.61 (s,  1H), 4.23 (s, 1H), 2.70 (s, 3H), 1.06 (s, 2H), 0.81 (s, 2H).
359
91.2%


 


4-67 




1H NMR (400 MHz, DMSO) δ 11.76 (s, 1H), 8.71 (s,  1H), 8.16 (d, J = 4.8 Hz, 1H), 7.81 (d, J = 8.8 Hz, 1H),  7.36 (s, 1H), 5.94 (dd, J = 3.4, 1.8 Hz, 1H), 5.10 (s, 1H),  4.22-4.08 (m, 1H), 2.33 (s, 3H), 1.09-0.88 (m, 4H).
378
97%


 


4-68 




1H NMR (400 MHz, DMSO) δ 12.33 (s, 1H), 8.92 (s,  1H), 8.35 (d, J = 4.4 Hz, 1H), 7.99 (d, J = 8.8 Hz, 1H),  7.87 (s, 1H), 7.77 (d, J = 7.8 Hz, 1H), 7.21 (dd, J = 7.7,  4.0 Hz, 1H), 4.47-4.34 (m, 2H), 2.69 (s, 3H), 1.28 (d, J =  6.6 Hz, 2H), 1.10 (s, 2H).
378
98%


 


4-69 




1H NMR (400 MHz, DMSO) δ 8.94 (s, 1H), 8.39 (t, J =  3.1 Hz, 1H), 8.08 (t, J = 9.0 Hz, 2H), 7.22 (dd, J = 8.1,  4.1 Hz, 1H), 6.74 (d, J = 2.9 Hz, 1H), 4.48-4.36 (m, 1H),  2.67 (s, 3H), 1.26 (d, J = 7.0 Hz, 4H), 1.09 (s, 4H).
392
98%


 


4-70 




1H NMR (400 MHz, DMSO) δ 8.94 (s, 1H), 8.39 (t, J =  3.1 Hz, 1H), 8.07 (t, J = 9.0 Hz, 1H), 7.21 (dt, J = 7.7,  3.7 Hz, 1H), 6.74 (d, J = 2.9 Hz, 1H), 4.50-4.32 (m, 1H),  2.67 (s, 3H), 1.33-1.19 (d, J = 7.0 Hz, 2H), 1.09 (s, 2H).
392
96%


 


4-71 




1H NMR (400 MHz, DMSO) δ 14.73 (s, 1H), 11.96 (s,  1H), 8.92(s, 1H), 8.24 (s, 1H), 8.06 (s, 1H), 8.00 (d, J =  8.7 Hz, 1H), 7.61 (t, J = 2.8 Hz, 1H), 6.57 (s, 1H), 4.59- 4.15 (dm, 1H), 2.64 (s, 3H), 1.26 (d, J = 6.8 Hz, 2H),  1.09 (m, 2H).
378
98%


 


4-72 




1H NMR (400 MHz, DMSO) δ 14.67 (s, 1H), 13.15 (s,  1H), 8.93 (s, 1H), 8.27 (d, J = 6.1 Hz, 1H), 8.01 (d, J =  8.8 Hz, 1H), 7.78 (d, J = 7.9 Hz, 1H), 7.19 (t, J = 7.1  Hz, 1H), 6.88 (s, 1H), 4.49-4.33 (m, 1H), 2.77 (s, 3H),  1.39-1.21 (d, J = 7.0 Hz, 2H), 1.15-1.01 (m, 2H).
394
98%


 


4-73 




1H NMR (400 MHz, DMSO) δ 14.63 (s, 1H), 12.94 (s,  1H), 8.93 (s, 1H), 8.72 (s, 1H), 8.65 (s, 1H), 8.04 (d, J =  8.7 Hz, 1H), 6.93 (s, 1H), 4.53-4.29 (m, 1H), 2.77 (s,  3H), 1.32-1.19 (m, 3H), 1.17-0.95 (m, 2H).
403
92%


 


4-74 




1H NMR (400 MHz, DMSO) δ 14.65 (s, 1H), 13.00 (s,  1H), 8.94 (s, 1H), 8.53 (s, 7H), 8.04 (d, J = 8 Hz, 1H),  7.69 (dd, J = 4.4, 2.4 Hz, 1H), 7.01 (s, 6H), 4.58-4.31  (m, 1H), 2.78 (s, 3H), 1.27 (d, J = 6.6 Hz, 15H), 1.18- 1.01 (m, 16H).
403
92%


 


4-75 




1H NMR (400 MHz, DMSO) δ 14.57 (s, 1H), 13.95 (s,  1H), 8.94 (s, 1H), 8.58 (s, 2H), 8.09 (d, J = 8.7 Hz, 1H),  7.60-7.51 (m, 1H), 4.53-4.33 (m, 1H), 2.73 (s, 3H),  1.35-1.17 (m, 2H), 1.15-1.01 (m, 2H)
423
86%


 


4-76 




1H NMR (400 MHz, DMSO) δ 13.25 (s, 1H), 8.99 (s,  1H), 8.36 (d, J = 5.9 Hz, 1H), 8.07 (d, J = 8.7 Hz, 1H),  7.95 (s, 1H), 7.52 (d, J = 8.0 Hz, 1H), 7.28 (t, J = 6.8  Hz, 1H), 4.54-4.44 (m, 1H), 2.76 (s, 3H), 1.34 (d, J =  6.8 Hz, 2H), 1.26-1.06 (m, 2H).
394
98%


 


4-77 




1H NMR (400 MHz, DMSO) δ 12.56 (s, 1H), 8.93 (s,  1H), 8.38 (t, J = 3.6 Hz, 1H), 8.20 (d, J = 7.4 Hz, 1H),  8.02 (d, J = 9.1 Hz, 1H), 7.26 (dd, J = 8.0, 4.1 Hz, 1H),  6.83 (s, 1H), 4.57-4.33 (m, 1H), 2.78 (s, 3H), 1.35-1.19  (d, J = 6.9 Hz, 2H), 1.15-1.01 (s, 2H).
378
98%


 


4-78 




1H NMR (400 MHz, DMSO) δ 14.65 (s, 1H), 12.47 (s,  1H), 11.98 (s, 1H), 8.91(s, 1H), 7.95 (m, 2H), 6.76 (s,  1H), 4.51-4.36 (m, 1H), 2.78 (s, 3H), 1.26 (d, J = 6.9  Hz, 2H), 1.17-1.01 (m, 2H).
395
95%


 


4-79 




1H NMR (400 MHz, DMSO) δ 14.57 (s, 1H), 13.19 (d,  J = 6.5 Hz, 1H), 9.29 (d, J = 2.9 Hz, 1H), 9.02 (d, J =  2.4 Hz, 1H), 6.94 (s, 1H), 8.05 (d, J = 8.8 Hz, 1H), 7.06  (s, 1H), 4.49-4.35 (m, 1H), 2.77 (s, 3H), 1.26 (d, J = 7.2  Hz, 2H), 1.13-0.99 (s, 2H).
379
98%


 


4-80 




1H NMR (400 MHz, DMSO) δ 15.167 (s, 1H), 14.59 (s,  1H), 13.80 (s, 1H), 9.32 (s, 1H), 8.96 (d, J = 2.3 Hz, 1H),  8.40 (d, J = 6.1 Hz, 1H), 8.25 (d, J = 6.0 Hz, 1H), 8.10  (d, J = 8.4 Hz, 1H), 7.27 (s, 1H), 4.51-4.39 (m, 1H), 2.76  (m, 3H), 1.29-1.17 (d, J = 7.0 Hz, 2H), 1.17-0.97 (m, 2H).
378
85%


 


4-81 




1H NMR (400 MHz, DMSO) δ 14.56 (s, 1H), 13.05 (s,  1H), 8.95 (s, 1H), 8.68 (s, 1H), 8.08 (d, J = 9.1 Hz, 1H),  7.62 (s, 1H), 7.12 (s, 1H), 4.51-4.36 (m, 1H), 2.76 (s,  3H), 1.33-1.19 (d, J = 7.1 Hz, 2H), 1.13-1.05 (s, 2H).
378
85%


 


4-82 




1H NMR (400 MHz, DMSO) δ 14.88 (s, 1H), 14.57 (s,  1H), 13.46 (s, 1H), 9.41 (s, 1H), 8.96 (s, 1H), 8.52 (d,  J = 6.5 Hz, 1H), 8.21-7.93 (m, 2H), 7.38 (s, 1H), 4.53- 4.29 (m, 1H), 2.77 (s, 3H), 1.35-1.17 (d, J = 6.7 Hz,  2H), 1.19-1.03 (s, 2H).
378
98%


 


4-83 





421
90%


 


4-84 





421
98%


 


4-85 





482
93%


 


4-86 




1H NMR (400 MHz, DMSO) δ 14.60 (s, 1H), 10.06 (s,  1H), 8.81 (s, 1H), 7.88 (d, J = 8.5 Hz, 1H), 7.21 (s, 1H),  7.05 (d, J = 8.1 Hz, 1H), 6.80 (d, J = 8.1 Hz, 1H), 4.36  (m, 1H), 3.06 (s, 2H), 1.06 (m, 4H).
392
95%


 


4-87 




1H NMR (400 MHz, DMSO) δ 14.57 (s, 1H), 8.91 (s,  1H), 8.03 (d, J = 9.3 Hz, 1H), 7.80 (d, J = 7.7 Hz, 1H),  7.73 (d, J = 8.3 Hz, 1H), 7.56-7.22 (m, 3H), 4.57-4.32  (m, 1H), 2.84 (s, 3H), 1.27 (m, 2H), 1.06 (m, 2H).
378
98%


 


4-88 




1H NMR (400 MHz, DMSO) δ 14.50 (s, 1H), 13.22 (s,  1H), 8.84 (s, 1H), 8.10-7.80 (m, 2H), 7.74-7.58 (s, 1H),  7.49 (s, 1H), 4.38 (m, 1H), 2.78 (s, 3H), 1.30-1.12 (m,  2H), 1.00 (m, 2H).
422
98%


 


4-89 




1H NMR (400 MHz, DMSO) δ 14.56 (s, 1H), 8.93 (s,  1H), 8.02 (d, J = 9.2 Hz, 1H), 7.76 (dd, J = 8.8, 3.5 Hz,  1H), 7.61 (d, J = 8.6 Hz, 1H), 7.41 (s, 1H), 7.28 (t, J =  9.3 Hz, 1H), 4.43 (m, 1H), 2.82 (s, 3H), 1.26 (d, J = 6.4  Hz, 3H), 1.05 (s, 2H).
396
98%


 


4-90 




1H NMR (400 MHz, DMSO) δ 8.88 (s, 1H), 7.95 (d, J =  8.9 Hz, 1H), 7.76 (s, 1H), 7.61 (d, J = 8.9 Hz, 1H), 7.36  (s, 1H), 7.20 (t, J = 9.0 Hz, 1H), 4.35 (m, 1H), 2.76 (s,  3H), 1.30-1.09 (m, 3H), 0.96 (s, 2H).
396
98%


 


4-91 




1H NMR (400 MHz, DMSO) δ 14.57 (s, 1H), 8.86 (s,  1H), 7.96 (m, 3H), 7.59 (s, 1H), 7.41 (d, J = 5.1 Hz,  2H), 4.35 (m, 1H), 2.72 (s, 3H), 1.17 (m, 2H), 1.00  (m, 2H).
394
96%


 


4-92 




1H NMR (400 MHz, DMSO) δ 14.65 (s, 1H), 8.86 (s,  1H), 8.08 (d, J = 7.6 Hz, 1H), 7.97 (m, 2H), 7.36 (m,  3H), 4.32 (m, 1H), 2.57 (s, 3H), 1.03 (m, 4H).
394
98%


 


4-93 




1H NMR (400 MHz, DMSO) δ 14.51 (s, 1H), 8.92 (ss,  1H), 8.32 (d, J = 8.1 Hz, 1H), 8.28 (d, J = 8.0 Hz, 1H),  8.05 (t, J = 13.1 Hz, 1H), 7.90 (s, 1H), 7.70 (t, J = 8.2  Hz, 1H), 4.45 (m, 1H), 2.86 (s, 3H), 1.26 (t, J = 11.6  Hz, 2H), 1.10 (d, J = 21.6 Hz, 2H).
423
98%


 


4-94 




1H NMR (400 MHz, DMSO) δ 14.46 (s, 1H), 8.69 (s,  1H), 8.14 (s, 1H), 7.75 (d, J = 9.2 Hz, 1H), 7.52 (dd,  J = 8.8, 3.5 Hz, 1H), 7.20-7.11 (m, 3H), 4.43 (s, 1H),  2.64 (s, 3H), 1.26 (d, J = 6.4 Hz, 3H), 1.05 (s, 2H).
378
98%


 


4-95 




1H NMR (400 MHz, DMSO) δ 14.55 (s, 1H), 8.94 (s,  1H), 8.05 (d, J = 9.3 Hz, 1H), 7.64 (d, J = 2.9 Hz,  1H), 7.54 (s, 1H), 7.36 (d, J = 6.6 Hz, 2H), 4.44 (m,  1H), 2.85 (s, 3H), 1.34-1.19 (m, 2H), 1.06 (s, 2H).
396
96%


 


4-96 




1H NMR (400 MHz, DMSO) δ 8.91 (s, 1H), 8.38 (s,  1H), 8.04 (d, J = 9.2 Hz, 1H), 7.96 (d, J = 8.4 Hz,  1H), 7.88 (d, J = 8.5 Hz, 1H), 7.55 (s, 1H), 4.44 (m,  1H), 2.83 (s, 3H), 1.35-1.18 (m, 2H), 1.06 (m, 2H).
403
98%


 


4-97 




1H NMR (400 MHz, DMSO) δ 14.56 (s, 1H), 8.94 (s,  1H), 8.04 (d, J = 9.1 Hz, 1H), 7.95-7.77 (m, 2H),  7.53-7.33 (m, 2H) 4.45 (m, 1H), 2.83 (s, 3H), 1.27  (d, J = 6.3 Hz, 2H), 1.05 (s, 2H).
462
98%


 


4-98 




1H NMR (400 MHz, DMSO) δ 14.61 (s, 1H), 8.86 (s,  1H), 7.95 (d, J = 9.0 Hz, 1H), 7.43 (s, 1H), 7.03 (t, J =  8.1 Hz, 1H), 6.77 (d, J = 7.4 Hz, 1H), 6.39 (d, J = 7.1  Hz, 1H), 4.38 (m, 1H), 2.77 (s, 3H), 1.19 (m, 2H),  0.98 (m, 1H).
393
96%
















TABLE 5













 













Com-








pound




MS



No.
R3 =
R2 =
R1 =
NMR
(MH+)
HPLC





5-1 




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.72  (s, 1H), 10.91 (s, 1H), 8.89 (s, 1H),  7.94 (d, J = 8.60 Hz, 1H), 7.13-6.90  (m, 3H), 4.67 (s, 2H), 4.38 (s, 1H),  2.62 (s, 3H), 1.23 (d, J = 5.80 Hz,  2H), 1.04 (s, 2H).
409
97%


 


5-2 




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.71  (s, 1H), 10.78 (s, 1H), 8.90 (s, 1H),  7.95 (d, J = 8.72 Hz, 1H), 7.41 (s,  1H), 7.22 (d, J = 8.03 Hz, 1H), 7.13  (d, J = 8.17 Hz, 1H), 4.38 (s, 1H),  3.57 (s, 2H), 2.62 (s, 3H), 1.24 (d,  J = 6.14 Hz, 2H), 1.05 (s, 2H).
425
98%


 


5-3 




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.70  (s, 1H), 10.64 (s, 1H), 8.98 (s, 1H),  8.05 (d, J = 8.72 Hz, 1H), 7.90 (s,  1H), 7.62 (s, 1H), 4.92 (s, 2H), 4.46  (s, 1H), 2.71 (s, 3H), 1.30 (s, 3H),  1.15 (s, 2H).
454
97%


 


5-4 




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.66  (s, 1H), 11.39 (s, 1H), 8.90 (s, 1H),  7.96 (d, J = 8.72 Hz, 1H), 7.57 (s,  1H), 7.43 (s, 1H), 4.75 (s, 2H), 4.39  (s, 1H), 2.62 (s, 3H), 1.23 (d, J =  5.26 Hz, 2H), 1.06 (s, 2H).
434
98%


 


5-5 




OMe
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.72  (s, 1H), 10.94 (s, 1H), 8.80 (s, 1H),  7.90 (s, 1H), 7.11 (d, J = 26.18 Hz,  2H), 4.67 (s, 2H), 1.15 (s, 4H).
425
98%


 


5-6 




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.75  (s, 1H), 10.87 (s, 1H), 6.90 (s, 1H),  7.96 (d, J = 8.58 Hz, 1H), 7.14 (d,  J = 8.35 Hz, 1H), 6.97 (d, J = 8.15  Hz, 1H), 6.89 (s, 1H), 4.69 (s, 2H),  4.39 (s, 1H), 2.62 (s, 3H), 1.23 (s,  2H), 1.04 (s, 2H).
409
98%


 


5-9 




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.74  (s, 1H), 10.28 (s, 1H), 8.90 (s, 1H),  7.94 (d, J = 8.20 Hz, 1H), 7.23 (s,  1H), 7.17 (s, 1H), 7.03 (s, 1H), 4.38  (s, 2H), 2.97 (s, 2H), 2.63 (s, 2H),  1.23 (s, 2H), 1.04 (s, 2H).
407
85%


 


5-10 




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.71  (s, 1H), 11.47 (s, 1H), 11.39 (s, 1H),  8.91 (s, 1H), 7.98 (d, J = 8.50 Hz,  1H), 7.89 (s, 1H), 7.70 (d, J = 8.10  Hz, 1H), 7.35 (d, J = 8.11 Hz, 1H),  4.40 (s, 1H), 3.49 (d, J = 87.04 Hz,  2H), 2.62 (s, 3H), 1.23 (s, 2H), 1.08  (s, 3H).
422
98%


 


5-11 




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.67  (s, 1H), 11.96 (s, 1H), 11.63 (s, 1H),  8.92 (s, 1H), 8.69 (s, 1H), 8.34 (s,  1H), 8.00 (d, J = 8.65 Hz, 1H), 4.41  (s, 1H), 2.61 (d, J = 29.62 Hz, 3H),  1.24 (d, J = 5.11 Hz, 2H), 1.09 (s,  2H).
423
99%


 


5-12 




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.73  (s, 1H), 12.44-11.74 (m, 2H), 8.91  (s, 1H), 7.98 (d, J = 8.01 Hz, 1H),  7.53-7.03 (m, 3H), 4.39 (s, 1H), 2.61  (s, 3H), 1.20 (d, J = 26.27 Hz, 3H),  1.05 (s, 2H).
422
96%


 


5-13 




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.83  (s, 1H), 8.88 (s, 1H), 7.90 (s, 2H),  6.70 (s, 3H), 4.27 (d, J = 77.51 Hz,  4H), 2.60 (d, J = 25.07 Hz, 3H), 1.23  (s, 2H), 1.02 (s, 2H).
395
98%


 


5-14 




OMe
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.78  (s, 1H), 8.76 (s, 1H), 7.83 (d, J =  9.18 Hz, 1H), 6.92-6.81 (m, 2H),  6.70 (d, J = 7.26 Hz, 1H), 6.19 (d,  J = 22.26 Hz, 1H), 4.16 (s, 4H), 3.39  (s, 3H), 2.50 (s, 7H).
411
96%


 


5-15 




8-N
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.55  (s, 1H), 8.61 (s, 1H), 8.19 (d, J =  11.38 Hz, 1H), 7.55 (d, J = 8.31 Hz,  1H), 7.47 (s, 1H), 6.68 (s, 1H), 6.54  (d, J = 8.26 Hz, 1H), 4.00 (s, 2H),  3.73 (s, 1H), 1.15-0.91 (m, 5H).
382
94%


 


5-16 




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.90  (s, 1H), 8.94 (s, 1H), 7.94 (d, J = 9.06  Hz, 1H), 6.95 (d, J = 8.81 Hz, 2H),  6.63 (d, J = 7.73 Hz, 1H), 6.14 (s,  1H), 4.43 (s, 1H), 3.31 (s, 2H), 2.79 (s,  2H), 2.70 (s, 3H), 1.90 (s, 2H), 1.30 (s,  2H), 1.08 (s, 2H).
393
94%


 


5-17 




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.71  (s, 1H), 8.89 (s, 1H), 8.60 (s, 1H), 7.94  (d, J = 8.81 Hz, 1H), 7.67 (s, 1H), 7.10  (s, 1H), 4.38 (s, 1H), 4.27 (s, 2H), 3.63  (s, 2H), 2.66 (s, 3H), 1.24 (d, J = 5.67  Hz, 2H), 1.07 (s, 2H).
440
97%


 


5-18 




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 10.19  (s, 1H), 8.89 (s, 1H), 7.91 (d, J = 8.74  Hz, 1H), 6.33 (s, 1H), 6.24 (s, 1H),  4.57 (s, 2H), 4.38 (s, 2H), 2.64 (s,  3H), 1.23 (d, J = 5.42 Hz, 3H), 1.03  (s, 2H). 
424
97%


 


5-19 




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 8.88  (s, 1H), 7.91 (s, 1H), 6.29 (s, 1H),  6.18 (s, 1H), 4.37 (s, 2H), 4.18 (s,  3H), 3.10 (s, 2H), 2.65 (d, J = 16.81  Hz, 6H), 1.23 (s, 3H), 1.03 (s, 2H).
424
97%


 


5-20 




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 8.97  (s, 1H), 8.01 (d, J = 9.26 Hz, 1H),  7.85-7.65 (m, 2H), 7.64-7.40 (m,  1H), 7.36 (s, 1H), 4.46 (s, 1H), 4.32  (s, 3H), 3.63 (s, 3H), 2.74 (s, 3H),  1.30 (d, J = 5.75 Hz, 2H), 1.11 (s,  2H).
396
98%


 


5-21 




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.72  (s, 1H), 8.85 (d, J = 23.76 Hz, 1H),  7.87 (t, J = 19.93 Hz, 1H), 7.17 (s,  1H), 6.99 (d, J = 9.29 Hz, 2H), 4.37  (s, 1H), 4.20 (s, 2H), 3.59 (s, 1H),  3.44 (s, 2H), 2.53 (s, 3H), 1.24 (s,  2H), 1.07 (d, J = 23.80 Hz, 2H).
420
95%


 


5-22 




OMe
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.67  (s, 1H), 8.78 (s, 1H), 7.87 (d, J = 9.24  Hz, 1H), 7.26 (d, J = 10.63 Hz, 1H),  7.11 (s, 1H), 7.04 (s, 1H), 4.20 (s,  3H), 2.00 (dd, J = 7.56, 15.22 Hz,  1H), 1.21 (d, J = 14.05 Hz, 4H).
436
98%


 


5-24 




OMe
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 8.77  (s, 1H), 7.87 (d, J = 9.25 Hz, 1H),  7.75 (s, 1H), 7.20 (s, 1H), 7.14 (s,  1H), 4.17 (s, 3H), 3.47 (s, 3H), 1.32- 1.05 (m, 8H).
412
96%


 


5-25 




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.82  (s, 1H), 10.92 (s, 1H), 10.86 (s, 1H),  8.96 (s, 1H), 7.98 (t, J = 12.31 Hz,  1H), 7.15 (d, J = 7.60 Hz, 1H), 7.00  (d, J = 8.89 Hz, 2H), 4.44 (s, 1H), 2.67  (s, 3H), 1.28 (s, 2H), 1.12 (s, 2H).
394
98%


 


5-26 




OMe
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.63  (s, 1H), 10.94 (s, 1H), 10.87 (s, 1H),  8.86 (s, 1H), 7.97 (d, J = 8.82 Hz, 1H),  7.17 (d, J = 7.41 Hz, 3H), 4.29 (s, 1H),  1.23 (s, 4H).
410
98%


 


5-27 




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 8.95  (s, 1H), 7.96 (d, J = 8.75 Hz, 1H),  6.96 (d, J = 10.17 Hz, 1H), 6.92 (d,  J = 8.04 Hz, 1H), 6.72 (d, J = 7.83  Hz, 1H), 4.44 (s, 1H), 3.63 (s, 2H), 3.09 (s, 2H), 2.70 (s, 3H), 1.30 (d,  J = 5.29 Hz, 2H), 1.10 (s, 2H).
411
98%


 


5-28 




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.74  (s, 1H), 8.89 (s, 1H), 7.94 (d, J = 8.48  Hz, 1H), 7.53 (s, 1H), 7.44 (s, 1H),  7.33 (d, J = 8.57 Hz, 1H), 6.94 (d, J =  8.45 Hz, 1H), 4.39 (s, 1H), 3.80 (s,  2H), 3.48 (s, 2H), 2.64 (s, 3H), 1.23  (s, 2H), 1.06 (s, 2H).
443
98%


 


5-29 




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.67  (s, 1H), 10.84 (s, 1H), 8.83 (s, 1H),  7.86 (d, J = 8.65 Hz, 1H), 6.52 (s, 2H),  4.38 (s, 2H), 4.31 (s, 1H), 3.89 (s, 2H),  2.54 (s, 3H), 1.16 (s, 2H), 1.00 (s, 2H).
436
98%


 


5-30 




OMe
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.71 (s,  1H), 10.91 (s, 1H), 8.79 (s, 1H), 7.88 (d,  J = 9.15 Hz, 1H), 6.75 (d, J = 14.51 Hz,  2H), 4.45 (t, J = 4.51 Hz, 2H), 4.27-4.16  (m, 1H), 3.96 (t, J = 4.53 Hz, 2H), 1.17  (d, J = 7.20 Hz, 4H).
452
99%


 


5-31 




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 8.94 (s,  1H), 7.95 (d, J = 8.62 Hz, 1H), 6.79 (dd,  J = 7.23, 14.68 Hz, 3H), 4.43 (s, 1H),  4.23 (d, J = 10.57 Hz, 1H), 4.06 (d, J =  10.42 Hz, 1H), 3.60-3.41 (m, 3H), 2.70  (s, 3H), 1.30 (d, J = 5.98 Hz, 2H), 1.09  (s, 2H).
425
99%


 


5-32 




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 8.95 (s,  1H), 7.98 (d, J = 8.04 Hz, 1H), 7.09 (s,  1H), 6.96 (s, 2H), 4.44 (s, 1H), 4.15 (s,  2H), 3.29 (s, 3H), 2.69 (s, 3H), 2.02 (s,  2H), 1.30 (s, 2H), 1.10 (s, 2H).
409
99%


 


5-33 




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 8.76 (s,  1H), 7.77 (d, J = 6.81 Hz, 1H), 6.59 (s,  3H), 4.25 (s, 1H), 4.04 (s, 2H), 3.27 (d,  J = 11.94 Hz, 1H), 2.96-2.79 (m, 1H),  2.52 (s, 3H), 1.18 (t, J = 8.54 Hz, 3H),  1.12 (d, J = 5.48 Hz, 2H), 0.91 (s, 2H).
409
98%


 


5-34 




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 8.71 (s,  1H), 7.72 (d, J = 8.62 Hz, 1H), 6.54 (s,  3H), 4.20 (s, 2H), 4.03 (d, J = 10.38 Hz,  2H), 3.52 (t, J = 8.97 Hz, 1H), 3.31 (s,  1H), 2.46 (s, 3H), 1.07 (d, J = 5.70 Hz,  2H), 0.96 (d, J = 4.88 Hz, 3H), 0.86 (s,  2H).
409
98%


 


5-35 




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 10.57 (s,  1H), 8.89 (s, 1H), 7.93 (d, J = 8.73 Hz,  1H), 7.48 (d, J = 52.24 Hz, 1H), 6.96 (d,  J = 7.83 Hz, 1H), 6.80 (s, 1H), 6.74 (d,  J = 7.83 Hz, 1H), 4.38 (s, 1H), 3.76 (d,  J = 12.76 Hz, 1H), 2.63 (s, 3H), 2.07 (s,  1H), 1.85 (s, 1H), 1.66 (s, 1H), 1.58- 1.37 (m, 3H), 1.23 (d, J = 6.52 Hz, 2H),  1.06 (s, 2H).
462
98%


 


5-36 




Cl
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 10.92 (s,  1H), 10.70 (s, 1H), 8.92 (s, 1H), 8.09 (d,  J = 8.43 Hz, 1H), 7.82 (s, 1H), 7.04 (d,  J = 22.18 Hz, 1H), 6.64 (d, J = 10.90 Hz,  2H), 4.52-4.28 (m, 3H), 4.01-3.82 (m,  2H), 1.20 (t, J = 10.03 Hz, 2H), 1.12 (d,  J = 3.28 Hz, 2H). 
456
97%


 


5-37 




8-Me




1H NMR (400 MHz, DMSO) δ 8.85 (d,  J = 3.12 Hz, 1H), 7.90 (d, J = 8.88 Hz,  1H), 6.71 (d, J = 5.48 Hz, 3H), 5.23 (d,  J = 3.10 Hz, 1H), 5.07 (d, J = 2.78 Hz,  1H), 4.42-4.27 (m, 1H), 4.22-4.12 (m,  2H), 2.55 (s, 3H), 1.74 (ddd, J = 8.97,  14.93, 17.91 Hz, 1H), 1.62-1.45 (m, 1H).
413
98%


 


5-38 




8-Me




1H NMR (400 MHz, DMSO) δ 14.44 (d,  J = 137.56 Hz, 2H), 10.82 (d, J = 68.59  Hz, 1H), 8.85 (t, J = 9.38 Hz, 1H), 7.93  (t, J = 10.51 Hz, 1H), 6.56 (t, J = 40.40  Hz, 2H), 4.44 (d, J = 4.54 Hz, 3H),  4.39-4.29 (m, 1H), 4.04-3.90 (m, 3H),  2.54 (s, 3H), 1.64 (m, 2H). 
454
98%


 


5-39 




Cl
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 8.92 (s,  1H), 8.10 (d, J = 8.56 Hz, 1H), 7.69 (s,  1H), 7.18 (s, 1H), 4.41 (s, 2H), 4.23-4.19  (m, 3H), 3.51 (s, 2H), 1.22 (d, J = 6.34  Hz, 2H), 1.11 (s, 2H).
416
98%


 


5-40 




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.67 (s,  1H), 8.91 (s, 1H), 7.97 (d, J = 8.68 Hz,  1H), 7.35 (s, 1H), 6.99 (s, 1H), 4.68 (d,  J = 4.53 Hz, 2H), 4.58 (d, J = 4.64 Hz,  2H), 4.40 (dd, J = 3.32, 6.77 Hz, 1H),  2.61 (s, 3H), 1.24 (d, J = 6.14 Hz, 2H),  1.10 (s, 2H).
434
98%


 


5-41 




8-OMe




1H NMR (400 MHz, DMSO) δ 14.59 (s,  1H), 10.91 (s, 1H), 8.62 (s, 1H), 7.89 (d,  J = 9.04 Hz, 1H), 6.74 (d, J = 14.28 Hz,  2H), 5.08 (d, J = 64.31 Hz, 1H), 4.45 (s,  2H), 4.19 (s, 1H), 3.96 (s, 2H), 1.80 (d,  J = 26.47 Hz, 1H), 1.65 (dd, J = 7.14,  16.55 Hz, 1H).
470
98%


 


5-42 




8-OMe




1H NMR (400 MHz, DMSO) δ 8.80 (s,  1H), 7.86 (d, J = 9.34 Hz, 1H), 6.87 (d,  J = 8.16 Hz, 1H), 6.84 (s, 1H), 6.70 (d,  J = 8.14 Hz, 1H), 5.18 -4.96 (m, 1H),  4.17 (s, 3H), 3.36 (s, 2H), 1.84-1.58  (m, 2H).
429
98%


 


5-43 




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.75- 14.70 (s, 1H), 8.80-8.76 (s, 1H), 7.89- 7.83 (d, J = 9.4 Hz, 1H), 6.92-6.86 (d,  J = 11.4 Hz, 1H), 6.77-6.73 (s, 1H),  6.16-6.10 (s, 1H), 4.27-4.15 (s, 3H),  3.47-3.41 (s, 3H), 3.40-3.34 (q, J =  3.6 Hz, 2H), 1.20-1.09 (dd, J = 14.4,  5.5 Hz, 4H).
429
90%


 


5-44 




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.77- 14.65 (s, 1H), 8.80-8.76 (s, 1H), 7.89- 7.83 (d, J = 9.3 Hz, 1H), 7.09-7.03 (t,  J = 1.6 Hz, 1H), 6.90-6.84 (t, J = 1.6  Hz, 1H), 6.19-6.10 (s, 1H), 4.26-4.15  (m, 3H), 3.48-3.39 (s, 5H), 1.20-1.09  (ddd, J = 10.6, 5.5, 3.0 Hz, 4H).
445
100%


 


5-45 




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 8.80- 8.74 (s, 1H), 7.68-7.80 (d, J = 9.3 Hz,  1H), 6.81-6.71 (dd, J = 17.1, 2.1 Hz,  2H), 4.28-4.18 (tt, J = 7.2, 4.3 Hz,  1H), 4.18-4.12 (t, J = 4.2 Hz, 2H),  3.44-3.35 (m, 5H), 2.16-2.10 (s, 3H),  1.20-1.08 (m, 4H).
425
100%


 


5-46 




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 8.79- 8.75 (s, 1H), 7.87-7.81 (d, J = 9.3 Hz,  1H), 6.55-6.49 (s, 1H), 6.43-6.39 (s,  1H), 4.27-4.18 (s, 1H), 4.16-4.10 (t,  J = 4.3 Hz, 2H), 3.33-3.5 (s, 2H),  2.57-2.52 (s, 3H), 1.20-1.09 (m, 4H).
426
96%


 


5-47 




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.83- 14.56 (s, 1H), 8.81-8.77 (s, 1H), 8.66- 8.59 (m, 1H), 7.95-7.89 (d, J = 9.3 Hz,  1H), 7.89-7.84 (t, J = 1.7 Hz, 1H), 7.24- 7.19 (s, 1H), 4.30-4.18 (m, 3H), 3.67- 3.60 (q, J = 3.8 Hz, 2H), 3.52-3.44 (s,  3H), 1.20-1.12 (td, J = 6.5, 5.8, 2.7 Hz,  4H).
456
100%


 


5-48 




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 15.22- 14.17 (m, 1H), 8.97-8.90 (s, 1H), 8.84- 8.80 (s, 1H), 7.97-7.90 (d, J = 9.0 Hz,  1H), 7.51-7.47 (s, 1H), 7.07-7.02 (s,  1H), 4.69-4.57 (s, 4H), 4.28-4.18 (p,  J = 5.7 Hz, 1H), 3.42-3.35 (s, 3H),  1.21-1.12 (d, J = 5.6 Hz, 4H).
436
100%


 


5-49 




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.70- 14.66 (s, 1H), 8.84-8.80 (s, 1H), 7.97- 7.92 (d, J = 9.0 Hz, 1H), 7.78-7.74 (s,  1H), 7.08-7.04 (s, 1H), 5.00-4.94 (t,  J = 4.9 Hz, 2H), 4.82-4.74 (t, J = 4.8  Hz, 2H), 4.27-4.18 (p, J = 5.7 Hz, 1H),  3.43-3.38 (s, 3H), 1.21-1.13 (d, J = 5.6  Hz, 4H).
437
85%


 


5-50 




OMe
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.72  (s, 1H), 8.94 (s, 1H), 7.87 (d, J = 9.4  Hz, 1H), 6.89 (d, J = 11.4 Hz, 1H), 6.75  (s, 1H), 6.13 (s, 1H), 4.21 (m, 3H), 3.40  (s, 3H), 1.31-0.94 (m, 4H).
429
90%


 


5-51 




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.72  (s, 1H), 8.88 (s, 1H), 7.91 (d, J = 8.8  Hz, 1H), 6.91 (s, 1H), 6.72 (s, 1H), 6.07  (s, 1H). 4.48-4.30 (m, 1H), 4.20 (m, 2H),  3.43 (m, 2H), 2.70-2.56 (m, 3H), 1.24 (d,  J = 4.0 Hz, 2H), 1.04 (s, 2H).
429
98%


 


5-52 




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.5 (b,  1H), 8.91 (s, 1H), 8.86 (s, 1H), 7.97 (d,  J = 8.8 Hz, 1H), 7.34 (s, 1H), 6.90 (s,  1H), 4.63 (s, 4H), 4.39 (mz, 1H), 2.61  (s, 3H), 1.24 (d, J = 4.6 Hz, 2H), 1.09  (s, 2H).
420
98%


 


5-53 




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.73 (s,  1H), 8.88 (s, 1H), 7.90 (d, J = 8.8 Hz,  1H), 7.22 (s, 1H), 6.76 (s, 1H), 4.44- 4.28 (m, 1H), 4.15 (m, 2H), 3.43 (m,  2H), 2.65 (s, 3H), 1.24 (s, 2H), 1.04  (s, 2H).
521
97%


 


5-54 




Me
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 14.73  (s, 1H), 8.89 (s, 1H), 7.91 (d, J = 7.8  Hz, 1H), 6.75 (d, J = 11.3 Hz, 1H),  6.59 (s, 1H), 4.37 (m, 1H), 4.22 (s,  2H), 3.39 (s, 2H), 2.65 (s, 3H), 1.22  (m, 2H), 1.00 (m, 2H).
413
97%


 


5-55 




Cl
Cyclopropyl
1H NMR (400 MHz, DMSO) δ 8.90  (s, 1H), 8.05 (d, J = 8.6 Hz, 1H), 6.91- 6.49 (m, 3H), 4.46-4.36 (m, 1H), 4.16  (m, 2H), 3.49 (m, 2H), 2.67 (s, 3H),  1.19 (t, J = 15.1 Hz, 2H), 1.09 (s, 2H).
415
98%


 











5-56 




1H NMR (400 MHz, DMSO) δ 8.77  (s, 1H), 8.15 (d, J = 7.00 Hz, 1H),  7.24-7.02 (m, 2H), 6.78 (d, J = 8.23  Hz, 1H), 4.28-4.13 (m, 2H), 4.05- 3.86 (m, 1H), 3.49-3.34 (m, 2H),  2.90 (d, J = 2.66 Hz, 3H), 1.44-1.32  (m, 2H), 1.28-1.17 (m, 2H).
395
98%


 


5-57 




1H NMR (400 MHz, DMSO) δ 15.13  (s, 1H), 8.84 (s, 1H), 8.16 (d, J = 8.2  Hz, 1H), 7.71 (s, 1H), 7.20-7.06 (m,  2H), 6.73 (t, J = 16.6 Hz, 1H), 4.30  (m, 1H), 4.22-4.17 (m, 2H), 3.68 (s,  2H), 3.44 (s, 3H), 1.43-0.95 (m, 4H).
393
98%
















TABLE 6













 












Com-







pound



MS



No.
R3 =
R2 =
NMR
(MH+)
HPLC





6-1




Me
1H NMR (400 MHz, MeOD) δ 7.92 (s, 1H), 7.35 (m, 2H), 6.96 (s, 1H), 6.80 (m, 2H), 4.30-4.19 (m, 1H), 3.75 (s, 3H), 2.59 (s, 3H), 0.96 (m, 2H), 0.79 (m, 2H).
368
98%


 


6-2




Me
1H NMR (400 MHz, DMSO) δ 14.75 (s, 1H), 8.89 (s, 1H), 7.92 (d, J = 8.6 Hz, 1H), 7.50 (t, J = 7.7 Hz, 1H), 7.24 (dd, J = 15.3, 7.9 Hz, 2H), 7.14 (d, J = 7.4 Hz, 1H), 4.38 (m, 1H), 3.76 (s, 3H), 2.55 (s, 3H), 1.41- 1.15 (m, 2H), 1.12-0.96 (m, 2H).
482
90%


 


6-3




Me
1H NMR (400 MHz, DMSO) δ 14.80 (s, 1H), 8.95 (s, 1H), 8.00 (d, J = 8.8 Hz, 1H), 7.57 (d, J = 7.2 Hz, 2H), 7.49 (t, J = 7.3 Hz, 2H), 7.45-7.36 (m, 3H), 7.26 (d, J = 8.6 Hz, 2H), 5.25 (s, 2H), 4.54-4.32 (m, 1H), 2.67 (s, 3H), 1.30 (d, J = 6.2 Hz, 2H), 1.11 (s, 2H).
444
99%


 


6-4




Me
1H NMR (400 MHz, DMSO) δ 14.76 (s, 1H), 8.90 (s, 1H), 7.94 (d, J = 8.5 Hz, 1H), 7.35 (d, J = 8.0 Hz, 2H), 7.12 (d, J = 8.2 Hz, 2H), 4.33 (s, 1H), 3.84 (s, 3H), 2.61 (s, 3H), 1.23 (d, J = 6.2 Hz, 2H), 1.05 (s, 2H).
368
96%


 


6-5




Me
1H NMR (400 MHz, DMSO) δ 14.63 (s, 1H), 8.88 (s, 1H), 7.92 (d, J = 8.9 Hz, 1H), 7.31 (d, J = 8.4 Hz, 2H), 7.08 (d, J = 8.7 Hz, 2H), 4.71 (dt, J = 12.0, 6.0 Hz, 1H), 4.38 (m, 1H), 2.58 (d, J = 26.0 Hz, 3H), 1.32 (d, J = 6.0 Hz, 6H), 1.23 (q, J = 6.9 Hz, 2H), 1.02 (s, 2H).
396
99%


 


6-6




Me
1H NMR (400 MHz, DMSO) δ 14.68 (s, 1H), 8.91 (s, 1H), 7.98 (d, J = 8.8 Hz, 1H), 7.58 (s, 4H), 4.52- 4.24 (m, 1H), 2.60 (s, 3H), 1.23 (q, J = 7.0 Hz, 2H), 1.15-1.01 (m, 2H).
422
99%


 


6-7




Me
1H NMR (400 MHz, DMSO) δ 14.66 (s, 1H), 8.91 (s, 1H), 7.99 (d, J = 8.8 Hz, 1H), 7.72 (t, J = 7.9 Hz, 1H), 7.54 (d, J = 8.3 Hz, 1H), 7.52-7.44 (m, 2H), 4.52-4.20 (m, 1H), 2.80 (s, 3H), 1.23 (d, J = 6.8 Hz, 2H), 1.08 (s, 2H).
422
99%


 


6-8




Me
1H NMR (400 MHz, DMSO) δ 14.48 (s, 1H), 8.76 (s, 1H), 7.86 (d, J = 8.7 Hz, 1H), 7.60-7.52 (m, 1H), 7.45 (ddd, J = 10.9, 9.8, 4.6 Hz, 3H), 4.25 (dt, J = 10.7, 3.6 Hz, 1H), 2.43 (s, 3H), 1.06 (dq, J = 9.4, 7.1 Hz, 2H), 0.99-0.71 (m, 3H).
422
99%


 


6-9




Me
1H NMR (400 MHz, DMSO) δ 14.64 (s, 1H), 8.83 (s, 1H), 7.87 (d, J = 8.7 Hz, 1H), 6.61 (s, 2H), 4.33 (m, 1H), 3.74 (s, 6H), 3.68 (s, 3H), 2.57 (s, 3H), 1.18 (d, J = 6.4 Hz, 2H), 1.01 (s, 2H).
428
95%


 


6-10




Me
1H NMR (400 MHz, DMSO) δ 14.80 (s, 1H), 8.88 (s, 1H), 7.90 (d, J = 8.6 Hz, 1H), 7.17 (d, J = 8.3 Hz, 1H), 6.76 (d, J = 2.2 Hz, 1H), 6.70 (dd, J = 8.4, 2.3 Hz, 1H), 4.47-4.28 (m, 1H), 3.85 (s, 3H), 3.75 (s, 3H), 2.55 (s, 3H), 1.21 (dd, J = 6.7, 4.5 Hz, 2H), 1.02 (dd, J = 10.3, 4.5 Hz, 2H).
398
96%


 


6-11




Me
1H NMR (400 MHz, DMSO) δ 14.70 (s, 1H), 8.80 (s, 1H), 7.86 (d, J = 8.1 Hz, 1H), 7.32 (m, 2H), 7.16 (d, J = 7.2 Hz, 1H), 4.25 (s, 1H), 3.92 (s, 3H), 2.57 (s, 3H), 1.41-1.10 (m, 2H), 0.89 (m, 2H).
386
96%


 


6-12




Me
1H NMR (400 MHz, DMSO) δ 14.74 (s, 1H), 8.90 (s, 1H), 7.93 (d, J = 8.8 Hz, 1H), 7.13 (d, J = 8.3 Hz, 1H), 6.97 (s, 1H), 6.93 (dd, J = 8.2, 1.7 Hz, 1H), 4.39 (tt, J = 7.1, 3.8 Hz, 1H), 3.84 (s, 3H), 3.79 (s, 3H), 2.63 (s, 3H), 1.24 (d, J = 6.8 Hz, 2H), 1.07 (s, 2H).
398
99%


 


6-13




Me
1H NMR (400 MHz, DMSO) δ 14.70 (s, 1H), 8.90 (s, 1H), 7.94 (d, J = 8.7 Hz, 1H), 7.54 (s, 1H), 7.35 (dd, J = 18.3, 8.3 Hz, 2H), 4.39 (m, 1H), 3.95 (s, 3H), 2.62 (s, 3H), 1.23 (d, J = 5.8 Hz, 2H), 1.06 (s, 2H).
402
99%


 


6-14




Me
1H NMR (400 MHz, DMSO) δ 14.69 (s, 1H), 8.91 (s, 1H), 7.97 (d, J = 8.6 Hz, 1H), 7.72 (d, J = 8.6 Hz, 1H), 7.67 (s, 1H), 7.47 (d, J = 8.6 Hz, 1H), 4.40 (m, 1H), 3.99 (s, 3H), 2.61 (s, 3H), 1.24 (d, J = 5.6 Hz, 2H), 1.08 (s, 2H).
436
99%


 


6-15




Me
1H NMR (400 MHz, DMSO) δ 14.76 (s, 1H), 8.89 (s, 1H), 7.93 (d, J = 8.5 Hz, 1H), 7.20 (d, J = 12.7 Hz, 2H), 7.11 (d, J = 8.0 Hz, 1H), 4.38 (m, 1H), 3.87 (s, 3H), 2.64 (s, 3H), 2.23 (s, 3H), 1.23 (m, 2H), 1.07 (m, 2H).
362
99%


 


6-16




Me
1H NMR (400 MHz, DMSO) δ 14.78 (s, 1H), 8.88 (s, 1H), 7.91 (d, J = 8.6 Hz, 1H), 6.95 (d, J = 7.4 Hz, 1H), 6.62 (s, 1H), 6.52 (d, J = 6.8 Hz, 1H), 4.94 (s, 2H), 4.39 (s, 1H), 3.84 (s, 3H), 2.63 (s, 3H), 1.23 (s, 2H), 1.03 (s, 2H).
383
95%


 


6-17




Me
1H NMR (400 MHz, DMSO) δ 14.66 (s, 1H), 10.16 (s, 1H), 8.91 (s, 1H), 7.96 (d, J = 8.9 Hz, 2H), 7.26 (dd, J = 28.6, 8.1 Hz, 2H), 4.39 (m, 1H), 4.24 (m, 2H), 3.86 (m, 4H), 3.33 (m, 4H), 2.63 (s, 3H), 1.22 (d, J = 6.1 Hz, 2H), 1.05 (s, 2H).
510
90%


 


6-18




Me
1H NMR (400 MHz, DMSO) δ 14.73 (s, 1H), 9.12 (s, 1H), 8.90 (s, 1H), 7.95 (d, J = 9.0 Hz, 1H), 7.29 (s, 1H), 7.26 (s, 2H), 4.39 (m, 1H), 3.92 (s, 3H), 3.01 (s, 3H), 2.62 (s, 3H), 1.35-1.15 (m, 2H), 1.06 (m, 2H).
461
98%


 


6-19




Me
1H NMR (400 MHz, DMSO) δ 14.76 (s, 1H), 8.89 (s, 1H), 8.14 (d, J = 14.8 Hz, 2H), 7.94 (d, J = 8.9 Hz, 1H), 7.14 (d, J = 8.3 Hz, 1H), 6.90 (d, J = 7.9 Hz, 1H), 6.28 (s, 2H), 4.39 (s, 1H), 3.93 (s, 3H), 2.65 (s, 3H), 1.19 (m, 2H), 1.04 (m, 2H).
426
98%


 


6-20




Me
1H NMR (400 MHz, DMSO) δ 14.73 (s, 1H), 8.91 (s, 1H), 7.97 (d, J = 8.7 Hz, 1H), 7.56 (d, J = 6.9 Hz, 2H), 7.31 (d, J = 8.5 Hz, 1H), 4.39 (m, 1H), 3.91 (s, 3H), 2.62 (s, 3H), 1.52 (s, 9H), 1.24 (m, 2H), 1.07 (m, 2H).
468
98%


 


6-21




Me
1H NMR (400 MHz, DMSO) δ 14.80 (s, 1H), 12.93 (s, 1H), 8.97 (s, 1H), 8.02 (d, J = 8.8 Hz, 1H), 7.70 (s, 1H), 7.62 (d, J = 8.8 Hz, 1H), 7.38 (d, J = 0.8 Hz, 1H), 4.39 (m, 1H), 3.67 (s, 3H), 2.62 (s, 3H), 1.52 (s, 9H), 1.30 (m, 2H), 1.13 (m, 2H).
412
98%


 


6-22




Me
1H NMR (400 MHz, DMSO) δ 14.72 (s, 1H), 8.92 (s, 1H), 8.52 (s, 1H), 7.97 (d, J = 8.3 Hz, 1H), 7.81 (s, 3H), 7.57 (d, J = 7.9 Hz, 1H), 7.36 (d, J = 8.4 Hz, 1H), 4.39 (s, 1H), 3.96 (d, J = 24.7 Hz, 3H), 3.54 (s, 2H), 2.99 (s, 2H), 2.69-2.54 (m, 3H), 1.23 (d, J =
454
95%





5.3 Hz, 2H), 1.07 (s, 2H).




 


6-24




Me
1H NMR (400 MHz, DMSO) δ 14.72 (s, 1H), 9.40 (s, 1H), 8.92 (s, 1H), 8.60 (s, 1H), 7.99 (s, 1H), 7.61 (s, 1H), 7.57 (s, 1H), 7.38 (s, 1H), 4.40 (s, 1H), 4.00 (s, 3H), 3.66 (s, 2H), 3.28 (s, 2H), 2.85 (s, 6H), 2.61 (s, 3H), 1.24 (s, 2H), 1.07 (s, 2H).
462
99%


 


6-25




Me
1H NMR (400 MHz, DMSO) δ 14.73 (s, 1H), 8.91 (s, 1H), 8.37 (s, 1H), 7.96 (d, J = 8.3 Hz, 1H), 7.75 (s, 1H), 7.53 (d, J = 8.2 Hz, 1H), 7.33 (d, J = 8.4 Hz, 1H), 6.95 (s, 1H), 4.40 (s, 1H), 3.98 (s, 3H), 3.33 (d, J = 5.1 Hz, 2H), 3.13 (d, J = 5.4 Hz,
554
95%





2H), 2.61 (s, 3H), 1.36 (s, 9H), 1.24 (d, J = 4.4 Hz,







2H), 1.07 (s, 2H).




 


6-26




Me
1H NMR (400 MHz, DMSO) δ 14.72 (s, 1H), 10.43 (s, 1H), 8.91 (s, 1H), 7.97 (d, J = 8.7 Hz, 1H), 7.74 (d, J = 8.8 Hz, 1H), 7.70 (s, 1H), 7.45 (d, J = 8.6 Hz, 1H), 4.39 (m, 1H), 4.02 (s, 3H), 2.61 (s, 3H), 1.23 (m, 2H), 1.07 (m, 2H).
396
98%


 


6-27




Me
1H NMR (400 MHz, DMSO) δ 14.65 (s, 1H), 8.91 (s, 1H), 8.47 (s, 1H), 7.97 (d, J = 8.7 Hz, 1H), 7.71 (s, 1H), 7.66 (s, 1H), 7.44 (d, J = 8.7 Hz, 1H), 7.38 (d, J = 8.6 Hz, 1H), 4.40 (m, 1H), 4.05 (s, 3H), 2.65 (s, 3H), 1.25 (d, J = 6.7 Hz, 2H), 1.08 (s, 2H).
435
90%


 


6-28




Me
1H NMR (400 MHz, DMSO) δ 14.71 (s, 1H), 8.90 (s, 1H), 7.96 (d, J = 8.4 Hz, 1H), 7.40 (d, J = 11.8 Hz, 2H), 7.26 (d, J = 8.0 Hz, 1H), 4.39 (s, 1H), 3.94 (s, 5H), 2.62 (s, 3H), 1.23 (s, 2H), 1.06 (s, 2H).
407
95%


 


6-29




Me
1H NMR (400 MHz, DMSO) δ 14.68 (s, 1H), 10.43 (s, 1H), 8.91 (s, 1H), 7.97 (d, J = 8.8 Hz, 1H), 7.86- 7.62 (m, 2H), 7.44 (d, J = 8.5 Hz, 1H), 4.39 (s, 1H), 4.02 (s, 2H), 2.64 (s, 3H), 1.23 (s, 2H), 1.07 (s, 2H).
396
95%


 


6-30




Me
1H NMR (400 MHz, DMSO) δ 14.66 (s, 2H), 8.93 (s, 1H), 8.33 (s, 1H), 8.02 (d, J = 8.6 Hz, 1H), 7.80 (s, 2H), 7.71 (d, J = 8.5 Hz, 1H), 7.56 (d, J = 8.4 Hz, 1H), 7.46 (s, 2H), 4.42 (s, 1H), 4.17 (s, 3H), 2.66 (s, 3H), 1.35-1.15 (m, 2H), 1.09 (s, 2H).
484
85%


 


6-31




Me
1H NMR (400 MHz, DMSO) δ 14.74 (s, 1H), 11.37 (s, 1H), 8.90 (s, 1H), 8.35 (s, 1H), 7.96 (d, J = 8.1 Hz, 1H), 7.64 (s, 1H), 7.43 (d, J = 8.1 Hz, 1H), 7.27 (d, J = 8.5 Hz, 1H), 4.39 (s, 1H), 3.92 (s, 3H), 2.63 (s, 3H), 1.23 (d, J = 5.2 Hz, 2H), 1.06 (s, 2H).
411
95%


 


6-32




Me
1H NMR (400 MHz, DMSO) δ 14.75 (s, 1H), 8.91 (s, 1H), 7.97 (d, J = 8.7 Hz, 1H), 7.76 (s, 2H), 7.70 (s, 1H), 7.54 (d, J = 8.2 Hz, 1H), 7.33 (d, J = 8.4 Hz, 1H), 4.40 (s, 1H), 3.98 (s, 3H), 2.61 (s, 3H), 1.23 (s, 2H), 1.07 (s, 2H).
411
94%


 


6-33




Me
1H NMR (400 MHz, DMSO) δ 14.73 (s, 1H), 8.92 (s, 1H), 7.96 (d, J = 8.6 Hz, 1H), 7.37 (s, 2H), 7.23 (d, J = 7.3 Hz, 1H), 4.39 (m, 1H), 3.89 (s, 3H), 3.74 (m, 4H), 3.07 (s, 4H), 2.76 (s, 3H), 2.62 (s, 3H), 1.24 (s, 2H), 1.06 (s, 2H).
480
96%


 


6-34




Me
1H NMR (400 MHz, DMSO) δ 14.73 (s, 1H), 8.92 (s, 1H), 8.87 (s, 1H), 7.97 (d, J = 8.1 Hz, 1H), 7.48 (s, 2H), 7.29 (d, J = 8.7 Hz, 1H), 4.40 (m, 1H), 4.18 (s, 2H), 3.94 (s, 3H), 2.63 (s, 3H), 2.55 (s, 3H), 1.24 (s, 2H), 1.05 (s, 2H).
411
86%


 


6-35




Me
1H NMR (400 MHz, DMSO) δ 14.69 (s, 1H), 8.91 (s, 1H), 7.97 (d, J = 8.6 Hz, 1H), 7.91 (s, 1H), 7.75 (d, J = 6.1 Hz, 1H), 7.44 (d, J = 8.1 Hz, 1H), 4.39 (s, 1H), 4.02 (s, 3H), 2.61 (s, 3H), 1.23 (s, 2H), 1.07 (s, 2H).
393
95%


 


6-36




Me
1H NMR (400 MHz, DMSO) δ 14.78 (s, 1H), 8.90 (s, 1H), 7.95 (d, J = 8.7 Hz, 1H), 7.37 (s, 1H), 7.26 (d, J = 8.0 Hz, 1H), 7.13 (d, J = 8.3 Hz, 1H), 5.18 (s, 1H), 4.57 (s, 2H), 4.39 (s, 1H), 3.87 (s, 3H), 2.62 (s, 3H), 1.23 (s, 2H), 1.05 (s, 2H).
398
95%


 


6-37




Me
1H NMR (400 MHz, DMSO) δ 14.71 (s, 1H), 9.63 (s, 1H), 8.92 (s, 1H), 8.51 (s, 1H), 7.98 (d, J = 8.5 Hz, 1H), 7.67 (s, 1H), 7.52 (d, J = 8.3 Hz, 1H), 7.32 (d, J = 8.5 Hz, 1H), 4.43 (m, 3H), 3.94 (s, 3H), 3.43 (s,
482
95%





2H), 2.80 (d, J = 24.7 Hz, 6H), 2.62 (s, 3H), 1.23 (s,







2H), 1.07 (s, 2H).




 


6-38




Me
1H NMR (400 MHz, DMSO) δ 14.74 (s, 1H), 8.90 (s, 1H), 7.93 (d, J = 9.2 Hz, 1H), 7.10 (d, J = 8.0 Hz, 1H), 7.02 (s, 1H), 6.86 (d, J = 8.0 Hz, 1H), 6.13 (s, 2H), 4.38 (m, 1H), 2.62 (s, 3H), 1.23 (m, 2H), 1.05 (m, 2H).
382
98%


 


6-39




Me
1H NMR (400 MHz, DMSO) δ 14.67 (s, 1H), 10.11 (s, 1H), 8.91 (s, 1H), 7.97 (d, J = 8.7 Hz, 1H), 7.33 (d, J = 1.6 Hz, 1H), 7.29 (d, J = 1.6 Hz, 1H), 6.45-6.21 (s, 2H), 4.41-4.30 (m, 1H), 2.74-2.56 (s, 3H), 1.33-1.17 (d, J = 6.6 Hz, 2H), 1.12-0.96 (t, J = 3.1 Hz, 2H).
410
98%


 


6-40




Me
1H NMR (400 MHz, DMSO) δ 14.69 (s, 1H), 11.53 (s, 1H), 8.90 (s, 1H), 8.16 (s, 1H), 7.95 (d, J = 8.7 Hz, 1H), 7.08 (d, J = 1.7 Hz, 1H), 7.02 (d, J = 1.7 Hz, 1H), 6.21 (s, 2H), 4.48-4.16 (m, 1H), 2.64 (s, 3H), 1.35- 1.21 (d, J = 6.8 Hz, 2H), 1.12-1.01 (m, 2H).
425
98%


 


6-41




Me
1H NMR (400 MHz, DMSO) δ 14.64 (s, 1H), 8.90 (s, 1H), 7.96 (d, J = 8.8 Hz, 1H), 7.36 (d, J = 1.6 Hz, 1H), 7.4 (d, J = 1.6 Hz, 1H), 6.36 (s, 2H), 4.52-4.26 (m, 1H), 2.63 (s, 3H), 1.35-1.15 (d, J = 6.6 Hz, 2H), 1.10-0.99 (m, 2H).
407
98%


 


6-42




Me
1H NMR (400 MHz, DMSO) δ 14.68 (s, 1H), 8.89 (s, 1H), 794 (d, J = 8.7 Hz, 1H), 7.06 (d, J = 1.5 Hz, 1H), 6.95 (d, J = 1.5 Hz, 1H), 6.22 (s, 2H), 4.57- 4.46 (s, 1H), 4.42-4.30 (m, 1H), 2.63 (s, 3H), 1.33- 1.15 (d, J = 6.2 Hz, 2H), 1.12-0.90 (m, 1H).
406
95%


 


6-43




OMe
1H NMR (400 MHz, DMSO) δ 14.70 (s, 1H), 8.80 (s, 1H), 7.90 (d, J = 9.1 Hz, 1H), 7.06 (s, 1H), 7.01 (s, 1H), 6.13 (s, 2H), 5.31 (t, J = 5.6 Hz, 1H), 4.54 (d, J = 5.6 Hz, 2H), 4.34-4.12 (mz, 1H), 3.44 (s, 3H), 1.33-0.99 (m, 4H).
428
97%


 


6-44




Me
1H NMR (400 MHz, DMSO) δ 14.69 (s, 1H), 8.89 (s, 1H), 7.93 (d, J = 8.7 Hz, 1H), 6.97 (s, 1H), 6.93 (s, 1H), 6.73 (dd, J = 17.7, 11.3 Hz, 1H), 6.20 (s, 2H), 6.00 (d, J = 17.6 Hz, 1H), 5.49 (d, J = 11.5 Hz, 1H), 4.53-4.25 (m, 1H), 2.75-2.57 (s, 3H), 1.32-1.17 (d, J = 6.7 Hz, 2H), 1.11-0.89 (s, 2H).
408
95%


 


6-45




OMe
1H NMR (400 MHz, DMSO) δ 14.66 (s, 1H), 8.80 (s, 1H), 7.90 (d, J = 9.1 Hz, 1H), 7.17 (s, 1H), 7.09 (s, 1H), 6.23 (s, 2H), 4.49 (s, 1H), 4.34-4.14 (m, 1H), 3.47-3.42 (s, 3H), 1.31-0.96 (m, 4H).
422
98%


 


6-46




OMe
1H NMR (400 MHz, DMSO) δ 14.62 (s, 1H), 8.81 (s, 1H), 7.93 (d, J = 9.1 Hz, 1H), 7.45 (s, 1H), 7.44 (s, 1H), 6.36 (s, 2H), 4.39-4.04 (m, 1H), 3.46 (s, 3H), 1.26-1.06 (m, 4H)
423
98%


 


6-47




OMe
1H NMR (400 MHz, DMSO) δ 14.65 (s, 1H), 8.80 (s, 1H), 7.92 (d, J = 9.1 Hz, 1H), 7.30 (s, 1H), 7.19 (s, 11H), 7.17 (t, J = 56 Hz, 1H), 6.27 (s, 2H), 4.33-4.17 (m, 1H), 3.45 (s, 3H). 1.29-0.97 (m, 4H).
448
92%


 


6-48




OMe
1H NMR (400 MHz, DMSO) δ 14.67 (s, 1H), 8.80 (s, 1H), 7.93 (d, J = 9.1 Hz, 1H), 7.77 (s, 1H), 7.42 (t, J = 1.4 Hz, 1H), 7.28 (t, J = 1.3 Hz, 1H), 7.25 (s, 1H), 6.27 (s, 2H), 4.33-4.13 (m, 1H), 3.449 (s, 3H), 1.37-0.87 (m, 4H).
441
98%


 


6-49




OMe
1H NMR (400 MHz, DMSO) δ 14.66 (s, 1H), 10.12 (d, J = 1.2 Hz, 1H), 8.81 (s, 1H), 7.93 (d, J = 9.5 Hz, 1H), 7.44 (s, 1H), 7.42 (s, 1H), 6.35 (s, 2H), 4.33-4.17 (m, 1H), 3.46 (s, 3H), 1.32- 0.97 (m, 4H).
426
98%


 


6-50




OMe
1H NMR (400 MHz, DMSO) δ 14.68 (s, 1H), 8.80 (s, 1H), 7.89 (d, J = 9.1 Hz, 1H), 6.83-6.80 (t, J = 1.3 Hz, 1H), 6.80-6.76 (t, J = 1.2 Hz, 1H), 6.11 (s, 2H), 4.34-4.12 (m, 1H), 3.86 (s, 3H), 3.31 (s, 3H), 1.26-1.02 (m, 4H).
428
98%


 


6-51




OMe
1H NMR (400 MHz, DMSO) δ 14.70-14.61 (s, 1H), 8.84-8.78 (s, 1H), 7.96-7.88 (d, J = 9.0 Hz, 1H), 7.14 (s, 1H), 7.13 (s, 1H), 6.33-6.22 (s, 2H), 4.26- 4.18 (m, 1H), 3.46 (s, 3H), 1.20-1.11 (m, 4H).
432
95%


 


6-52




OMe
1H NMR (400 MHz, DMSO) δ 14.67 (s, 1H), 8.80 (s, 1H), 7.92 (d, J = 9.1 Hz, 1H), 7.77 (s, 1H), 7.42 (s, 1H), 7.28 (s, 1H), 7.25 (s, 1H), 6.27 (s, 2H), 4.22 (m, 1H), 3.44 (s, 3H), 1.17 (m, 4H).
441
85%


 











6-53




1H NMR (400 MHz, DMSO) δ 14.49 (s, 1H), 8.83 (s, 1H), 7.94 (d, J = 8.0 Hz, 1H), 7.42 (s, 1H), 6.36 (s, 2H), 5.10 (m, 1H), 4.18 (m, 1H), 3.47 (s, 3H), 1.82-1.63 (m, 4H).
441
98%


 


6-54




1H NMR (400 MHz, DMSO) δ 14.50 (s, 1H), 11.55 (s, 1H), 8.83 (s, 1H), 8.16 (s, 1H), 7.92 (d, J = 8.0 Hz, 1H), 7.27 (s, 1H), 7.10 (s, 1H), 6.22 (s, 1H), 5.10 (m, 1H), 4.18 (m, 1H), 3.47 (s, 3H), 1.82-1.63 (m, 4H).
459
95%


 


6-55




1H NMR (400 MHz, DMSO) δ 14.47 (s, 1H), 8.82 (s, 1H), 8.10 (d, J = 8.7 Hz, 1H), 8.00-7.87 (m, 1H), 7.66 (t, J = 9.4 Hz, 1H), 7.37 (t, J = 8.3 Hz, 1H), 7.21 (d, J = 8.0 Hz, 2H), 7.06 (d, J = 8.1 Hz, 2H), 3.81 (s, 3H).
440
99%


 


6-56




1H NMR (400 MHz, DMSO) δ 15.44-15.10 (s, 1H), 9.12-8.99 (t, J = 1.7 Hz, 1H), 8.03-7.92 (dt, J = 8.4, 1.8 Hz, 1H), 7.67-7.56 (dd, J = 8.6, 2.5 Hz, 3H), 7.16-6.98 (m, 2H), 5.03-4.89 (d, J = 7.3 Hz, 1H), 4.60-4.47 (d, J = 11.4 Hz, 1H), 4.44-4.33 (d, J = 11.5 Hz, 1H), 3.86-3.75 (t, J = 1.7 Hz, 3H), 1.53- 1.42 (d, J = 6.3 Hz, 3H).
352
99%
















TABLE 7













 












Com-







pound



MS



No.
R18 =
R2 =
NMR
(MH+)
HPLC





7-1
H
Me
1H NMR (400 MHz, DMSO) δ 14.74 (s, 1H), 8.90 (s, 1H), 7.95 (d, J = 9.3 Hz, 1H), 7.80
344
100%





(s, 2H), 7.27 (s, 1H), 4.39 (s, 1H), 2.68 (s, 3H), 1.23 (s, 3H), 1.03 (s, 2H).




 


7-2




Me
1H NMR (400 MHz, DMSO) δ 14.69 (s, 1H), 9.37 (s, 2H), 8.91 (s, 1H), 7.96 (d, J = 8.9 Hz, 1H), 7.87 (s, 1H), 7.51 (s, 1H), 4.43 (s, 3H), 3.00 (d, J = 6.2 Hz, 2H), 2.71 (s, 3H), 1.24 (d, J = 6.4 Hz, 5H), 1.03 (s, 2H).
401
 95%


 


7-3




Me
1H NMR (400 MHz, DMSO) δ 14.70 (s, 1H), 13.87 (s, 1H), 8.91 (s, 1H), 7.98 (d, J = 8.1 Hz, 2H), 7.60 (s, 1H), 4.41 (s, 1H), 2.70 (s, 3H), 1.23 (s, 2H), 1.06 (s, 2H).
412
100%


 


7-4
CH2CN
Me
1H NMR (400 MHz, DMSO) δ 14.75 (s, 1H), 8.90 (s, 1H), 7.95 (d, J = 8.8 Hz, 1H), 7.76
383
 97%





(s, 1H), 7.22 (s, 1H), 5.76 (s, 2H), 4.40 (m, 1H), 2.69 (s, 3H), 1.23 (m, 2H), 1.04 (s, 2H).




7-5
CHO
Me
1H NMR (400 MHz, DMSO) δ 14.67 (s, 1H), 10.03 (s, 1H), 8.92 (s, 1H), 8.39 (s, 1H),
372
 98%





8.23 (s, 1H), 7.99 (d, J = 9.1 Hz, 1H), 4.42 (s, 1H), 2.71 (s, 3H), 1.24 (d, J = 6.4 Hz,







2H), 1.05 (s, 2H).




 


7-6




Me
1H NMR (400 MHz, DMSO) δ 14.70 (s, 1H), 11.34 (d, J = 16.3 Hz, 1H), 8.90 (s, 1H), 8.40 (s, 1H), 7.96 (d, J = 8.6 Hz, 1H), 7.78 (s, 1H), 7.42 (d, J = 14.9 Hz, 1H), 4.40 (s, 1H), 2.71 (s, 3H), 1.24 (d, J = 5.8 Hz, 2H), 1.04 (s, 2H).
387
 96%


 


7-7




Me
1H NMR (400 MHz, DMSO) δ 13.57-13.17 (m, 1H), 11.49 (s, 1H), 9.30 (s, 1H), 8.77 (s, 1H), 8.09 (s, 1H), 7.90 (d, J = 9.3 Hz, 1H), 7.83 (s, 1H), 4.33 (s, 1H), 2.66 (s, 3H), 1.22 (d, J = 7.5 Hz, 2H), 0.97 (s, 2H).
403
100%


 


7-8
CONH2
Me
1H NMR (400 MHz, DMSO) δ 14.70 (s, 1H), 8.91 (s, 1H), 8.12 (s, 1H), 7.98 (m, 2H),
387
100%





7.89 (s, 1H), 7.57 (s, 1H), 4.41 (s, 1H), 2.71 (s, 3H), 1.25 (d, J = 5.7 Hz, 2H), 1.03 (s, 2H).




7-9
CO2H
Me
1H NMR (400 MHz, DMSO) δ 14.69 (s, 1H), 13.34 (s, 1H), 8.91 (s, 1H), 8.12 (s, 1H),
388
100%





7.96 (d, J = 8.7 Hz, 1H), 7.86 (s, 1H), 4.40 (s, 1H), 2.69 (s, 3H), 1.24 (d, J = 6.2 Hz,







2H), 1.05 (s, 2H).




 


7-10




Me
1H NMR (400 MHz, DMSO) δ 14.68 (s, 1H), 12.49 (s, 1H), 8.87 (s, 1H). 7.96 (d, J = 11.9 Hz, 2H), 7.81 (d, J = 15.8 Hz, 1H), 7.69 (s, 1H), 6.30 (d, J = 15.7 Hz, 1H), 4.40 (s, 1H), 2.71 (s, 3H), 1.24 (d, J = 6.4 Hz, 2H), 1.04 (s, 2H).
414
 95%


 


7-11




Me
1H NMR (400 MHz, DMSO) δ 14.69 (s, 1H), 8.92 (s, 1H), 8.13 (s, 1H), 8.00 (d, J = 8.7 Hz, 1H), 7.91 (s, 1H), 4.42 (s, 1H), 2.74 (s, 3H), 1.24 (s, 2H), 1.06 (s, 2H).
412
100%


 


7-12




Me
1H NMR (400 MHz, DMSO) δ 14.75 (s, 1H), 11.75 (s, 1H), 8.90 (s, 1H), 7.97 (s, 1H),  7.58 (s, 1H), 7.46 (s, 1H), 7.26 (s, 1H), 7.13 (s, 1H), 7.00 (s, 2H), 4.41 (s, 1H), 4.17 (d,  J = 6.9 Hz, 2H), 2.75 (s, 3H), 1.99 (s, 2H), 1.23 (s, 3H), 1.04 (s, 2H), 0.85 (s, 2H).
481
100%


 


7-13




Me
1H NMR (400 MHz, DMSO) δ 14.70 (s, 1H), 8.91 (s, 1H), 8.49 (s, 1H), 7.97 (d, J = 8.7 Hz, 1H), 7.91 (s, 1H), 7.64 (s, 2H), 4.41 (s, 1H), 2.73 (s, 3H), 1.25 (d, J = 6.5 Hz,  2H), 1.05 (s, 2H).
411
 95%


 


7-14




Me
1H NMR (400 MHz, DMSO) δ 14.90-14.46 (m, 1H), 8.93 (s, 1H), 8.05 (s, 1H), 8.02 (d, J = 8.4 Hz, 2H), 7.63 (s, 2H), 7.28 (s, 2H), 4.44 (s, 1H), 2.78 (s, 3H), 1.27 (d, J =  6.4 Hz, 2H), 1.07 (s, 2H).
460
100%


 


7-15




Me
1H NMR (400 MHz, DMSO) δ 6.92 (s, 1H), 8.07 (d, J = 6.7 Hz, 2H), 7.99 (d, J = 8.8 Hz, 1H), 7.91 (s, 1H), 7.79 (s, 1H), 7.54 (s, 3H), 4.42 (s, 1H), 2.76 (s, 3H), 1.25 (d, J = 6.0 Hz, 3H), 1.07 (m, 2H).
487
 95%


 


7-16




Me
1H NMR (400 MHz, DMSO) δ 14.68 (b, 1H), 13.75 (s, 1H), 8.90 (s, 1H), 7.96 (d, J = 8.9 Hz, 1H), 7.77 (s, 1H), 7.61 (s, 1H), 4.47-4.32 (m, 1H), 2.73 (s, 3H), 2.41 (s, 3H),  1.25 (t, J = 6.3 Hz, 2H), 1.07 (s, 2H).
425
 98%


 


7-17
CN
OMe
1H NMR (400 MHz, DMSO) δ 14.63 (s, 1H), 8.80 (s, 1H), 8.42 (s, 1H), 7.28 (s, 1H), 
385
 98%





7.96 (d, J = 9.2 Hz, 1H), 4.47-4.32 (m, 1H), 3.47 (s, 3H), 1.23-1.15 (m, 4H).




 


7-18




OMe
1H NMR (400 MHz, DMSO) δ 8.57 (s, 1H), 7.72 (s, 2H), 7.58 (s, 1H), 7.43 (d, J =  9.7 Hz, 1H), 4.13 (m, 1H), 3.27 (s, 3H), 2.20 (s, 3H), 1.05-0.81 (m, 4H).
441
 98%


 


7-19




Cl
1H NMR (400 MHz, DMSO) δ 8.93 (s, 1H), 8.13 (d, J = 8.0 Hz, 1H), 7.86 (s, 1H),  7.67 (s, 1H), 4.13 (m, 1H), 2.40 (s, 3H), 1.24-1.12 (m, 4H).
445
 85%
















TABLE 8-1













 










Compound


MS


No.
R19 =
R2 =
(MH+)





8-1
H
Me
352.36


8-2
3-NH2
Me
337.34


8-3
4-F
Me
355.33


8-4
4-CO2H
Me
381.35


8-5
2-NH2
Me
352.36


8-6
3-Me
Me
351.37


8-7
4-Me
Me
351.37


8-8
2,3-Dimethyl
Me
365.4 


8-9
2-Cl
Me
371.79


8-10
4-Cl
Me
371.79


8-11
3-CO2H
Me
381.35


8-12
3-CF3
Me
405.34


8-13
3,4-Dichloro
Me
406.23


8-14
3-F
Me
355.33


8-15
4-tBu
Me
393.45


8-16
4-MeO
Cyclopropyl
393.41


8-17
4-Ph
Me
413.44


8-18
4-NO2
Me
382.34


8-19
3,4-Dichloro
MeO
404.24


8-20
4-MeO
Me
365.38


8-21
3,4-Dimethyl
Me
365.4 


8-22
4-CF3
Me
405.34


8-24
3-CONH2
Me
380.37


8-25
4-NH2
Me
352.36


8-26
4-OH
Me
353.34


8-27
4-OMe
F
353.34


8-28
4-OMe
NO2
398.34


8-29
4-OMe
Cl
387.79


8-30
4-OMe
NH2
368.36


8-31
4-OMe
Br
432.24


8-32
4-OMe
H
353.34


8-33
4-OMe
CN
378.35


8-34
4-OMe
CH2F
385.36


8-35
4-OMe
MeO
383.37


8-36
4-OMe
CH2Br
446.27


8-37
4-OMe
CH2OH
383.37


8-38
4-OMe
CHF2
403.35


8-39
4-Amino-3-hydroxy
Me
368.36


8-40
4-OMe
CHO
381.35


8-41
4-OMe
C≡CH
377.37


8-42
4-OMe
Et
381.4 


8-43
4-OMe
CH═CH2
379.38


8-44
3,4-Diamino
Me
367.37


8-45
4-Amino-3-nitro
Me
397.36


8-46
4-Methylamino-3-nitro
Me
411.38


8-47
3-Dimethylamino
Me
380.41


8-48
2,4-Dinitro-3-
Me
470.41



dimethylamino




8-49
4-Nitro-3-dimethylamino
Me
425.41


8-50
2-Nitro-3-dimethylamino
Me
425.41


8-51
4-Dimethylamino-3-nitro
Me
425.41


8-52
4-Ethylamino-3-nitro
Me
425.41


8-53
4-Dimethylamino
Me
380.41


8-54
3-Formyl-4-nitro
Me
410.35


8-55
4-Amino-3-nitro
Me
413.36


8-56
3-Fluoro-4-nitro
Me
400.33
















TABLE 8-2













 










Compound


MS


No.
R3 =
R2 =
(MH+)





8-57




Me
451.45


 


8-58




Me
465.47


 


8-59




Me
480.49


 


8-60




Me
495.48


 


8-61




Me
508.54


 


8-62




Me
452.44


 


8-63




Me
456.46


 


8-64




Me
467.45


 


8-65




Me
411.38


 


8-66




Me
415.35


 


8-67




Me
425.41


 


8-68




Me
429.37


 


8-69




Me
426.35


 


8-70




Me
454.45


 


8-71




Me
449.39


 


8-72




Me
454.45


 


8-73




Me
463.42


 


8-74




Me
447.46


 


8-75




Me
406.45


 


8-76




Me
421.46


 


8-77




Me
418.42
















TABLE 9













 










Compound


MS


No.
R3 =
R2 =
(MH+)





9-1




Me
407.19


 


9-2




Me
404.39


 


9-3




Me
394.35


 


9-4




Me
397.4 


 


9-5




Me
392.38


 


9-6




Me
326.32


 


9-7




Me
326.32


 


9-8




Me
394.4 


 


9-9




Me
380.41


 


9-10




Me
395.43


 


9-11




Me
355.36


 


9-12




Me
393.37


 


9-13




Me
327.31


 


9-14




Me
406.2 


 


9-15




Me
409.43


 


9-16




Me
372.3 


 


9-17




Me
328.34


 


9-18




Me
397.44


 


9-19




Me
354.33


 


9-20




Me
354.33


 


9-21




Me
422.33


 


9-22




Me
342.36


 


9-24




Me
411.47









Experimental Example 1
In Vitro Antibacterial Activity
All compounds were dissolved in dimethyl sulfoxide (DMSO, Merck, purity >99.9%) to achieve final 1 mg/ml desired concentrations.
MICs (minimum inhibitory concentrations) were determined by the broth microdilution technique with 96-well microdilution plates. The antimicrobials were tested using the following MIC ranges: 0.008 to 8 μg/ml. The plates were filled with 100 μl of reinforced clostridial medium (Oxoid; Unipath Ltd., Basingstoke, United Kingdom) per well containing the final antibiotic concentrations. The plates were thawed and preincubated for 3 hours in an anaerobic chamber (Thermal, USA) containing an atmosphere of 80% N2, 15% CO2, and 5% H2. The bacterial inocula were prepared by suspending growth from 48 hours cultures in reinforced clostridial medium. The final inoculum was approximately 1.0×105-6 CFU/well. The plates were incubated for 48 hours at 37° C. in the anaerobic chamber. The MIC was defined as the lowest antibiotic concentration that inhibited visible growth. Ciprofloxacin, vancomycin and metronidazole were used as a positive control. The results are shown in Table 10.







TABLE 10







MIC of example compounds against C. difficile (μg/mL)











Com-






pound
C. difficile
C. difficile
C. difficile
C. difficile


No. 
ATCC43255
ATCC7000057
ATCC70092
IQCC23903





2-18
 0.016-0.063
0.016-0.063
≲0.008-0.063 
 0.032-0.063


2-46
 0.032-0.125
0.032-0.25 
0.063-0.25
0.125-0.25


5-14
0.125-0.25
0.125-0.5 
0.125-0.25
0.125-0.5 


2-49
0.063-0.25
0.063-0.25 
0.063-0.5 
0.063-0.25


3-11
≲0.008-0.032 
0.016-0.032
≲0.008-0.032 
≲0.008-0.063 


2-31
≲0.008-0.032 
0.016-0.032
 0.016-0.032
 0.016-0.063


1-2 
 0.032-0.125
0.032-0.125
 0.032-0.125
0.063-0.25


3-21
 0.016-0.032
0.016-0.063
 0.016-0.063
 0.032-0.063


2-38
 0.016-0.032
0.016-0.032
 0.032-0.063
 0.016-0.032


3-30
 0.032-0.063
0.063-0.125
 0.063-0.125
0.063-0.25









Experimental Example 2
In Vivo Antibacterial Efficacy
In vivo efficacy was evaluated in a hamster intestinal infection treatment model. Male Golden Syrian hamsters were purchased from Charles River Laboratories (Kingston, N.Y., USA) and were about 6 weeks of age, with weights ranging from 80 to 100 g at the start of the study. The animals were housed individually in filtered polycarbonate shoe-box style cages equipped with water bottles, and Harlan Toklab Global Diet 2016 was available ad libitrum via food hoppers. The hamsters were pre-treated with clindamycin (1 mg/kg, p.o.) and vancomycin (50 mg/kg, p.o.), formulated in arabic gum, at Day 0. At Day 7, each hamster was inoculated via oral gavage with 0.5 mL of a suspension of C. difficile ATCC 43255 (105 CFU/body, p.o.). To prepare this inoculum, C. difficile was grown in GAM agar (Japan) for 5 days at 37° C., and the bacteria were harvested by centrifugation, rinsed twice with arabic gum, resuspended in arabic gum and the exact bacteria density was determined using the dilution plate count method. Oral dosing of compounds, pulverized and formulated in arabic gum was commenced the following day (Day 8). Treatments were administered once a day for 5 consecutive days at specified doses (10, 2, and 0.4 mg/kg), with five hamsters per group. Controls were included an uninfected group and an infected but untreated group, and vancomycin was used as positive control. The hamsters were observed daily to record clinical signs (duration, time of onset, time of recovery or death), and animals in a lethargic, clearly moribund state were euthanized. A necropsy was performed on animals that were either found dead or were euthanized at the end of the study (37 days). The results are shown in FIG. 1 and FIG. 2.
Preparation Example 1
An injection preparation is prepared from the following components.














Components
Amount









Compound 1-2
200 mg



Glucose
250 mg



Distilled water for injection
g.s.



Total
5 ml










Compound 1-2 and glucose are dissolved in distilled water for injection, and the solution is added to a 5 ml ampoule, which is purged with nitrogen gas and then subjected to sterilization at 121° C. for 15 minutes to give an injection preparation.
Preparation Example 2
Film coated tablets are prepared from the following components.














Components
Amount




















Compound 2-18
100 
g



Avicel (registered trademark)
40 
g



Corn starch
30 
g



Magnesium stearate
2 
g



TC-5 (registered trademark)
10 
g



Polyethylene glycol 6000
3 
g



Castor oil
40 
g



Ethanol
40 
g










Compound 2-18, Avicel (registered trademark of microcrystalline cellulose, manufactured by Asahi Kasei Corporation, Japan), corn starch and magnesium stearate are mixed and kneaded, and the mixture is tabletted using a conventional pounder (R 10 mm) for sugar coating (manufactured by Kikusui Seisakusho Ltd., Japan). The tablets thus obtained are coated with a film coating agent consisting of TC-5 (registered trademark of hydroxypropyl methylcellulose, manufactured by Shin-Etsu Chemical Co., Ltd., Japan), polyethylene glycol 6000, castor oil and ethanol to give film coated tablets.
Preparation Example 3
An ointment is prepared from the following components.














Components
Amount




















Compound 3-11
2 
g



Purified lanolin
5 
g



Bleached beeswax
5 
g



White petrolatum
88 
g



Total 
100 
g










Bleached beeswax is made liquid by heating, and thereto are added compound 3-11, purified lanolin and white petrolatum, and the mixture is heated until it becomes liquid. The mixture is stirred until it is solidified to give an ointment.

## Claims

1. A compound selected from the group consisting of compounds represented by the following formulae






or a salt thereof.

2. The compound of claim 1, which is a compound represented by the formula



or a salt thereof.

3. The compound of claim 1, which is a compound represented by the formula



or a salt thereof.

4. The compound of claim 1, which is a compound represented by the formula



or a salt thereof.

5. The compound of claim 1, which is a compound represented by the formula



or a salt thereof.

6. The compound of claim 1, which is a compound represented by the formula



or a salt thereof.

7. The compound of claim 1, which is a compound represented by the formula



or a salt thereof.

8. The compound of claim 1, which is a compound represented by the formula



or a salt thereof.

9. The compound of claim 1, which is a compound represented by the formula



or a salt thereof.

10. The compound of claim 1, which is a compound represented by the formula



or a salt thereof.

11. The compound of claim 1, which is a compound represented by the formula



or a salt thereof.

12. A pharmaceutical composition comprising a compound of claim 1 or a salt thereof and a pharmaceutically acceptable carrier.

13. An antimicrobial agent comprising a compound of claim 1 or a salt thereof.

14. A method for treating a bacterial infection which comprises administering an effective amount of a compound of claim 1 or a salt thereof to a human or an animal.